Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended SeptemberendedSeptember 30 2020, 2021

 

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the transition period from ________________ to ________________

 

Commission File Number 001-35073

 


 

GEVO, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware

87-0747704

(State or other jurisdiction of

incorporation or organization)

 

87-0747704

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

 

345 Inverness Drive South, Building C, Suite 310

Englewood, CO

 

80112

(Address of principal executive offices)

 

(Zip Code)

 

(303) 858-8358

(Registrant's telephone number,

including area code)

 


 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.01 per share

GEVO

Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

 

 

Accelerated filer

 

       

Non-accelerated filer

 

 

Smaller reporting company

 

       

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of October 30, 2020, 119,628,203 29, 2021, 201,879,978 shares of the registrant’s common stock were outstanding.

 



 

 

 

 

GEVO, INC.

 

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 20202021

TABLE OF CONTENTS

 

 

 

Page

PART I.  FINANCIAL INFORMATION
   

Item 1.

Financial Statements

3

 

Consolidated Balance Sheets as of September 30, 20202021 (unaudited) and December 31, 20192020

3

 

Consolidated Statements of Operations for the three and nine months ended September 30, 2021 and 2020 and 2019 (unaudited)

4
Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2021 and 2020 (unaudited)5
 Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30,, 2021 and 2020 and 2019 (unaudited)56

 

Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 and 2019 (unaudited)

67

 

Notes to Consolidated Financial Statements (unaudited)

89

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

3132

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

4043

Item 4.

Controls and Procedures

4044

 

 

 

PART II.  OTHER INFORMATION

  

 

 

Item 1.

Legal Proceedings

4145

Item 1A.

Risk Factors

4145

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

4247

Item 3.

Defaults Upon Senior Securities

4247

Item 4.

Mine Safety Disclosures

4247

Item 5.

Other Information

4247

Item 6.

Exhibits

4348

 

 

 

 

Signatures

4650

 

2

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

GEVO, INC.

Consolidated Balance SheetsCONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

 

 

September 30,

2020

(unaudited)

  

December 31,

2019

  September 30, 2021  

December 31, 2020

 

Assets

            

Current assets:

        

Current assets

 

Cash and cash equivalents

 $80,621  $16,302  $16,201  $78,338 

Accounts receivable

  370   1,135 
Marketable securities (current) 285,236  0 
Restricted cash (current) 49,804  0 

Accounts receivable, net

 513  527 

Inventories

  2,551   3,201  2,341  2,491 

Prepaid expenses and other current assets

  4,614   3,590   7,243   1,914 

Total current assets

  88,156   24,228  361,338  83,270 
         

Property, plant and equipment, net

  63,324   66,696  102,163  66,408 
Investment in Juhl 1,500  1,500 
Long-term marketable securities 101,003  0 
Long-term restricted cash 70,168  0 
Operating right-of-use assets 1,591  133 
Finance right-of-use assets 27,665  176 
Intangible assets, net 9,098  114 

Deposits and other assets

  507   935   2,329   1,998 
       

Total assets

 $153,487  $93,359  $675,355  $152,099 
         

Liabilities

               

Current liabilities:

        

Current liabilities

 

Accounts payable and accrued liabilities

 $4,904  $5,678  $24,582  $3,943 
2020/21 Notes (current), net 12,506   
2020 Notes (current), net   13,900 

2020/21 Notes embedded derivative liability

  29    
Operating lease liabilities (current) 0  172 
Finance lease liabilities (current) 2,727  10 

Loans payable - other (current)

  704   516   165   807 

Total current liabilities

  18,143   20,094  

27,474

  4,932 
         
2021 Bonds payable (long-term) 66,303  0 

Loans payable - other (long-term)

  583   233  357  447 
Operating lease liabilities (long-term) 1,732  0 
Finance lease liabilities (long-term) 19,598  162 

Other long-term liabilities

  172   528   91   

179

 

Total liabilities

  18,898   20,855   115,555   5,720 
         

Commitments and Contingencies (see Note 12)

        

Commitments and Contingencies (See Note 12)

          
         

Stockholders' Equity

               

Common stock, $0.01 par value per share; 250,000,000 authorized; 119,578,203 and 14,083,232 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively.

  1,196   141 

Common stock, $0.01 par value per share; 250,000,000 authorized; 201,879,978 and 128,138,311 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively.

 2,019  1,282 

Additional paid-in capital

  613,511   530,349  1,098,939  643,269 
Accumulated other comprehensive loss (296) 0 

Accumulated deficit

  (480,118)  (457,986)  (540,862)  (498,172)

Total stockholders' equity

  134,589   72,504   559,800   146,379 
       

Total liabilities and stockholders' equity

 $153,487  $93,359  $675,355  $152,099 

 

See the accompanying Notes to the unaudited Consolidated Financial Statements.

 

3

 

 

GEVO, INC.

Consolidated Statements of OperationsCONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

(unaudited)

 

 Three Months Ended September 30,     Nine Months Ended September 30,     

Three Months Ended September 30,

  Nine Months Ended September 30, 
 2020  2019  2020  2019  2021  

2020

  2021  2020 

Revenue and cost of goods sold

                          

Ethanol sales and related products, net

 $21  $5,554  $3,804  $16,184  $16  $

21

  $16  $3,804 

Hydrocarbon revenue

  101   550   1,085   1,381  104  101  463 1,085 
Other revenue  70   6   116   34   22   70   178   116 

Total revenues

  192   6,110   5,005   17,599  142  192  657 5,005 
                    

Cost of goods sold

  2,260   9,893   13,043   27,306   3,482   2,260   8,270   13,043 
                    

Gross loss

  (2,068)  (3,783)  (8,038)  (9,707)  (3,340)  (2,068)  (7,613)  (8,038)
                    

Operating expenses

                          

Research and development expense

  870   1,789   2,127   3,712  1,541  870  4,323 2,127 

Selling, general and administrative expense

  3,215   2,431   8,917   6,705  9,335  2,892  18,027 8,179 
Preliminary stage project costs 313  323  8,512 700 
Loss on disposal of assets 183  0  5,137  38 
Restructuring expenses  (50)     254      0   (50)  0   254 

Total operating expenses

  4,035   4,220   11,298   10,417   11,372   4,035   35,999   11,298 
                    

Loss from operations

  (6,103)  (8,003)  (19,336)  (20,124)  (14,712)  (6,103)  (43,612)  (19,336)
                    

Other income (expense)

                          
Gain on forgiveness of SBA Loans 0  0  641 0 

Interest expense

  (473)  (605)  (1,559)  (2,127) (67) (473) (78) (1,559)

(Loss) on modification of 2020 Notes

        (726)    0  0  0 (726)
(Loss) on conversion of 2020/21 Notes to common stock (543)   (543)   0  (543) 0 (543)

(Loss) gain from change in fair value of derivative warrant liability

     (2)  8   1 

Gain (loss) from change in fair value of 2020/21 Notes and 2020 Notes embedded derivative liability

  247      (29)  394 

Other income (expense)

  36   (9)  53   11 

Gain (loss) from change in fair value of derivative warrant liability

 6  0  (4) 8 

Gain (loss) from change in fair value of 2020/21 Notes embedded derivative liability

 0  247  0 (29)

Other income (expense), net

  393   36   363   53 

Total other income (expense), net

  (733)  (616)  (2,796)  (1,721)  332   (733)  922   (2,796)
                    

Net loss

 $(6,836) $(8,619) $(22,132) $(21,845) $(14,380) $(6,836) $(42,690) $(22,132)
                    

Net loss per share - basic and diluted

 $(0.09) $(0.66) $(0.62) $(1.87) $(0.07) $(0.09) $(0.22) $(0.62)
                    

Weighted-average number of common shares outstanding - basic and diluted

  

77,049,896

   12,968,265   35,682,794   11,679,530   199,341,519   77,049,896   193,739,605   35,682,794 

 

 

See the accompanying Notes to the unaudited Consolidated Financial Statements.

 

4

 

 

GEVO, INC.

CONSOLIDATED STATEMENTSCONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY COMPREHENSIVE INCOME (LOSS)

(In thousands, except share amounts)in thousands)

(unaudited)

 

  

Common Stock

  

Paid-In

  

Accumulated

  

Stockholders’

 
  

Shares

  

Amount

  

Capital

  

Deficit

  

Equity

 
                     

Balance, December 31, 2019

  14,083,232  $141  $530,349  $(457,986) $72,504 
                     

Issuance of common stock, net of issue costs

  425,776   4   902      906 

Non-cash stock-based compensation

        336      336 
Issuance of common stock under stock plans, net of taxes  105,882             

Net loss

           (9,253)  (9,253)
                     
Balance, March 31, 2020  14,614,890   145   531,587   (467,239)  64,493 
                     
Issuance of common stock, net of issue costs  917,345   9   1,238      1,247 
Non-cash stock-based compensation        497      497 
Issuance of common stock under stock plans, net of taxes  (18,137)     (307)     (307)
Net loss           (6,043)  (6,043)
                     
Balance, June 30, 2020  15,514,098   154   533,015   (473,282)  59,887 
                     
Issuance of common stock and common stock warrants, net of issue costs  

42,772,687

   428   61,265      61,693 

Issuance of common stock upon exercise of warrants

  52,953,400   530   16,117      16,647 
Issuance of common stock upon conversion of 2020/21 Notes  4,169,426   42   2,441      2,483 
Issuance of common stock in exchange for services rendered  101,730   1   93      94 
Non-cash stock-based compensation        642      642 
Issuance of common stock under stock plans, net of taxes  4,066,862   41   (62)     (21)
Net loss           (6,836)  (6,836)
                     
Balance, September 30, 2020  119,578,203  $1,196  $613,511  $(480,118) $134,589 
                     

Balance, December 31, 2018

  8,640,583  $86  $518,027  $(429,326) $88,787 
                     

Issuance of common stock, net of issue costs

  3,244,941   33   9,611      9,644 

Non-cash stock-based compensation

        234      234 

Net loss

           (6,136)  (6,136)
                     

Balance, March 31, 2019

  11,885,524   119   527,872   (435,462)   92,529 
                     
Issuance of common stock, net of issue costs        (14)     (14)
Non-cash stock-based compensation        172      172 
Net loss           (7,090)  (7,090)
                     
Balance, June 30, 2019  11,885,524   119   528,030   (442,552)   85,597 
                     
Issuance of common stock, net of issue costs        (161)     (161)
Non-cash stock-based compensation        304      304 
Issuance of common stock under stock plans, net of taxes  1,483,477   14   (215)     (201)
Net loss           (8,619)  (8,619)
                     
Balance, September 30, 2019  13,369,001  $133  $527,958  $(451,171) $76,920 
  

Three Months Ended September 30,

  Nine Months Ended September 30, 
  2021  

2020

  2021  2020 
                 

Net loss

 $(14,380) $(6,836 (42,690) $(22,132

Other comprehensive income (loss)

      

 

         
Unrealized gain (loss) on available-for-sale securities, net of tax  45   0   (262)  0 

Adjustment for net gain (loss) realized and included in net income, net of tax

  (34)  0   (34)  0 
Total change in unrealized gain (loss) on marketable securities  11   0   (296)  0 

 

                
Comprehensive loss $(14,369) $(6,836) $(42,986) $(22,132)

 

 

See the accompanying Notes to the unaudited Consolidated Financial Statements.

 

5

 

 

GEVO, INC.

Consolidated Statements of Cash FlowsCONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(in thousands)In thousands, except share amounts)

(unaudited)

 

  

Nine Months Ended September 30,

 
  2020  

2019

 

Operating Activities

        

Net loss

 $(22,132) $(21,845)

Adjustments to reconcile net loss to net cash used in operating activities:

        

(Gain) from change in fair value of derivative warrant liability

  (8)  (1)

Loss (gain) from change in fair value of 2020/21 Notes and 2020 Notes embedded derivative liability

  29   (394)
Loss on conversion of 2020/21 Notes to common stock  543    
Loss (gain) on retirement of property, plant and equipment  38   (19)

Stock-based compensation

  1,347   938 

Depreciation and amortization

  4,754   4,849 
Non-cash lease expense  45   25 

Non-cash interest expense

  606   1,089 
      Other non-cash expense     

1

 

Changes in operating assets and liabilities:

        

Accounts receivable

  765   148 

Inventories

  650   204 

Prepaid expenses and other current assets, deposits and other assets

  (613)  (23)

Accounts payable, accrued expenses and long-term liabilities

  (605)  230 

Net cash used in operating activities

  (14,581)  (14,798)
         

Investing Activities

        

Acquisitions of property, plant and equipment

  (1,756)   (5,779)
   Proceeds from sale of property, plant and equipment     19 
   Investment in Juhl     (1,500)

Net cash used in investing activities

  (1,756)  (7,260)
         

Financing Activities

        
Proceeds from SBA loans  1,006    
Debt and equity offering costs  (6,170)  (178)

Proceeds from issuance of common stock and common stock warrants

  69,985   9,647 
Proceeds from exercise of warrants  16,647    
Net settlement of common stock under stock plans  (331)  (201)
Payment of loans payable - other  (481)   

Net cash provided by financing activities

  80,656   9,268 
         

Net increase (decrease) in cash and cash equivalents

  64,319   (12,790)
         

Cash and cash equivalents

        

Beginning of period

  16,302   33,734 
         

End of period

 $80,621  $20,944 
  

Common Stock

  

Paid-In

  

Accumulated Other Comprehensive

  

Accumulated

  

Stockholders’

 
  

Shares

  

Amount

  

Capital

  Loss  

Deficit

  

Equity

 
                         
Balance, June 30, 2021  197,964,476  $1,980  $1,100,932  $(307) $(526,482) $576,123 
                         
Issuance of common stock, net of issue costs  0   0   (162)  0   0   (162)
Non-cash stock-based compensation     0   1,880   0   0   1,880 
Issuance of common stock under stock plans, net of taxes  3,915,502   39   (3,711)  0   0   (3,672)
Other comprehensive income     0   0   11   0   11 
Net loss     0   0   0   (14,380)  (14,380)
                         
Balance, September 30, 2021  201,879,978  $2,019  $1,098,939  $(296) $(540,862) $559,800 
                         
Balance, December 31, 2020  128,138,311  $1,282  $643,269  $  $(498,172) $146,379 
                         
Issuance of common stock, net of issue costs  68,170,579   682   456,801   0   0   457,483 
Issuance of common stock upon exercise of warrants  1,866,758   18   1,103   0   0   1,121 
Non-cash stock-based compensation     0   3,300   0   0   3,300 
Issuance of common stock under stock plans, net of taxes  3,704,330   37   

(5,534

)  0   0   (5,497)
Other comprehensive loss     0   0   (296)  0   (296)
Net loss     0   0   0   (42,690)   (42,690)
                         
Balance, September 30, 2021  201,879,978  $2,019  $1,098,939  $(296) $(540,862) $559,800 
                         
Balance, June 30, 2020  15,514,098  $154  $533,015  $0  $(473,282) $59,887 
                         
Issuance of common stock and common stock warrants, net of issue costs  42,772,687   428   61,265   0   0   61,693 
Issuance of common stock upon exercise of warrants  52,953,400   530   16,117   0   0   16,647 
Issuance of common stock upon conversion of 2020/21 Notes  4,169,426   42   2,441   0   0   2,483 
Issuance of common stock in exchange for services rendered  101,730   1   93   0   0   94 

Non-cash stock-based compensation

     0   642   0   0   642 
Issuance of common stock under stock plans, net of taxes  4,066,862   41   (62)  0   0   (21)

Net loss

     0   0   0   (6,836)  (6,836)
                         
Balance, September 30, 2020  119,578,203  $1,196  $613,511  $0  $(480,118) $134,589 
                         
Balance, December 31, 2019  14,083,232  $141  $530,349  $0  $(457,986) $72,504 
                         
Issuance of common stock and common stock warrants, net of issue costs  44,115,808   441   63,405   0   0   63,846 
Issuance of common stock upon exercise of warrants  52,953,400   530   16,117   0   0   16,647 
Issuance of common stock upon conversion of 2020/21 Notes  4,169,426   42   2,441   0   0   2,483 
Issuance of common stock in exchange for services rendered  101,730   1   93   0   0   94 
Non-cash stock-based compensation     0   1,475   0   0   1,475 
Issuance of common stock under stock plans, net of taxes  4,154,607   41   (369)  0   0   (328)
Net loss     0   0   0   (22,132)  (22,132)
                         
Balance, September 30, 2020  119,578,203  $1,196  $613,511  $0  $(480,118) $134,589 

 

See the accompanying Notes to the unaudited Consolidated Financial Statements.

 

6

 

GEVO, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

  

Nine Months Ended September 30,

 
  2021  

2020

 

Operating Activities

        

Net loss

 $(42,690) $(22,132)

Adjustments to reconcile net loss to net cash used in operating activities:

        

Loss (gain) from change in fair value of derivative warrant liability

  4   (8)
Loss (gain) from change in fair value of 2020/21 Notes and 2020 Notes embedded derivative liability  0   29 
Loss on conversion of 2020/21 Notes to common stock  0   543 
Loss on disposal of assets  

5,137

   38 
(Gain) on forgiveness of SBA Loans  (641)  0 

Stock-based compensation

  5,823   

1,347

 

Depreciation and amortization

  

3,572

   4,754 
Non-cash lease expense  7   45 

Non-cash interest expense

  65   606 
Other non-cash expenses  5   0 

Changes in operating assets and liabilities:

        

Accounts receivable

  14   765 

Inventories

  150   650 

Prepaid expenses and other current assets, deposits and other assets

  (4,463)  (613)

Accounts payable, accrued expenses and long-term liabilities

  4,324   (605)

Net cash used in operating activities

  (28,693)  (14,581)
         

Investing Activities

        

Acquisitions of property, plant and equipment

  (30,955)  (1,756)
Acquisition of patent portfolio  (9,000)  0 
Proceeds from sale of marketable securities  34,332   0 
Purchase of marketable securities  (422,362)  0 

Net cash used in investing activities

  (427,985)  (1,756)
         

Financing Activities

        
Proceeds from issuance of 2021 Bonds  68,995   0 
Debt and equity offering costs  (34,919)  (6,170)

Proceeds from issuance of common stock and common stock warrants

  487,549   69,985 
Proceeds from exercise of warrants  1,119   16,647 
Net settlement of common stock under stock plans  (5,137)  (331)
Payment of loans payable - other  

(98

)  (481)
Payment of finance lease liabilities  (2,996)  0 
Proceeds from SBA Loans  0   1,006 

Net cash provided by financing activities

  

514,513

   80,656 
         

Net increase (decrease) in cash and cash equivalents

  57,835   64,319 
         

Cash, cash equivalents and restricted cash 

        

Beginning of period

  78,338   16,302 
         

End of period

 $136,173  $80,621 

See the accompanying Notes to the unaudited Consolidated Financial Statements.

7

GEVO, INC. 

Consolidated Statements of Cash Flows - Continued

(in thousands)

(unaudited)

 

Supplemental disclosures of cash and non-cash investing and financing transactions

 

Nine Months Ended September 30,

 
  2020  

2019

 
         

Cash paid for interest

 $953  $1,038 
Non-cash purchase of property, plant and equipment $2  $41 
Issuance of common stock upon exchange of debt and make-whole $2,517  $ 
Issuance of common stock in exchange for services rendered $94  $ 
Original issue discount paid with 2020/21 Notes $282  $ 
Right-of-use asset purchased with financing lease $13  $ 
Schedule of cash, cash equivalents and restricted cash Nine Months Ended September 30, 
  2021  2020 
         

Cash and cash equivalents

  $16,201   $80,621 

Restricted cash (current)

  49,804   0 

Long-term restricted cash

  70,168   0 
         
 Total cash, cash equivalents and restricted cash  $136,173   $80,621 

Supplemental disclosures of cash and non-cash investing and financing transactions

 

Nine Months Ended September 30,

 
  2021  

2020

 
         

Cash paid for interest

 $11  $

953

 
Non-cash purchase of property, plant and equipment $12,164  $2 
Issuance of common stock upon exchange of debt and make-whole $0  $2,517 
Issuance of common stock in exchange for services rendered $0  $94 
Original issue discount paid with 2020/21 Notes $0  $282 
Right-of-use asset purchased with financing leases $28,416  $13 
Right-of-use asset purchased with operating lease $1,611  $0 

 

See the accompanying Notes to the unaudited Consolidated Financial Statements.

 

78

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

 

1. Nature of Business, Financial Condition and Basis of Presentation

 

Nature of Business. Gevo, Inc. (“Gevo” or the “Company,” which, unless otherwise indicated, refers to Gevo, Inc. and its subsidiaries), is a growth-oriented company focused on transforming renewable energy into energy dense liquid hydrocarbons that can be used as renewable fuels, company that is commercializingsuch as sustainable aviation fuel (“SAF”) and renewable isooctane (which the next generation of renewable low-carbon liquid transportation fuelsCompany refers to as “renewable premium gasoline”), with the potential to achieve a “net zero”“net-zero” greenhouse gas (“GHG”) footprint and address global needs of reducing GHG emissions with sustainable alternatives to petroleum fuels. Gevo currently owns one production facility in Luverne, Minnesota (the "Luverne Facility"). Gevo plans to develop, own (in whole or in part), and operate additional production facilities that use a combination of (i) renewable energy sources such a photosynthetic energy, renewable electricity, biogas, renewable hydrogen, and (ii) renewable carbon sources such as residual carbohydrates. 

As next generation renewable fuels, Gevo’sGevo's hydrocarbon transportation fuels have the advantage of being “drop-in” substitutes for conventional fuels that are derived from crude oil, working seamlessly and without modification in existing fossil-fuel based engines, supply chains and storage infrastructure. In addition, with SAF, the carbon footprint of air travel can be reduced, or in the long run, eliminated, on a net carbon basis, without changes to planes or fuel systems. In addition to the potential of net net-zero carbon emissions across the whole fuel life-cycle, Gevo’sGevo's renewable fuels should eliminate other pollutants associated with the burning of traditional fossil fuels, such as particulates and sulfur, while delivering superior performance.

 

Gevo uses low-carbon, renewable resource-based raw materials as feedstock. In the near-term, Gevo’s feedstocks will primarily consist of non-food corn. As Gevo’s technology is applied globally, feedstocks can consist of sugar cane, molasses or other cellulosic sugars derived from wood, agricultural residues and waste. Gevo’s patented fermentation yeast biocatalyst produces isobutanol, a four-carbon alcohol, via the fermentation of renewable plant biomass carbohydrates. The resulting renewable isobutanol has a variety of direct applications but, more importantlytechnology pathway that converts carbohydrates to Gevo’s fundamental strategy, serves asalcohols via a building blockfermentation process. The alcohols are then converted to make renewable isooctane (which we refer to ashydrocarbon fuels using a renewable premium gasoline) and renewable jet fuelcatalytic chemical process. By using simple and common chemical conversion processes. Gevo also reduces or eliminates fossil-based process energy inputs by replacing them with renewable energy suchacross the production process, in combination with sustainable feedstocks, like low carbon non-food corn, the greenhouse gas emissions are expected to be substantially reduced or eliminated as wind-powered electricitymeasured across the whole of the life cycle. The processes used to convert carbohydrates to drop-in hydrocarbons using isobutanol as the intermediate alcohol is protected by a patent portfolio with more than 500 patents, as well as proprietary processes and renewable natural gasknow-how. The production technology to convert ethanol to hydrocarbons has been exclusively licensed to Gevo in the United States by Axens North America, Inc. (“RNG”Axens”)., and incorporates more than 60 patents, as well as proprietary production technology and know-how. 

 

Ultimately, the Company believes that the attainment of profitable operations is dependent upon future events, including, but not limited to (i) completing certain capital improvements at the Company’s production facility located in Luverne, Minnesotasuccessful development of the Company's initial Net-Zero Project (the "Luverne Facility""Net-Zero 1 Project") to increaseand future projects for the production capacity of energy dense liquid hydrocarbons using renewable gasolineenergy and jet fuelour proprietary technology; and other related products that can be made from isobutanol; (ii) completing the Company's development activities resulting in commercial production and salesachievement of renewable hydrocarbon products; (iii) obtaining adequate financing to complete the Company's development activities, including the build out of isobutanol and renewable hydrocarbon capacity; (iv) gaining market acceptance and demand for the Company's products and services; (v) attracting and retaining qualified personnel; and (vi) achieving a level of revenues adequate to support the Company'sits cost structure.

 

COVID-19.COVID-19. The novel coronavirus ("COVID-19"COVID-19") pandemic has had an adverse impact on global commercial activity, including the global transportation industry and its supply chain, and has contributed to significant volatility in the financial markets. It resulted in travel restrictions and extended shutdowns of businesses in various industries including, among others, the airline industry, and significantly reduced overall economic output. It is possible that that the impact of the COVID-19 pandemic on general economic activity could continue to negatively impact the Company's revenue and operating results for the remainder of 2021 and beyond. In light of the current and potential future disruption to the Company'sits business operations and those of its customers, suppliers and other third parties with whom the Company does business, the Companymanagement considered the impact of the COVID-19COVID-19 pandemic on its business. This analysis considered the Company's resilience and continuity plans, financial modeling and stress testing of liquidity and financial resources.

business. The Company expects that the impact of the COVID-19COVID-19 pandemic on general economic activitythe global transportation industry could negatively impact its revenuecontinue to result in less demand for the Company's transportation fuel products, which could have a material adverse effect on the Company's business, financial condition and operating resultsprospects for the foreseeable future.

During the first quarter of 2020, we suspended our ethanol production at leastour Luverne Facility due to COVID-19 and an unfavorable commodity environment, largely the remainderresult of 2020 and beyond.greater corn costs as compared to national markets than the region has historically produced. The suspension of ethanol production at the Company's Luverne Facility and a reduction in the Company's workforce that occurred during the first quarter of 2020 due to the impact of COVID-19COVID-19 had an adverse impact on the Company’sCompany's financial results for the third quarter of 2020 nine months ended September 30, 2021, reducing revenue by 97%87% compared to the same periodnine months ended September 30, 2020. The change in 2019. The Company expects thatrevenue for the suspension of ethanol production atthree months ended September 30, 2021 was negligible compared thethree months ended September 30, 2020. The Luverne Facility re-commenced operations during July 2021 and reduction in workforceis expected to produce isobutanol that will allow itbe used as a feedstock for us to continueproduce SAF and renewable premium gasoline to reduce its cash burn during 2020.

With many of the Company’s employees working remotely, the Company faces the risk that unusual working arrangements could impact the effectiveness of its operations or controls. A potential COVID-19 infection of any of its key employees could materially and adversely impact its operations. In addition, it is possible that COVID-19 restrictions could create difficulty for satisfying the Company’s legal or regulatory filing or other obligations, including with the SEC and other regulators.

8

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

fulfill existing sales contracts. There is also a risk that the COVID-19 pandemicCOVID-19 could continue to have a material adverse impact on the development of the Company's Net-Zero 1 Project, customer demand and cash flow, fordepending on the remainderextent of 2020 and beyond. The Company will continue to monitor the situation and assess possible implications to the Company's business and its stakeholders and will take appropriate actions to help mitigate adverse consequences. The extent to which COVID-19 continues to impact the Company's business and financial position will depend onour future developments, which are difficult to predict, including the severity, duration and scope of the COVID-19 outbreak as well as the types of measures imposed by governmental authorities to contain the virus or address its impact and the duration of those actions and measures.production activities.

 

The Company has considered multiple scenarios, with both positive and negative inputs, as part of the significant estimates and assumptions that are inherent in its financial statements and are based on trends in customer behavior and the economic environment throughout the quarterthree and nine months ended September 30, 2020 2021 and beyond as the COVID-19COVID-19 pandemic has impacted the industries in which the Company operates. These estimates and assumptions include the collectability of billed and unbilled receivables and the estimation of revenue and tangible and intangible assets. With regard to collectability, the Company believes it may face atypical delays in client payments going forward, but the Company has not experienced significant delays in collection as of September 30, 2020.2021. In addition, management believes that the demand for certain discretionary lines of business may decrease, and that such decrease will impact its financial results in succeeding periods. Non-discretionary lines of business may also be adversely affected, for example because reduced economic activity or disruption in hydrocarbon markets reducescould reduce demand for or the extent of renewable alcohol-to-jet fuel (“ATJ”),SAF, isooctane and isooctene. The Company believes that these trends and uncertainties are comparable to those faced by other registrants as a result of the COVID-19 pandemic.

 

In response

9

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

Basis of Presentation. The unaudited consolidated financial statements of the Company (which include the accounts of its wholly-owned subsidiaries Gevo Asset, LLC, Gevo RNG Holdco, LLC, Gevo NW Iowa RNG, LLC ("Gevo RNG"), Gevo Net-Zero HoldCo, LLC, Gevo Net-Zero 1, LLC, and Agri-Energy, LLC (“Agri-Energy”)) have been prepared, without audit, pursuant to the impactrules and regulations of the COVID-19 pandemic, eachU.S. Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all information and footnotes required by accounting principles generally accepted in the United States (“GAAP”) for complete financial statements. These statements reflect all normal and recurring adjustments which, in the opinion of Patrick R. Gruber,management, are necessary to present fairly the Company's Chief Executive Officer, Christopher M. Ryan,financial position, results of operations and cash flows of the Company's President, Chief Operating Officer and Chief Technology Officer, L. Lynn Smull, the Company's Chief Financial Officer, Timothy J. Cesarek, the Company's Chief Commercial Officer, Geoffrey T. Williams, Jr., the Company's General Counsel and Secretary, and Carolyn M. Romero, the Company's Vice President - Controller and Principal Accounting Officer (collectively, the “Officers”) accepted 20% reductions to their base salaries. These reductions became effectiveCompany as of, and for the three and nine months ended, September 30, 2021 and are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included under the heading “Financial Statements and Supplementary Data” in Part II, Item 8 of the Company’s Annual Report on Form 10-K for the year ended December 31,2020.

Reclassifications. The Company reclassified certain prior period amounts to conform to the current period presentation, including the categorization of preliminary stage project costs on the Consolidated Statements of Operations. These reclassifications had no impact on total revenues, total cost of goods sold, total operating expenses, net loss or stockholders' equity for any period.

January 2021Offering. On January 19, 2021, the Company completed a registered direct offering pursuant to a securities purchase agreement withcertain institutional and accredited investors providing for the issuance and sale by the Company of an aggregate of 43,750,000 shares of the Company’s common stock at a price of $8.00 per share (the “January 2021 Offering”). The net proceeds to the Company from the January 2021 Offering were approximately $321.9 million, after deducting placement agent fees and other estimated offering expenses payable by the Company.

At-the-Market Offering Program. In February 2018, the Company commenced an at-the-market offering program, which allows it to sell and issue shares of its common stock from time-to-time. In September 2021, the at-the-market offering program was amended to increase the available capacity to $500 million.

During the nine months ended September 30, 2021, the Company issued 24,420,579 shares of common stock under the at-the-market offering program for total proceeds of $135.8 million, net of commissions and other offering related expenses totaling $3.6 million. There were 0 shares issued during the three months ended September 30, 2021.

As of September 30, 2021, the Company has remaining capacity to issue up to approximately $500 million of common stock under the at-the-market offering program.  

2021 Bonds. On April 1, 202015, 2021, the Iowa Finance Authority (the “Authority”) issued an aggregate principal amount of $68,155,000 of its Solid Waste Facility Revenue Bonds (Gevo NW Iowa RNG, LLC Renewable Natural Gas Project), Series 2021 (Green Bonds) (the “2021 Bonds”) in a public offering for the benefit of Gevo RNG (as defined below), a subsidiary of Gevo, to finance the construction of the Gevo RNG project.

The 2021 Bonds are reported at their amortized cost. The 2021 Bonds were issued at a premium of $0.8 million. Debt issuance costs totaled $3.0 million. The Company will amortize the debt issuance costs and continued until July 31, 2020. Inthe premium as a component of interest expense over the life of the related debt instrument using the interest method. The 2021 Bonds have been recorded as a long-term liability and will become current on the earlier of (i) one year prior to the Initial Mandatory Tender Date or (ii) upon the Company’s exercise of its call option to tender or redeem the Bonds. See Note 9, Debt, for further information.

Debt Issue Costs and Debt Discounts/Premiums. Debt issue costs are costs with third parties incurred in connection with the 20% salaryCompany’s debt financings that have been capitalized and are being amortized over the stated maturity period or estimated life of the related debt using the effective interest method. Debt issue costs are presented as a direct reduction of the Officers were granted Company common stockcarrying amount of the related debt. Debt discounts, including fees paid to lenders, and debt premiums are amortized over the life of the related debt using the effective interest method. Debt discounts and premiums are presented as a reduction and increase, respectively, in the formcarrying amount of restricted stock awardsthe related debt. Amortization of debt issue costs, discounts, and premiums is included in an amount equal to the 20% reduction. Certain remaining employees that earn above a certain dollar threshold also agreed to take a 20% salary reduction through July 31, 2020, with the 20% portion to be paid in the form of restricted stock awards.interest expense.

 

New Contracts. As previously disclosed, Gevo and Praj Industries Ltd. (“Praj”) entered into a Construction License Agreement (“CLA”) effective April 4, 2019, a Joint Development Agreement, effective as of April 1, 2018 (as amended, the “Feedstock JDA”) and a Development License Agreement, effective as of April 1, 2018. On August 13, 2020, the Company and Praj entered into a Master Framework Agreement (the “MFA”) to collaborate on providing renewable jet fuel and premium gasoline in India and neighboring countries which replaced the CLA.

Pursuant to the licenses granted by the Company to Praj under the MFA, Praj has exclusive rights to cause the Company to enter into negotiations with third-parties (each, a “Plant Operator”) that own or operate refineries for the production of Biobutanol (defined in the MFA), including conversion of ethyl alcohol to Biobutanol or for the production of isooctane, jet fuel and/or similar hydrocarbons (the “Hydrocarbon Transportation Fuel”) either in the Territory (as defined in the MFA) or who are named on the Plant List (as defined in the MFA). The MFA allows Praj to provide services (such as basic engineering and design package, supply of critical equipment, supervision services, engineering, procurement and construction services and additional related services) (the “Services”) to the applicable Plant Operator for (a) production of Biobutanol from juice, syrup, and/or molasses from sugarcane, beets, bagasse, rice straw, wheat straw or corn stover, and other additional feedstocks using the process design package developed under the Feedstock JDA and (b) for the production of Hydrocarbon Transportation Fuel using the Hydrocarbon PDPs (as defined in the MFA) for the conversion of Biobutanol to Hydrocarbon Transportation Fuel. Praj has no rights to commercially produce Biobutanol or otherwise convert Biobutanol to Hydrocarbon Transportation Fuel under the MFA.

 

910

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

Restricted Cash and Restricted Cash Equivalents. The Company’s restricted cash and restricted cash equivalents consists of unused proceeds from the issuance of the 2021 Bonds which are restricted for the purpose of constructing the Gevo NW Iowa RNG, LLC Renewable Natural Gas Project as well as amounts pledged and assigned to Citibank, N.A., in its capacity as credit facility provider of the 2021 Bonds (the "Credit Facility Provider") as collateral for the reimbursement obligations of Gevo. As of September 30, 2021, the unused restricted bond proceeds of $48.8 million included in restricted cash is classified as current since the proceeds will be distributed within twelve months. As of September 30, 2021, the restricted collateral included in restricted cash totaled $71.2 million, $1.0 million of which secures interest payments to be made within twelve months and is classified as current. The Company willis entitled to receive certain finder’s feesinterest income on the restricted cash at an agreed rate of return of 0.10% but has no ability to direct the use of the restricted cash. See Note 9, Debt, for further information.

The proceeds from issuance of the 2021 Bonds are maintained by the Trustee under a Trust Indenture dated April 15, 2021 and released to the Company only to pay costs of the construction of the biogas facility operated by Gevo RNG. See Note 9, Debt, for further information on the Trust Indenture. As the proceeds of the 2021 Bonds are restricted, the amounts from bond trustee are also considered to be restricted cash. Restricted cash is included with cash and cash equivalents on the Statements of Cash Flows. 

The restricted cash held by the bond trustee as set forthof September 30, 2021 is made up of the following (in thousands):

  

September 30, 2021

 
     

Bond proceeds

 $68,995 

Disbursement of funds

  (20,005

)

Interest paid on bonds

  (216)

Interest income

  10 
     
Total restricted cash held by bond trustee $48,784 

Marketable Securities. The Company’s marketable securities consist of marketable debt securities and have been classified and accounted for as available-for-sale. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company classifies its marketable securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable securities with maturities of 12 months or less are classified as short-term and marketable securities with maturities greater than 12 months are classified as long-term. The Company’s marketable securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive income in shareholders’ equity, with the exception of unrealized losses believed to be other-than-temporary, which are reported in earnings in the MFAcurrent period. The cost of securities sold is based upon the specific identification method. Interest receivable related to the extent onemarketable securities of $1.5 million was included within prepaid expenses and other current assets on the accompanying Consolidated Balance Sheets as of September 30, 2021.

Leases, Right-of-Use Assets and Related Liabilities. The Company enters into various arrangements which constitute a lease as defined by ASC 842,Leases, as part of its ongoing business activities and operations. Leases represent a contract or part of a contract that conveys the right to control the use of identified property, plant or equipment (an identified asset) for a period of time in exchange for consideration. Such contracts result in both (a) right-of-use assets, which represent the Company’s right to use an underlying asset for the term of the contract; and (b) a corresponding lease liability which represents the Company’s third party licensees (a)obligation to make the lease payments arising from the contract. The Company has elected not to recognize a right-of-use asset and lease liability for any lease with an original lease term of 12 months or less. Lease expense for such leases is not previously identified inrecognized on a straight-line basis over the various agreementslease term.

A lease is classified as a finance lease when one or not located in certain specified areas, (b) uses Praj’s enfinity Technology (as defined inmore of the MFA) in concert withfollowing criteria are met: (1) the Feedstock PDP and (c)lease transfers ownership of the constructed facilities are of a certain commercial scale. The MFA contains customary representations, warranties and covenants, indemnification provisions and other terms. The MFA will continue in effect for 10 years, unless earlier terminatedasset by either party as set forth in the MFA, and automatically renews for additional one year terms until terminated or either party provides at least 30 days’ notice prior to the end of the current term. If Praj failslease term, (2) the lease contains an option to fully commission Authorized Plants (as defined inpurchase the MFA) withasset that is reasonably certain to be exercised, (3) the cumulative capacity to generate five million gallons per year of Biobutanol or Hydrocarbon Transportation Fuel by the fifth contract year, the exclusive license grants will terminate (unless otherwise mutually agreed in writing by the parties).

On August 14, 2020, Gevo entered intolease term is for a Renewable Hydrocarbons Purchase and Sale Agreement (the “Agreement”) with Trafigura Trading LLC (“Trafigura”), whereby the Company agreed to supply renewable hydrocarbons to Trafigura. The initial termmajor part of the Agreement is 10 years, and Trafigura has the option to extend the initial term. Performance under the Agreement is subject to certain conditions as set forth below, including acquiring a production facility to produce the renewable hydrocarbon products contemplated by the Agreement and closing a financing transaction for sufficient funds to acquire and retrofit the production facility contemplated by the Agreement.

If the Company does not provide to Trafigura the design, capabilities (including the expected annual production capacity), specifications, required governmental authorizations, delivery logistics and location of an additional new project that the Company plans to develop or acquire (the “Production Facility”) (collectively, the “Facility Design”) to meet the requirements set forth in the Agreement on or before December 31, 2020, either party may terminate the Agreement. The parties respective obligations under the Agreement are also subject to certain Conditions Precedent (as defined in the Agreement), including, but not limited to, the Company securing initial financing for the constructionremaining useful life of the Production Facility, andasset, (4) the Company having entered into engineering, procurement, and construction agreements for the constructionpresent value of the Production Facility, in form and substance reasonably satisfactory to the Company.

Subject to the satisfactionlease payments equals or waiver ofexceeds substantially all of the Conditions Precedent,fair value of the Companyasset, and (5) the asset is requiredof such a specialized nature that it is expected to have no alternative use commercially reasonable efforts to cause the “Commercial Operations Date”lessor at the end of the lease term. If a lease does not meet any of these criteria, the lease is classified as an operating lease.

Lease liabilities are initially measured at the lease commencement date based on the present value of lease payments over the lease term, discounted using an estimate of the Company’s incremental borrowing rate for a collateralized loan with the same term and payment as the lease. Right-of-use assets are measured based on the amount of the lease liability adjusted for any lease payments made to occur onthe lessor at or before the lease commencement date less any lease incentives received. All right-of-use assets are evaluated for impairment in accordance with accounting standards applicable to long-lived assets as further described in the significant accounting policy “Impairment of Property, Plant and Equipment” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The Commercial Operations Date will be2020.

Renewal options are included in the date on whichcalculation of our right-of-use assets and lease liabilities when the CompanyCompany’s determines that the production facilityoption is capablereasonably certain of consistently producing renewable hydrocarbons conforming to specification and in quantities set forth under the Agreement, provided that the expected annual production capability is at least equal to 85%exercise based on an analysis of the annual production capability contemplated by the Facility Design. If the Commercial Operations Date has not taken place on or before December 31, 2023 (as may be adjusted in accordance with the Agreement), then the Company will be required to pay Trafigura certain liquidated damages.

Restructuring Expenses. During the first quarter of 2020, the Company suspended its ethanol production at the Luverne Facility. In addition, due to the impactrelevant facts and circumstances. Certain of the COVID-19 pandemicCompany’s leases require variable lease payments that do not depend on an index or rate and such payments are excluded from the global economycalculation of the right-of-use asset and the Company’s industry, in March 2020, the Company reduced its workforce, impacting 26 people at the Luverne Facilitylease liability and four people at the Company's corporate headquarters. Affected employees were offered a severance package which included a one-time payment, one month of health insurance and acceleration of vesting for any unvested restricted stock awards.are recognized as variable lease cost when incurred.

 

The Company incurred $0.1 million relatedhas elected the practical expedient to severance costsaccount for the lease and $0.2 million related tonon-lease components as a single lease agreementscomponent for which it will no longer receive value duringour dairy lease and fuel supply asset class. This results in a significantly higher right-of-use assets and lease liabilities than if the nine months ended September 30, 2020, which are recordedCompany had not elected this practical expedient.

Lease cost for operating leases consists of the fixed lease payments recognized on a straight-line basis over the lease term plus variable lease payments as Restructuring expensesincurred. Lease cost for finance leases consists of amortization of the right-of-use assets on a straight-line basis over the lease term, interest expense on the Consolidated Statements of Operations. Restructuring expense totaled $0.02 millionlease liability, and $0.3 million for Gevo and Gevo Development/Agri-Energy segments, respectively, during the nine months ended September 30, 2020.variable lease payments as incurred.


 

1011

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

Intangible assets. Intangible assets consist primarily 

The Company intends to continue developing its hydrocarbon business, including the planned expansion of the Luverne Facility, and the Company expects to move forward in securing the project funding needed to expand the Luverne Facility. The expansion is designed to allow the Company to produce large quantities of low carbon isobutanol, sustainable aviation fuel and renewable isooctane. The Company also expects to continue engineering efforts for the expansion of isobutanol production and the construction of a commercial renewable hydrocarbon production facility, as well as additional decarbonization projects, at the Luverne Facility.

As of September 30, 2020, the Company had the following liabilities outstandingpatents. Costs related to patents, including legal fees, are capitalized and amortized over the restructuring expensesestimated useful lives using the straight-line method. Amortization expense is recorded in "Research and development expense" in the Consolidated Statements of Operations. For patents purchased in an asset acquisition, the useful life is determined by valuation estimates of remaining economic life. Intangible assets are included in "Accounts payable""Deposits and accrued liabilities"other assets" in the Consolidated Balance Sheets:Sheets.

The Company periodically evaluates the amortization period and carrying value of its patents to determine whether any events or circumstances warrant revised estimated useful life or reduction in value.

On September 21, 2021, the Company entered into an asset purchase agreement with Butamax Advanced Biofuels LLC and its affiliate, Danisco US Inc. (collectively, “Butamax”), pursuant to which the Company purchased all of Butamax’s rights, title and interests in certain U.S. and foreign patents and patent applications, subject to specified conditions and encumbrances, relating to the production, recovery and use of biobutanol that were owned by Butamax, for $9.0 million. Management evaluated the patents to determine whether the patents (i) supported current products; (ii) supported planned research and development (iii) prevent others from competing with Gevo's products. The Company used a valuation of the investment value of the patent portfolio performed in July 2021 to determine the relative fair value of the patents acquired. Based on the Company's estimated purchase price allocation, approximately $4.2 million of the purchase price was allocated to the purchase of patents to support current products and planned product research and $4.8 million for patents purchased for defensive purposes.  The patents are included in the Gevo Segment.

Identifiable intangible assets as of September 30, 2021 comprised the following (in thousands):

  September 30, 2021 
  

Gross Carrying Amount

  

Accumulated Amortization

  

Identifiable Intangible Assets, Net

  

Weighted-Average Useful Life (Years)

 

Finite-lived intangible assets:

                

Patents

 $4,496  $(202) $4,294   7.3 

Defensive assets

  4,804   0   4,804   8.4 
                 

Identifiable intangible assets

 $9,300   $(202)  $9,098   7.9 

  December 31, 2020 
  

Gross Carrying Amount

  

Accumulated Amortization

  

Identifiable Intangible Assets, Net

  

Weighted-Average Useful Life

 

Finite-lived intangible assets:

                

Patents

 $300  $(186) $114   5.2 

 

  

December 31, 2019

  

Additions

  

Payments

  

September 30, 2020

 
                 

Severance (including payroll taxes)

 $  $96  $(96) $ 

Lease agreements

     158   (158)   
                 

Total

 $  $254  $(254)  $ 
12

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

The following table details the estimated net amortization of identifiable intangible assets as of September 30, 2021 (in thousands):

Year Ending December 31,

 

Patents

 

Defensive Assets

 

Total

          

2021 (remaining)

 $147 $144 $291

2022

  601  575  1,176

2023

  601  575  1,176

2024

  601  575  1,176

2025

  601  575  1,176

2026 and thereafter

  1,743  2,360  4,103
          

Total

 $4,294 $4,804 $9,098

Total amortization of intangible assets was less than $0.1 million for the three and nine months ended September 30, 2021 as well as for the three and nine months ended September 30, 2020. 

Capitalized Internal-Use Software Costs. Software development costs are capitalized when module development begins, it is probable that the project will be completed, and the software will be used as intended. Costs associated with preliminary project stage activities, training, maintenance and all other post implementation stage activities are expensed as incurred. Internal-use software is amortized on a straight-line basis, generally over a three to five years. We evaluate the useful lives of these assets on an annual basis and test for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. 

Borrowing Costs. The borrowing costs that are directly attributable to acquisition and construction of an asset that needs a substantially long period of time for its intended use commence to be capitalized and recorded as part of the cost of the asset when expenditures for the asset and borrowing costs have been incurred, and the activities relating to the acquisition and construction that are necessary to prepare the asset for its intended use have commenced. The capitalization of borrowing costs ceases when the asset under acquisition or construction becomes ready for its intended use and the borrowing costs incurred thereafter are recognized in profit or loss for the current period. Capitalization of borrowing costs is suspended during periods in which the acquisition or construction of an asset is interrupted abnormally and the interruption lasts for more than 3 months, until the acquisition or construction is resumed. Total interest of $0.8 million and $1.5 million was incurred during the three and nine months ended September 30, 2021, respectively. Interest of $0.4 million and $0.8 million relating to our borrowings, and interest of $0.3 million and $0.6 million relating to certain of our finance leases, was capitalized for the three and nine months ended September 30, 2021, respectively. Total interest of $0.5 million and $1.6 million was incurred and charged to expense during the three and nine months ended September 30, 2020, respectively.

Preliminary Stage Project Costs. Preliminary stage project costs consist of research and development expense in addition to selling, general and administrative expenses related to our Gevo RNG and Net-Zero projects.

Income Taxes. There is 0 provision for income taxes because the Company has incurred operating losses since inception.

Concentration of Business Risk. As of September 30, 2021, two customers, Oil & Octane and KLM Commodities LLC ("KLM") comprised approximately 61% and 38%, or approximately 98% in total, of the Company's outstanding trade accounts receivable, respectively. As of December 31,2020, HCS Group GmbH ("HCS") comprised approximately 79% of the Company's outstanding trade accounts receivable.

For the three months ended September 30, 2021, HCS, New Vision, LLC ("New Vision") and KLM accounted for approximately 66%, 17% and 11%, or approximately 94% in total, of the Company's consolidated revenue, respectively. For the three months ended September 30, 2020, Coryton Advanced Fuels Ltd ("Coryton") and Total Petrochemicals & Refining USA, Inc. ("Total") accounted for approximately 52% and 39%, or approximately 91% in total, of the Company's consolidated revenue, respectively. For the nine months ended September 30, 2021, HCS, New Vision and Titan Aviation Fuel ("Titan") accounted for approximately 57%, 26% and 10%, or approximately 93% in total, of the Company's consolidated revenue, respectively. For the nine months ended September 30, 2020, Eco-Energy, LLC ("Eco-Energy"), Purina Animal Nutrition, LLV ("Purina") and HCS accounted for approximately 57%, 17% and 15%, or approximately 89% in total, of the Company's consolidated revenue, respectively. 

Total, HCS, KLM, Coryton and Titan are customers of the Company's Gevo segment. Juhl, New Vision, Eco-Energy and Purina are customers of the Company's Agri-Energy segment (see Note 14).

13

Financial Condition. The Company has incurred consolidated net losses since inception and had a significant accumulated deficit as of September 30, 2020. 2021. The Company’s cash and cash equivalents totaled $16.2 million, restricted cash totaled $120.0 million and marketable securities totaled $386.2 million as of September 30, 2020 totaled $80.6 million2021. Gevo expects to use its cash, cash equivalents, restricted cash and are expected to be usedmarketable securities for the following purposes: (i) identification, development, of the Luverne Facility expansion plan; (ii) identificationacquisition and construction of new production facilities and to plan for expanded production to fulfill existing off-take agreements;agreements, including the Company's Net Zero Projects; (ii) investment in the Gevo NW Iowa RNG facility; (iii) development of the Luverne Facility; (iv) development, acquisition and operation of sustainable ethanol-to-SAF plants to produce SAF alone or with partners;  (v) operating activities at the Company’s corporate headquarters in Colorado, including research and development work; (iv) development projects associated with the Company's RNG projects; (v)(vi) exploration of strategic alternatives and additional financings, including project financing; and (vi)(vii) future debt service obligations.

 

The Company expects to incur future net losses as it continues to fund the development and commercialization of its product candidates. To date, the Company has financed its operations primarily with proceeds from issuance of equity and debt securities, borrowings under debt facilities and product sales. The Company’s transition to profitability is dependent upon, among other things, the successful development and commercialization of its product candidates, the development, acquisition and construction of additional production facilities to support that Company’s offtake agreement, the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability or positive cash flows,structure, and unless and until it does, the Company will continue to needability to raise capital to finance the development, acquisition and construction of additional capital.productions facilities. Management intends to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources, and it will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.

July 2020 Offering. On July 6, 2020, Gevo completed a public offering (the “July 2020 Offering”) of (i) 20,896,666 Series 1 units (the “Series 1 Units”)operations on acceptable terms, or at a price of $0.60 per Series 1 Unit, and (ii) 9,103,334 Series 2 units (the “Series 2 Units”)all. Management believes it has adequate cash to fund operations for at a price of $0.59 per Series 2 Unit. The July 2020 Offering was made under a registration statement on Form S-1 filed with the Securities and Exchange Commission, declared effective on September 30, 2020.

Each Series 1 Unit consisted of least one share of the Company’s common stock and one Series 2020-A warrant to purchase one share of the Company’s common stock (each, a “Series 2020-A Warrant”). Each Series 2 Unit consists of a pre-funded Series 2020-B warrant to purchase one share of the Company’s common stock (each, a “Series 2020-B Warrant” and, together with the Series 2020-A Warrants, the “Warrants”) and one Series 2020-A Warrant. The Series 2020-A Warrants are exercisable beginning on the date of original issuance and will expire five years year from the date of issuance, at an exercise price of $0.60 per share. The pre-funded Series 2020-B Warrantsthe financial statements are exercisable beginning on the date of issuance at a nominal exercise price of $0.01 per share of common stock any time until the Series 2020-B Warrants are exercised in full. In connection with the July 2020 Offering, the Company issued Series 2020-A Warrants to purchase an aggregate of 30,000,000 shares of common stock. As of September 30, 2020, all of the Series 2020-B Warrants were exercised.issued.

 

11

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

The net proceeds to the Company from the July 2020 Offering were approximately $16.1 million, after deducting placement agent fees and other offering expenses payable by the Company, and not including any future proceeds from the exercise of the Warrants. The Company intends to use the net proceeds from the July 2020 Offering to fund working capital and for other general corporate purposes.

During the three months ended September 30, 2020, the Company received notices of exercise from holders of our Series 2020-A Warrants to issue an aggregate of 27,317,834 shares of common stock for total gross proceeds of approximately $16.4 million. Following these exercises, Series 2020-A Warrants to purchase 2,682,166 shares of the Company's common stock remain outstanding at an exercise price of $0.60 per share.

August 2020 Offering. On August 25, 2020, the Company completed a registered direct offering pursuant to a securities purchase agreement with certain institutional and accredited investors providing for the issuance and sale by the Company of an aggregate of (i) 21,929,313 shares of the Company’s common stock (the “Shares”) at a price of $1.30 per share, and (ii) 16,532,232 pre-funded Series 2020-C warrants to purchase one share of the Company’s common stock (each, a “Series 2020-C Warrant”) at a price of $1.29 per Series 2020-C Warrant, in a registered direct offering (the “August 2020 Offering”). The pre-funded Series 2020-C Warrants are exercisable beginning on the date of issuance at a nominal exercise price of $0.01 per share of common stock any time until the Series 2020-C Warrants are exercised in full.  As of September 30, 2020, all of the Series 2020-C Warrants were exercised.

The net proceeds to the Company from the August 2020 Offering were approximately $45.8 million, after deducting placement agent fees and other estimated offering expenses payable by the Company, and not including any future proceeds from the exercise of the Warrants. The Company intends to use the net proceeds from the August 2020 Offering to fund working capital and for other general corporate purposes.

The Company evaluated the Series 2020-A, Series 2020-B and Series 2020-C Warrants for liability or equity classification in accordance with the provisions of Accounting Standards Codification 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because neither the Series 2020-A, Series 2020-B or Series 2020-C Warrants met the definition of liability instruments.

The Warrants are classified as component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Warrants do not provide any guarantee of value or return. The Company valued the Series 2020-A, Series 2020-B and Series 2020-C Warrants at issuance using the Black-Scholes option pricing model and determined the fair value of the Series 2020-A, Series 2020-B and Series 2020-C Warrants to purchase the Company’s common stock at $8.3 million, $2.9 million and $21.4 million, respectively. The key inputs to the valuation model included a weighted average volatility of 130% to 141%, risk-free rate of 0.30% to 0.31% and an expected term of five years.

Conversion of 2020/21 Notes. On July 10, 2020, certain holders of the 2020/21 Notes converted $2.0 million in aggregate principal amount of 2020/21 Notes (including the conversion of an additional $0.3 million for make-whole payment) into an aggregate of 4,169,426 shares of common stock pursuant to the terms of the 2020/21 Indenture. The Company recorded a Loss on conversion of 2020/21 Notes of $0.5 million on its Consolidated Statements of Operations.

At-the-Market Offering Program. In February 2018, the Company commenced an at-the-market offering program, which allows it to sell and issue shares of its common stock from time-to-time. In August 2019, the at-the-market offering program was amended to provide available capacity under the at-the-market offering program of $10.7 million.

During the nine months ended September 30, 2020, the Company issued 1,343,121 shares of common stock under the at-the-market offering program for total proceeds of $2.2 million, net of commissions and other offering related expenses. No shares were issued under the at-the-market offering program during the three months ended September 30, 2020.

As of September 30, 2020, the Company has remaining capacity to issue up to approximately $6.5 million of common stock under the at-the-market offering program.

12

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

Basis of Presentation. The unaudited consolidated financial statements of the Company (which include the accounts of its wholly-owned subsidiaries Gevo Development, LLC (“Gevo Development”) and Agri-Energy, LLC (“Agri-Energy”)) have been prepared, without audit, pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all information and footnotes required by accounting principles generally accepted in the United States (“GAAP”) for complete financial statements. These statements reflect all normal and recurring adjustments which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows of the Company at September 30, 2020 and are not necessarily indicative of the results to be expected for the full year. These statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included under the heading “Financial Statements and Supplementary Data” in Part II, Item 8 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

Income Taxes. There is no provision for income taxes because the Company has incurred operating losses since inception.

Concentration of Business Risk.As of September 30, 2020, four customers, Coryton Advanced Fuels Ltd ("Coryton"), Total Petrochemicals & Refining USA, Inc. ("Total"), Eco-Energy, LLC ("Eco-Energy") and World Kinect Energy Services (" Kinect"), comprised approximately 27%, 20%, 14% and 12% of the Company's outstanding trade accounts receivable, respectively. As of December 31, 2019, three customers, Eco-Energy, Purina Animal Nutrition, LLC ("Purina"), and HCS Group GmbH ("HCS") comprised 57%, 13% and 15% of the Company's outstanding trade accounts receivable, respectively.

For the three months ended September 30, 2020, Coryton and Total accounted for approximately 52% and 39% of the Company's consolidated revenue, respectively. For the three months ended September 30, 2019, Eco-Energy and Purina represented approximately 73% and 16% of the Company's consolidated revenue, respectively. For the nine months ended September 30, 2020, Eco-Energy, Purina and HCS accounted for approximately 57%, 17% and 15% of the Company's consolidated revenue, respectively. For the nine months ended September 30, 2019, Eco-Energy and Purina accounted for approximately 73% and 16% of the Company's consolidated revenue, respectively. HCS, Coryton and Total Cray Valley are customers of the Company's Gevo segment. Eco-Energy and Purina are customers of the Company's Gevo Development/Agri-Energy segment (see Note 14).

Related Party Transaction. During the nine months ended September 30, 2020, Gevo paid Blocksize Capital GmbH ("Blocksize"), a company in which a director of Gevo has an indirect ownership interest, $0.1 million for block chain software development services. There were no amounts payable to Blocksize as of September 30, 2020.

13

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

2. Earnings Per Share

 

Basic earnings (loss) per share is computed by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share (“EPS”) includes the dilutive effect of common stock equivalents and is computed using the weighted-average number of common stock and common stock equivalents outstanding during the reporting period. Diluted EPS for the three and nine months ended September 30,, 20202021 and 20192020 excluded common stock equivalents because the effect of their inclusion would be anti-dilutive or would decrease the reported loss per share.

 

The following table sets forth securities outstanding that could potentially dilute the calculation of diluted earnings per share:

 

  

Three and Nine Months Ended September 30,

 
  2021  2020 
         

Warrants to purchase common stock - liability classified

  7,126   

52,032

 

Warrant to purchase common stock - equity classified

  90,608   2,682,166 
Conversion of 2020/21 Notes  0   5,789,209 

Outstanding options to purchase common stock

  4,670,279   1,552 
Stock appreciation rights  67,739   67,739 
         

Total

  4,835,752   8,592,698 

  

Three and Nine Months ended September 30,

 
  2020  

2019

 
         

Warrants to purchase common stock - liability classified

  52,032   54,989 

Warrant to purchase common stock - equity classified

  2,682,166    
Conversion of 2020/21 Notes  5,789,209    

Conversion of 2020 Notes

     997,914 

Outstanding options to purchase common stock

  1,552   1,564 
Stock appreciation rights  132,566   132,566 
         

Total

  8,657,525   1,187,033 

 

14

3. Revenues from Contracts with Customers and Other Revenues

 

The Company’s current and historical revenues have consisted of the following: (a) hydrocarbon revenue; (b) ethanol sales and related products revenue, net; (b) hydrocarbon revenue; and (c) grant and other revenue, which primarily has historically consistedconsists of revenues from governmental and cooperative research grants.

Ethanol sales and related products revenues. Ethanol sales and related products revenues are sold to customers on a free-on-board, shipping point basis. Revenue is recognized when the customer has control of the product. Each transaction occurs independent of any other sale, and once sold, there are no future obligations on the part of the Company to provide post-sale support or promises to deliver future goods or services.

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

Hydrocarbon revenue. Hydrocarbon revenues include sales of ATJ, isooctene and isooctane and is sold mostly on a free-on-board, shipping point basis. Revenue is recognized when the customer has control of the product. Each transaction occurs independent of any other sale, and once sold, there are no future obligations on the part of the Company to provide post-sale support or promises to deliver future goods or services.rental income.

 

The following table sets forth the components of the Company’s revenues between those generated from contracts with customers and those generated from arrangements that do not constitute a contract with a customer (in thousands):

 

 

Three Months Ended September 30, 2020

  

Three Months Ended September 30, 2021

 

Major Goods/Service Line

 

Revenues from

Contracts with

Customers

  

Other Revenues

  

Total

  

Revenues from

Contracts with

Customers

  

Other Revenues

  

Total

 
                      

Ethanol sales and related products, net

 $21  $  $21  $16  $0  $16 

Hydrocarbon revenue

  101      101  104  0  104 
Other revenue  70      70   0   22   22 
                        
 $192  $  $192  $120  $22  $142 

Timing of Revenue Recognition

                        

Goods transferred at a point in time

 $122  $  $122  $120  $(3) $117 

Services transferred over time

  70      70   0   25   25 
                        
 $192  $  $192  $120  $22  $142 

 

  

Three Months Ended September 30, 2019

 

Major Goods/Service Line

 

Revenues from

Contracts with

Customers

  

Other Revenues

  

Total

 
             

Ethanol sales and related products, net

 $5,554  $  $5,554 

Hydrocarbon revenue

  550      550 
Other revenue     6   6 
             
  $6,104  $6  $6,110 

Timing of Revenue Recognition

            
             

Goods transferred at a point in time

 $6,104  $  $6,104 

Services transferred over time

     6   6 
             
  $6,104  $6  $6,110 

  

Three Months Ended September 30, 2020

 

Major Goods/Service Line

 

Revenues from

Contracts with

Customers

  

Other Revenues

  

Total

 
             

Ethanol sales and related products, net

 $21  $0  $21 

Hydrocarbon revenue

  101   0   101 
Other revenue  70   0   70 
             
  $192  $0  $192 

Timing of Revenue Recognition

            

Goods transferred at a point in time

 $122  $0  $122 

Services transferred over time

  70   0   70 
             
  $192  $0  $192 

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

  

Nine Months Ended September 30, 2020

 

Major Goods/Service Line

 

Revenues from

Contracts with

Customers

  

Other Revenues

  

Total

 
             

Ethanol sales and related products, net

 $3,804  $  $3,804 

Hydrocarbon revenue

  1,085      1,085 

Other revenue

  116      116 
             
  $5,005  $  $5,005 

Timing of Revenue Recognition

            

Goods transferred at a point in time

 $4,889  $  $4,889 

Services transferred over time

  116      116 
             
  $5,005  $  $5,005 

  

Nine Months Ended September 30, 2021

 

Major Goods/Service Line

 

Revenues from

Contracts with

Customers

  

Other Revenues

  

Total

 
             
Ethanol sales and related products, net $16  $0  $16 

Hydrocarbon revenue

  463   0   463 
Other revenue  0   178   178 
             
  $479  $178  $657 

Timing of Revenue Recognition

            

Goods transferred at a point in time

 $479  $0  $479 

Services transferred over time

  0   178   178 
             
  $479  $178  $657 

  

Nine Months Ended September 30, 2020

 

Major Goods/Service Line

 

Revenues from

Contracts with

Customers

  

Other Revenues

  

Total

 
             

Ethanol sales and related products, net

 $3,804  $0  $3,804 

Hydrocarbon revenue

  1,085   0   1,085 
Other revenue  116   0   116 
             
  $5,005  $0  $5,005 

Timing of Revenue Recognition

            

Goods transferred at a point in time

 $4,889  $0  $4,889 

Services transferred over time

  116   0   116 
             
  $5,005  $0  $5,005 

 

  

Nine Months Ended September 30, 2019

 

Major Goods/Service Line

 

Revenues from

Contracts with

Customers

  

Other Revenues

  

Total

 
             

Ethanol sales and related products, net

 $16,184     $16,184 

Hydrocarbon revenue

  1,381      1,381 
Other revenue     34   34 
             
  $17,565  $34  $17,599 

Timing of Revenue Recognition

            
             

Goods transferred at a point in time

 $17,565  $  $17,565 

Services transferred over time

     34   34 
             
  $17,565  $34  $17,599 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

Goods transferred at a point-in-time. For the three and nine months ended September 30, 2020 and 2019, there were no contracts with customers for which consideration was variable or for which there were multiple performance obligations for any given contract. Accordingly, the entire transaction price is allocated to the goods transferred. As of September 30, 2020 and December 31, 2019, there were no remaining unfulfilled or partially fulfilled performance obligations.

All goods transferred are tested to ensure product sold satisfies contractual product specifications prior to transfer. The customer obtains control of the goods when title and risk of loss for the goods has transferred, which in most cases is “free-on-board, shipping point”. All material contracts have payment terms of between one to three months and there are no return or refund rights.

Services transferred over time. For the three and nine months ended September 30, 2020 and 2019, there were no contracts for which consideration was variable or for which there were multiple performance obligation for any given contract. Accordingly, the entire transaction price is allocated to the individual service performance obligation. As of September 30, 2020 and December 31, 2019, respectively, there were no material unfulfilled or partially fulfilled performance obligations.

Contract Assets and Trade Receivables. As of September 30, 2020 and December 31, 2019, there were no contract assets or liabilities as all customer amounts owed to the Company are unconditional and the Company does not receive payment in advance for its products. Accordingly, amounts owed by customers are classified as account receivables on the Company’s Consolidated Balance Sheets. In addition, due to the nature of the Company’s contracts, there are no costs incurred or to be paid in the future that qualify for asset recognition as a cost to fulfill or obtain a contract as of September 30, 2020 and December 31, 2019. The Company did not incur any impairment losses on any receivables as all amounts owed were paid or current as of September 30, 2020 or December 31, 2019.

4. Leases, Right-to-UseRight-of-Use Assets and Related Liabilities

 

The Company enters into various arrangements which constitute ais party to an operating lease as defined by Accounting Standards Codification ("ASC") 842, Leases, as part of its ongoing business activities and operations. Leases represent a contract or part of a contract that conveys the right to control the use of identified property, plant or equipment (an identified asset) for a period of time in exchange for consideration. Such contracts result in both (a) right-to-use assets, which represent the Company’s rightoffice and research facility in Englewood, Colorado, that expires in January 2029. The lease does not contain an option to use an underlying assetextend the lease that is reasonably certain to be exercised. All other operating leases qualified for the term ofshort-term scope exemption elected by the contract; and (b) a correspondingCompany. The Company recognizes rent expense on its operating lease liability which represents the Company’s obligation to make the lease payments arising from the contract, measured on a discountedstraight-line basis.

The contracts for the Company are comprised of facility, equipment and transportation leases necessary to conduct the Company’s day-to-day operations for which the Company maintains control of right-to-use assets and incurs the related liabilities. The facility lease includes variable payments for common area maintenance. In addition, the Company has one financingelected the practical expedient to not separate lease components from non-lease components for certain office equipment which isthese asset classes. As of September 30, 2021, right-of-use assets under operating leases totaling $1.6 million are included in "Loans payable - other"Operating right-of use assets," onand related lease liabilities totaling $1.7 million are included in "Operating lease liabilities (long-term)” in the Consolidated Balance Sheets.

 

There is one contractual agreementThe Company also has four finance leases for land under arrangements related to Gevo RNG. Under these contracts, the Company leases land from dairy farmers on which it is building three anaerobic digesters, related equipment improvementsand pipelines to condition raw biogas from cow manure provided by the farmers. The partially conditioned biogas will be transported from the three digester sites to a central gas upgrade system located at the Luverne Facilityfourth site that was not recognized as of September 30, 2020 as a result of operating contingencies which must be satisfied beforewill upgrade the biogas to pipeline quality natural gas for sale. These leases expire at various dates between 2031 and 2050. Certain leases provide the Company with the right to terminate the lease prior to the stated lease expiration date; however, the Company is obligated under the termsreasonably certain not to exercise such termination right and thus periods beyond this termination right have been recognized as part of the contract.Company’s right-of-use assets and lease liabilities. In addition, some of these leases include renewal periods that have been deemed to be reasonably certain to be exercised and as such have been recognized as part of the Company’s right-of-use assets and lease liabilities. The total estimated fair valueCompany has elected the practical expedient to not separate lease components from non-lease components for this dairy lease asset class and therefore, all amounts paid to the lessor under these arrangements for cow manure and nonlease services are classified as lease payments and included in the calculation of unrecognized right-to-use assetthe right-of-use assets and related lease liability relating toliabilities. This results in significantly higher right-of-use assets and lease liabilities than if the Company did not elect this contract was approximately $2.0 million aspractical expedient. As of September 30, 2020. There2021, right-of-use assets under finance leases totaling $27.7 million are two contractual agreements related to equipment improvements at the Luverne Facility that were not recognized as of December 31, 2019 as a result of operating contingencies which must be satisfied before the Company is obligated under the terms of the contract. The total estimated fair value of unrecognized right-to-useincluded in "Finance right-of-use assets," and related lease liabilities relating to these contracts was approximately $3.0totaling $22.3 million are included in the Consolidated Balance Sheets as follows: $2.7 million of December 31, 2019.lease liabilities included in "Finance lease liabilities (current) and $19.6 million included in "Finance lease liabilities (long-term)".

The Company leased its grain bins in Luverne, Minnesota in October 2020 through a short-term operating lease agreement which expired in July 2021. Rental income for the three and nine months ended September 30, 2021 totaled $0 and $0.2 million, respectively.

 

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

The following table presents the (a) costs by lease category and (b) other quantitative information relating to the Company’s leases (dollars in thousands):

 

 

Three Months Ended September 30,

  

Three Months Ended September 30,

  
 2020  

2019

  

2021

  

2020

  

Lease Cost

          

 

     
Financing lease cost $1  $ 
Finance lease cost:      
Amortization of right-of-use assets (1) $464  $0 
Interest on lease liabilities (2) 297  1  

Operating lease cost

  11   435  64  11  

Short-Term lease cost

  376   110  377  376  

Variable lease cost

  

36

   21 

Variable lease cost (3)

  94   36  
         

Total lease cost

 $424  $566  $1,296  $424  

  

Nine Months Ended September 30,

 
  

2021

  

2020

 

Lease Cost

  

 

     
Finance lease cost:        
Amortization of right-of use assets (1) $930  $1 
Interest on lease liabilities (2)  627   2 

Operating lease cost

  192   545 

Short-Term lease cost

  1,003   556 

Variable lease cost (3)

  164   108 
         

Total lease cost

 $2,916  $1,212 

(1)Amortization of right-of-use assets of $0.4 million and $0.9 million were capitalized as part of construction in progress during the three and nine months ended September 30, 2021, respectively, and included in "Property, plant and equipment, net" in the Consolidated Balance Sheets as the related Gevo RNG facilities are still under construction. 
(2)Interest on lease liabilities of $0.3 million and $0.6 million were capitalized as part of construction in progress during the three and nine months ended September 30, 2021, respectively, and included in "Property, plant and equipment, net" in the Consolidated Balance Sheets as the related Gevo RNG facilities are still under construction. 
(3)Represents amounts incurred in excess of minimum payments, including payments for common area expenses under our office and research facility lease, and additional amounts due under our Gevo RNG leases based on the number of cows maintained by the owners of the respective facilities.

  Nine Months Ended September 30 
  2021  2020 

Other Information

        

Cash paid for amounts included in the measurement of lease liabilities:

        
Operating cash flows from finance leases $627  $2 

Operating cash flows from operating leases

  192   545 
Finance cash flows from finance leases  5,975   1 
Right-of-use asset obtained in exchange for new finance lease liabilities  28,416   13 
Right-of-use asset obtained in exchange for new operating lease liabilities  1,611   0 
Weighted-average remaining lease term, finance lease (months)  225   53 

Weighted-average remaining lease term, operating leases (months)

  88   10 
Weighted-average discount rate - finance leases (3)  5%   21% 

Weighted-average discount rate - operating leases (3)

  5%   12% 

(3)The discount rate used for operating leases is based on our implicit borrowing rate ("IBR") at the date the Company entered into the lease. The Company estimated the IBR based collateralized borrowings for similar terms and payments.

 

  

Nine Months Ended September 30,

 
  

2020

  

2019

 

Lease Cost

  

 

     
Financing lease cost $

3

  $ 

Operating lease cost

  545   1,166 

Short-Term lease cost

  556   315 

Variable lease cost

  108   86 
         

Total lease cost

 $1,212  $1,567 
         

Other Information

        

Cash paid for the measurement of lease liabilities:

        
Operating cash flows from finance lease $2  $ 

Operating cash flows from operating leases

  545   1,166 
Finance cash flows from finance lease  1    
Right-to-use asset obtained in exchange for new financing lease liability  13    
Weighted-average remaining lease term, financing lease (months)  53    

Weighted-average remaining lease term, operating leases (months)

  10   22 
Weighted-average discount rate - financing lease  21%    

Weighted-average discount rate - operating leases

  12%   12% 
17

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

The table below shows the future minimum payments under non-cancelable financing and operating leases at September 30, 2020 (in2021 (in thousands):

 

Year Ending December 31,

 

Financing Leases

  

Operating Leases

  

Operating Leases

  

Finance Leases

 
         

2020 (remaining)

 $1  77 

2021

  4   180 

2021 (remaining)

 $

(241

) $

1,950

 

2022

  4     265  3,800 
2023  4     297  1,708 
2024 and thereafter  5    
2024 305  1,725 
2025 315  1,738 
2026 and thereafter  1,030   21,636 

Total

  18   257  1,971  

32,557

 

Less: Amounts representing present value discounts

  (6) 

(10

)  (374) 

(10,232

)
         

Total lease liabilities

  12  

247

  1,597 22,325 
Less: current portion  135  (2,727)
Long-term portion $1,732 $19,598 

 

18

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

5. Inventories

 

The following table sets forth the components of the Company’s inventory balances (in thousands):

 

 

September 30,

  

December 31,

  

September 30,

 

December 31,

 
 

2020

  

2019

  

2021

  

2020

 

Raw materials

             

Corn

 $  $267  $237  $0 

Enzymes and other inputs

  136   184  171  133 
Nutrients 1 

1

 
Palladium 267 235 
Work in process 55 5 

Finished goods

             
Jet Fuels, Isooctane and Isooctene 881  571 
Isobutanol   135  36  0 

Ethanol

     93 

Distiller's grains

     54 

Work in process

      

Agri-Energy

     254 

Gevo

  29   122 
SAF, Isooctane and Isooctene 211  756 

Spare parts

  1,505   1,521   1,363   1,361 
                

Total inventories

 $2,551  $3,201  $2,341  $2,491 

 

Work in process inventory includes unfinished jet fuel,SAF, isooctane and isooctene inventory.

 

During the three months and nine months ended September 30, 2021, the Company recorded an expense for lower of cost or market of $1.2 million and $2.0 million, respectively. During the three months and nine months ended September 30, 2020, the company recorded an expense for lower of cost or market of $0.4 million and $0.4 million, respectively, as a result of restarted production of isobutanol at the Luverne Facility.

1918

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

 

6. Property, Plant and Equipment

 

The following table sets forth the Company’s property, plant and equipment by classification (in thousands):

 

 

Useful Life

  

September 30,

  

December 31,

  

Useful Life

 

September 30,

 

December 31,

 
 

(in years)

  

2020

  

2019

  

(in years)

  

2021

  

2020

 
                          
Luverne retrofit asset  20   $70,820  $70,820   20   $

70,820

  $70,820 

Plant machinery and equipment

  10    17,374   17,413   10    17,949   17,374 

Site improvements

  10    7,157   7,054   10   7,157  7,157 

Lab equipment, furniture and fixtures and vehicles

  5    6,396   6,393   5   6,935  6,396 

Demonstration plant

  2    3,597   3,597   2   3,597  3,597 

Buildings

  10    2,543   2,543   

10

   2,543  2,543 

Leasehold improvements, pilot plant, land and support equipment

 2to5   2,523   2,523  2to7  2,523  2,523 
Computer, office equipment and software 3to6  2,021  2,034  3to6  2,240  1,983 
Construction in progress       8,909   7,710       51,033   13,132 
                      

Total property, plant and equipment

       121,340   120,087       

164,797

  125,525 

Less accumulated depreciation and amortization

       (58,016)  (53,391

)

       (62,634)  (59,117)
                          

Property, plant and equipment, net

      $63,324  $66,696       $102,163  $66,408 

Construction in progress includes $0.6 million for Gevo, $8.4 million for Agri-Energy, $36.0 million for Renewable Natural Gas and $6.0 for Net-Zero at September 30, 2021. Construction in progress includes $8.6 million for Agri-Energy and $4.5 million for Renewable Natural Gas (none for Gevo and Net-Zero) at December 31, 2020. Construction in progress is not subject to depreciation until the assets are placed into service. 

 

The Company recorded depreciation and amortization expense related to property, plant and equipment as follows (in thousands):

 

 

Three Months Ended September 30,

 

 

Three Months Ended September 30,

 

 

2020

 

2019

 

 

2021

  

2020

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

1,418 

 

$

1,578  $1,098  $1,418 

Operating expenses

 

 

52

 

 

30   96   52 

 

 

 

 

 

 

 

 

Total depreciation and amortization

 

$

1,470

 

$

1,608

 

 $1,194  $1,470 

 

 

Nine Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2020

 

2019

 

 

2021

  

2020

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

4,580 

 

$

4,697  $3,358  $4,580 

Operating expenses

 

 

158

 

 

92   198   158 

 

 

 

 

 

 

 

 

Total depreciation and amortization

 

$

4,738

 

$

4,789

 

 $3,556  $4,738 

 

 

19

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

 

7. Embedded Derivatives Liabilities 

2020 Notes Embedded Derivative

In June 2017, the Company issued its 12% convertible senior secured notes due 2020 (the “2020 Notes”) in exchange for its 12.0% convertible senior secured notes due 2017 (the “2017 Notes”). The 2020 Notes contained the following embedded derivatives: (i) a Make-Whole Payment (as defined in the indenture governing the 2020 Notes (the “2020 Notes Indenture”)) upon either conversion or redemption; (ii) right to redeem the outstanding principal upon a Fundamental Change (as defined in the 2020 Notes Indenture); (iii) issuer rights to convert into a limited number of shares in any given three-month period commencing nine months from the issuance date and dependent on the stock price exceeding 150% of the then in-effect conversion price over a ten-business day period; and (iv) holder rights to convert into either shares of the Company’s common stock or pre-funded warrants upon the election of the holders of the 2020 Notes.

Embedded derivatives are separated from the host contract and the 2020 Notes and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. The Company has concluded that certain embedded derivatives within the 2020 Notes meet these criteria and, as such, must be valued separate and apart from the 2020 Notes as one embedded derivative and recorded at fair value each reporting period.

The Company used a binomial lattice model in order to estimate the fair value of the embedded derivative in the 2020 Notes. A binomial lattice model generates two probable outcomes, whether up or down, arising at each point in time, starting from the date of valuation until the maturity date. A lattice was initially used to determine if the 2020 Notes would be converted by the holder, called by the issuer, or held at each decision point. Within the lattice model, the following assumptions were made: (i) the 2020 Notes will be converted by the holder if the conversion value plus the holder’s Make-Whole Payment is greater than the holding value; or (ii) the 2020 Notes will be called by the issuer if (a) the stock price exceeds 150% of the then in-effect conversion price over a ten-business day period and (b) if the holding value is greater than the conversion value plus the Make-Whole Payment at the time.

Using this lattice model, the Company valued the embedded derivative using a “with-and-without method”, where the value of the 2020 Notes including the embedded derivative were defined as the “with”, and the value of the 2020 Notes excluding the embedded derivative is defined as the “without”. This method estimates the value of the embedded derivative by comparing the difference in the values between the 2020 Notes with the embedded derivative and the value of the 2020 Notes without the embedded derivative. The lattice model requires the following inputs: (i) price of Gevo common stock; (ii) Conversion Rate (as defined in the 2020 Notes Indenture); (iii) Conversion Price (as defined in the 2020 Notes Indenture); (iv) maturity date; (v) risk-free interest rate; (vi) estimated stock volatility; and (vii) estimated credit spread for the Company.

2020/21 Notes Embedded Derivative

In January 2020, the Company issued 12% convertible senior secured notes due 2020/2021 (the “2020/21 Notes”) in exchange for its 12.0% convertible senior secured notes due March 2020 (the “2020 Notes”). The 2020/21 Notes contain the following embedded derivatives: (i) a Make-Whole Payment (as defined in the 2020/21 Notes Indenture (as defined below) upon either conversion or redemption in certain circumstances; (ii) holder right to require the Company to repurchase the outstanding principal upon a Fundamental Change (as defined in the 2020/21 Notes Indenture); and (iii) holder rights to convert into either shares of the Company’s common stock or pre-funded warrants upon the election of the holders of the 2020/21 Notes.

Embedded derivatives are separated from the host contract and the 2020/21 Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. The Company has concluded that certain embedded derivatives within the 2020/21 Notes meet these criteria and, as such, must be valued separate and apart from the 2020/21 Notes as one embedded derivative and recorded at fair value each reporting period.

The Company used a binomial lattice model in order to estimate the fair value of the embedded derivative in the 2020/21 Notes. Using this lattice model, the Company valued the embedded derivative using a “with-and-without method”.
GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

As of September 30, 2020 and December 31, 2019, the estimated fair value of the embedded derivatives was $0.03 million and $0, respectively. The Company recorded the estimated fair value of the embedded derivative with the 2020/21 Notes and 2020 Notes, net in the Consolidated Balance Sheets. The Company recorded a $0.2 million gain and a $0.03 million loss from the change in fair value of 2020/21 Notes embedded derivatives for the three and nine months ended September 30, 2020, respectively. The Company recorded a $0 and $0.4 million gain from the change in fair value of 2020 Notes embedded derivatives or the three and nine months ended September 30, 2019, respectively.
The following table sets forth the inputs to the lattice models that were used to value the embedded derivatives:
  September 30,  December 31, 
  

2020

  2019 
         

Stock price

 $1.00  $2.31 

Conversion Rate per $1,000

  409.50   67.95 

Conversion Price

 $2.44  $14.72 

Maturity date

 

December 31, 2020

  March 15, 2020 

Risk-free interest rate

  0.10%  1.52%

Estimated stock volatility

  247%  60%

Estimated credit spread

  36%  27%

Changes in certain inputs into the lattice model can have a significant impact on changes in the estimated fair value of the embedded featured within the 2020/21 Notes and 2020 Notes. For example, the estimated fair value will generally decrease with: (1) a decline in the stock price; (2) decreases in the estimated stock volatility; and (3) a decrease in the estimated credit spread.

 

Derivative Warrant Liability

 

The followingThere were no warrants were sold by the Company during the nine months ended September 30, 2020:

In July 2020, 2021. On September 13, 2021, the Company sold Series 2020-A Warrants to purchase 30,000,000 shares of the Company's common stock and Series 2020-B Warrants to purchase 9,103,334 shares of the Company's common stock, pursuant to an underwritten public offering.I warrants expired.

In August 2020, the Company sold Series 2020-C Warrants to purchase 16,532,232 shares of the Company's common stock, pursuant to a registered direct offering.

 

The following table sets forth information pertaining to shares issued upon the exercise of such warrants as of September 30, 2020:2021:

 

 

Issuance

Date

 

Expiration

Date

 

Exercise

Price as of

September 30,

2020

 

Shares

Underlying

Warrants on

Issuance Date

 

Shares Issued

upon Warrant

Exercises as of

September 30, 2020

 

Shares

Underlying

Warrants

Outstanding as of

September 30, 2020

 
                 

Series D Warrants

12/11/2015

 

12/11/2020

 $40.00  25,125  25,078  47 

Series F Warrants

04/01/2016

 

04/01/2021

 $40.00  25,733  11,692  14,041 

Series I Warrants

09/13/2016

 

09/13/2021

 $220.00  35,368    35,368 

Series K Warrants

02/17/2017

 

2/17/2022

 $2.00  311,236  308,660  2,576 
Series 2020-A Warrants (1)7/6/2020 7/6/2025 $0.60  30,000,000  27,317,834  2,682,166 
Series 2020-B Warrants (1)7/6/2020 7/6/2025 $0.01  9,103,334  9,103,334   
Series 2020-C Warrants (1)8/25/2020 8/25/2025 $0.01  16,532,232  16,532,232   
                 
         56,033,028  53,298,830  2,734,198 
  

Issuance

Date

  

Expiration

Date

  

Exercise

Price as of

September 30, 2021

  

Shares

Underlying

Warrants on

Issuance Date

  

Shares Issued

upon Warrant

Exercises as of

September 30, 2021

  

Shares

Underlying

Warrants

Outstanding as of

September 30, 2021

 
                         

Series K Warrants

 

2/17/2017

  

2/17/2022

  $2.00   315,986   308,860   7,126 
Series 2020-A Warrants (1) 7/6/2020  7/6/2025  $0.60   30,000,000   29,909,392   90,608 
                         
               30,315,986   30,218,252   97,734 

(1)

(1)   The Series 2020-A, Series 2020-B and Series 2020-C2020-A Warrants are equity-classified warrants.

 

During the nine months ended September 30, 2021, common stock was issued as a result of exercise of warrants as shown below (dollars in thousands):

  

Common Stock Issued

  

Proceeds

 
Series K Warrants  200  $1 
Series 2020-A Warrants  1,866,558   1,120 

 

  1,866,758  $1,121 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

The agreements governing the above warrants include the following terms:

certain warrants have exercise prices which are subject to adjustment for certain events, including the issuance of stock dividends on the Company’s common stock and, in certain instances, the issuance of the Company’s common stock or instruments convertible into the Company’s common stock at a price per share less than the exercise price of the respective warrants;

warrant holders may exercise the warrants through a cashless exercise if, and only if, the Company does not have an effective registration statement then available for the issuance of the shares of its common stock. If an effective registration statement is available for the issuance of its common stock a holder may only exercise the warrants through a cash exercise;

the exercise price and the number and type of securities purchasable upon exercise of the warrants are subject to adjustment upon certain corporate events, including certain combinations, consolidations, liquidations, mergers, recapitalizations, reclassifications, reorganizations, stock dividends and stock splits, a sale of all or substantially all of the Company’s assets and certain other events; and

in the event of an “extraordinary transaction” or a “fundamental transaction” (as such terms are defined in the respective warrant agreements), generally including any merger with or into another entity, sale of all or substantially all of the Company’s assets, tender offer or exchange offer, or reclassification of its common stock, in which the successor entity (as defined in the respective warrant agreements) that assumes the successor entity is not a publicly traded company, the Company or any successor entity will pay the warrant holder, at such holder’s option, exercisable at any time concurrently with or within 30 days after the consummation of the extraordinary transaction or fundamental transaction, an amount of cash equal to the value of such holder’s warrants as determined in accordance with the Black-Scholes option pricing model and the terms of the respective warrant agreement. In some circumstances, the Company or successor entity may be obligated to make such payments regardless of whether the successor entity that assumes the warrants is a publicly traded company.

During the three months ended September 30, 2020, common stock was issued as a result of exercise of warrants as described below (dollars in thousands):

 

Common Stock Issued

 

Proceeds

 
      

Series 2020-A Warrants

27,317,834 $16,391 

Series 2020-B Warrants

9,103,334  91 

Series 2020-C Warrants

16,532,232  165 
      
 52,953,400 $16,647 

 

8. Accounts Payable and Accrued Liabilities

 

The following table sets forth the components of the Company’s accounts payable and accrued liabilities in the consolidated balance sheetsConsolidated Balance Sheets (in thousands):

 

  

September 30,

  

December 31,

 
  

2020

  

2019

 

 

        
Accrued utilities and supplies $712  $645 

Accounts payable - trade

  1,441   1,474 

Accrued employee compensation

  1,593   1,946 

Other accrued liabilities

  1,158   1,613 
         

Total accounts payable and accrued liabilities

 $4,904  $5,678 

  

September 30,

 

December 31,

 
  

2021

 

2020

 

 

       

Accounts payable - trade

 $10,876 $897 
RNG accrued project costs   4,396  0 
Accrued employee compensation  4,286  1,960 
Net-Zero 1 accrued project costs  2,914  0 

Other accrued liabilities

  2,110  1,086 
        

Total accounts payable and accrued liabilities

 $24,582 $3,943 

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

9. Debt

2020 Notes and 2020/21 Notes

The following table sets forth information pertaining to the 2020 Notes and 2020/21 Notes which are included in the Company’s consolidated balance sheets (in thousands):

  

Principal

Amount of

2020 Notes

  

Principal

Amount of

2020/21 Notes

  

Debt

Discount

  

Debt Issue

Costs

  

Total

Notes

  

 

Embedded

Derivative

  

Total

 
                             

Balance - December 31, 2019

 $14,053  $  $(123

)

 $(30) $13,900  $  $13,900 
                             

Amortization of debt discount

        270      270      270 

Amortization of debt issue costs

           20   20      20 

Paid-in-kind interest

  47   269         316      316 
Exchange of 2020 Notes for 2020/21 Notes  (14,100)  14,100                
Original issue discount paid with 2020/21 Notes     282   (282)            
Conversion of 2020/21 Notes into common stock     (2,000)        (2,000)     (2,000)
Fair value of 2020/21 embedded derivative                 2,848   2,848 

Change in fair value of 2020/21 Notes embedded derivative

                 (2,819)  (2,819)
                             

Balance - September 30, 2020

 $  $12,651  $(135

)

 $(10) $12,506  $29  $12,535 

On June 20, 2017, the Company issued the 2020 Notes in exchange for its 12.0% convertible senior secured notes due 2017 (the "2017 Notes"), plus an amount in cash equal to the accrued and unpaid interest. The 2020 Notes had a maturity date of March 15, 2020 and were secured by a first lien on substantially all of our assets. The 2020 Notes had an interest rate equal to 12% per annum (with 2% potentially payable as PIK Interest (as defined and described below) at our option), payable on March 31, June 30, September 30 and December 31 of each year. To the extent that the Company paid any portion of the interest due on the 2020 Notes as PIK Interest, the maximum aggregate principal amount of the 2020 Notes that would have been convertible into shares of the Company's common stock increased.

Under certain circumstances, the Company had the option to pay a portion of the interest due on the 2020 Notes by either (a) increasing the principal amount of the 2020 Notes by the amount of interest then due or (b) issuing additional 2020 Notes with a principal amount equal to the amount of interest then due (interest paid in the manner set forth in (a) or (b) being referred to as “PIK Interest”).

Additional shares of the Company's common stock could also have become issuable pursuant to the 2020 Notes in the event the Company was required to make certain make-whole payments as provided in the 2020 Notes Indenture.

The 2020 Notes were convertible into shares of the Company's common stock, subject to certain terms and conditions. The initial conversion price of the 2020 Notes was equal to $14.72 per share of common stock, or 0.0679 shares of common stock per $1 principal amount of 2020 Notes.

 

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

9. Debt

2020/21 Notes2021 Bond Issuance

 

On April 15, 2021, 2021 Bonds were issued totaling $68,155,000. The 2021 Bonds initially bear interest at the rate of 1.50% per annum during the Initial Term Rate Period (as defined in the hereinafter defined Indenture), payable semi-annually on January 10, 2020, the Company entered into an Exchange 1 and Purchase Agreement (as amended, the “2020/21 Purchase Agreement”) with the guarantors party thereto (the "Guarantors"), the holder July 1 of the 2020 Noteseach year, commencing on July 1, 2021, mature on April 1,2042. The 2021 Bonds are callable on or after October 1, 2022, are remarketable, and Whitebox Advisors LLC ("Whitebox"), in its capacity as representative of the holder. Pursuantare also subject to mandatory tender for purchase pursuant to the terms of the 2020/21 Purchase Agreement, the holder of the 2020 Notes, subject to certain conditions, agreed to exchange all of the outstanding principal amount of the2020 Notes, which was approximately $14.1 million including unpaid accrued interest, for approximately $14.4 million in aggregate principal amount of the Company's newly created 2020/21 Notes (the “2020/21 Exchange”)Indenture (as defined below). Pursuant to the 2020/21 Purchase Agreement, the Company also granted an option to purchase up to an additional aggregate principal amount of approximately $7.1 million of 2020/21 Notes (the “2020/21 Option Notes”), at

The 2021 Bonds were issued under a purchase price equal to the aggregate principal amount of such 2020/21 Option Notes purchased less an original issue discount of 2.0%, having identical terms (other than with respect to the issue date and restrictions on transfer relating to compliance with applicable securities law) to the 2020/21 Notes issued, at any time during the period beginning on the date of closing of the 2020/21 Exchange and ending on the later of (a) 180 days thereafter, and (b) 30 days following June 3, 2020. The right to purchase 2020/21 Option Notes expired on July 3, 2020. On January 10, 2020, the Company completed the 2020/21 Exchange and cancelled the 2020 Notes. In addition, the Company entered into an Indenture by and among the Company, the guarantors named therein (the “2020/21 Notes Guarantors”) and FSB, as trustee and as collateral trustee (the “Original Indenture”), as supplemented by that certain First SupplementalTrust Indenture, dated as of April 7, 2020 (the “First Supplemental Indenture”1, 2021 (the “Indenture”), that certain Second Supplemental Indenture,between the Authority and Citibank, N.A., as trustee (the “Trustee”). The principal of and the interest on the 2021 Bonds is payable solely from (i) payments to be made by Gevo RNG to the Trustee pursuant to a separate financing agreement, dated as of July 2, 2020 (the “Second Supplemental Indenture”), and that certain Third Supplemental Indenture, dated as of August 24, 2020 (the “Third Supplemental Indenture” and, together with the Original Indenture, the First Supplemental Indenture and the Second Supplemental Indenture, the “2020/21 Notes Indenture”), pursuant to which the Company issued the 2020/21 Notes. The Company recognized an approximately $0.7 million loss. See "(Loss) on modification of 2020 Notes" within the Consolidated Statements of Operations.

The 2020/21 Notes will mature on December 31, 2020, provided that the maturity date will automatically be extended to April 1, 2021 if (the aggregate outstanding principal balance“Bond Financing Agreement”), between Gevo RNG and the Authority, (ii) all moneys received by the Authority or the Trustee in respect of payment of the 2020/21 Notes (including any 2020/21 Option Notes) asloan of December 15, 2020 is less than $7 million. The 2020/21 Notes bear interest at a rate equalthe proceeds of the 2021 Bonds from the Authority to 12% per annum (with 4% payable as PIK InterestGevo RNG pursuant to the Bond Financing Agreement, (iii) all moneys and investments in the “Bond Fund” established and maintained by the Trustee pursuant to the Indenture, including without limitation moneys received by the Trustee pursuant to the Letter of Credit (as defined below), (iv) all moneys and described below)investments in the “Project Fund” established and maintained by the Trustee pursuant to the Indenture from proceeds of the sale of the 2021 Bonds, and (v) all income and profit from the investment of the foregoing moneys, excluding any payments received by the Authority pursuant to rights of the Authority to receive certain additional payments and reimbursements of expenses as set forth in the Bond Financing Agreement. Pursuant to the Bond Financing Agreement, the proceeds of the 2021 Bonds will be loaned to Gevo RNG (1), payable to finance in part the construction of the biogas facility to be developed, designed, constructed, owned and operated by or on March 31, June 30, September 30behalf of Gevo RNG, which is comprised of (A) three anaerobic digesters and December 31 of each year. Under certain circumstances, the Companyrelated equipment situated on dairy farms located in Northwest Iowa that will have the optionproduce partially conditioned raw biogas from cow manure, (B) gathering pipelines to paytransport biogas to a centrally located gas upgrade system, (C) a centrally located gas upgrade system located in Doon, Iowa that will upgrade biogas to pipeline quality natural gas and interconnect to Northern Natural Gas’ interstate pipeline and (D) other related improvements, (2) to capitalize a portion of the interest due on the 2020/21 Notes2021 Bonds during the Initial Term Rate Period to be used to reimburse the Credit Facility Provider (as defined below) for interest draws on the Letter of Credit during such period, and (3) to pay a portion of the costs of issuing the 2021 Bonds.

On April 15, 2021, Gevo obtained a letter of credit for $71.2 million (the “Letter of Credit”) from the Credit Facility Provider, pursuant to the terms of a letter of credit reimbursement agreement dated as of April 1, 2021 (the “Reimbursement Agreement”), between Gevo and the Credit Facility Provider. The Letter of Credit will permit the Trustee to draw thereon in accordance with its terms in amounts sufficient to pay the principal and purchase price of the 2021 Bonds and up to 203 days’ interest on the 2021 Bonds. Pursuant to the terms of the Reimbursement Agreement, Gevo is obligated to reimburse the Credit Facility Provider for amounts drawn under the Letter of Credit. It is expected that payments of the principal and interest on the 2021 Bonds, and the purchase price of 2021 Bonds that are tendered for mandatory purchase and not remarketed, will be made by either (a) increasingdraws on the Letter of Credit. Gevo has pledged and assigned restricted cash to the Credit Facility Provider as security for the reimbursement obligations of Gevo pursuant to the Reimbursement Agreement in an amount equal to the principal amount of the 2020/21 Notes by the amount2021 Bonds plus three years of interest then due or (b) issuing additional 2020/21 Notes with a principal amount equal to the amount of interest then due (interest paid in the manner set forth in (a) or (b) being referred to as “PIK Interest”). In the event the Company pays any portion of the interest duepayments on the 2020/21 Notes as PIK Interest,2021 Bonds.

Gevo anticipates remarketing the maximum aggregate principal amount2021 Bonds under revised terms that will include a long-term maturity date and be non-recourse to Gevo. Upon a successful remarketing, Gevo anticipates that the Letter of 2020/21 Notes that could be convertible into sharesCredit, the Reimbursement Agreement and the associated pledge of the Company’s common stockcash will be increased.

The 2020/21 Notes are convertible into shares of the Company’s common stock at the conversion price, subject to certain terms and conditions. The initial conversion price of the 2020/21 Notes is equal to $2.442 per share of the Company’s common stock (the “2020/21 Notes Conversion Price”), or 0.4095 shares of the Company’s common stock per $1 principal amount of 2020/21 Notes. The Company and the holders may also mutually agree on other conversions of the 2020/21 Notes into shares of the Company’s common stock on a monthly basis (a “Contractual Conversion”) pursuant to the terms of the 2020/21 Notes Indenture. The 2020/21 Notes Conversion Price in a Contractual Conversion will be reduced to the lesser of the then-applicable 2020/21 Notes Conversion Price or a 10% discount to the average of the daily volume weighted average price of the Company’s common stock for the three forward trading days prior to the date of the Contractual Conversion.

Each holder has agreed not to convert its 2020/21 Notes into shares of the Company’s common stock to the extent that, after giving effect to such conversion, the number of shares of the Company’s common stock beneficially owned by such holder and its affiliates would exceed 4.99% of the Company’s common stock outstanding at the time of such conversion (the “4.99% Ownership Limitation”); provided that a holder may, at its option and upon 61 days’ prior notice to the Company, increase such threshold to 9.99% (the “9.99% Ownership Limitation”). If a conversion of 2020/21 Notes by a holder would exceed the 4.99% Ownership Limitation or the 9.99% Ownership Limitation, as applicable, the 2020/21 Purchase Agreement contains a provision granting the holder a fully funded prepaid warrant for such common stock with a term of nine months, subject to a six-month extension, which it can draw down from time to time.

The 2020/21 Notes may be redeemed in whole or in part, at the Company’s option, for cash at any time June 3, 2020 and upon 120 days’ notice to the holders of the 2020/21 Notes. A Redemption Make-Whole Payment (as defined in the 2020/21 Notes Indenture) applies only to a redemption of 2020/21 Notes that occurs on or after December 31, 2020. Following a notice of redemption of the 2020/21 Notes by the Company, the holders may elect to convert the 2020/21 Notes into shares of the Company’s common stock at the same conversion price as applicable to a Contractual Conversion.

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

The 2020/21 Notes do not contain any anti-dilution adjustments for future equity issuances that are below the 2020/21 Notes Conversion Price, and adjustments to the 2020/21 Notes Conversion Price will only generally be made in the event that there is a dividend or distribution paid on shares of the Company’s common stock, a subdivision, combination or reclassification of the Company’s common stock, or at the discretion of the Board of Directors of the Company in limited circumstances and subject to certain conditions.

The 2020/21 Notes are secured by a lien on substantially all of the assets of the Company and the 2020/21 Notes Guarantors, including intellectual property and real property, and are guaranteed by the Company’s existing subsidiaries.

Additional shares of the Company's common stock could also become issuable pursuant to the 2020/21 Notes in the event the Company is required to make certain make-whole payments as provided in the 2020/21 Notes Indenture.

Under certain circumstances, the Company may file one or more registration statements on Form S-3 or amend filings in order to register shares of common stock for sale or resale, as necessary in connection with the 2020/21 Notes.

Conversion of 2020/21 Notes

On July 10, 2020, certain holders of the 2020/21 Notes converted $2.0 million in aggregate principal amount of 2020/21 Notes (including the conversion of an additional $0.3 million for make-whole payment) into an aggregate of 4,169,426 shares of common stock pursuant to the terms of the 2020/21 Indenture. The Company recorded a Loss on conversion of 2020/21 Notes of $0.5 million on its Consolidated Statements of Operations.terminated.

 

Loans Payable - Other

 

During the first quarter of 2020, the Company purchased equipment under a financing lease. During the fourth quarter 2019, the Company purchased equipment and financed part of its insurance obligation. The equipment notes and financing lease pay interest between 4% and 21%, have total monthly payments of $0.1 million and mature at various dates from August 2020 to February 2025. The equipment loans are secured by the related equipment.

 

In April 2020, the Company and Agri-Energy each entered into a loan agreement with Live Oak Banking Company, pursuant to which the Company and Agri-Energy obtained loans from the Small Business Administration's Paycheck Protection Program (“SBA PPP”) totaling $1.0 million in the aggregate (the "SBA Loans").

On April 15, 2021, the Small Business Administration forgave the entire balance of $0.5 million of the Company's and $0.1 million of Agri-Energy's loans and accrued interest obtained through the SBA PPP. The remaining SBA Loans will mature in April 2022 and bearLoan for Agri-Energy totals $0.4 million, bears interest at a rate equal to 1% per annum, subject to the potential for partial or full loan forgiveness as dictated by U.S. federal law. Principal1.0% and matures in April 2025. Monthly payments of $8,000, including interest, are deferred until Augustbegan on June 5, 2021 and interest continues to accrue during the deferral period. The SBA Loans are payable monthly beginning August 5, 2021, with aggregate payments totaling $0.06 million per month, including interest and principal. The SBA Loans must be used for payroll, rent payments, mortgage interest payments and utilities payments as governed by the SBA PPP and are subject to partial or full forgiveness for the initial 24-week period following the loan disbursement if all proceeds are used for eligible purposes and within certain thresholds, the Company maintains certain employment levels and the Company maintains certain compensation levels.through April 2025.

 

The balance of these loans at September 30, 2020 and December 31, 2019 are as follows (in thousands):

  September 30, 2020  December 31, 2019 
         
SBA Loans $1,006  $ 
Equipment  281   321 
Insurance     428 
         
Total notes payable - other  1,287   749 
Less current portion  (704)  (516)
         
Long-term portion $583  $233 

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

The summary of the 2021 Bonds and Loans payable - other at September 30, 2021 and December 31, 2020 are as follows (in thousands):

  

Interest Rate

 Maturity Date September 30, 2021  December 31, 2020 
                 
2021 Bonds  1.5%  January 2042 $66,303  $0 
SBA Loans  1.0%  April 2025  344   1,006 
Equipment 4%to5% February 2022toDecember 2024  178   248 
                 
Total loans payable - other          66,825   1,254 
Less current portion          (165)  (807)
                 
Long-term portion         $66,660  $447 

Future principal payments for the Company's long-term debt are as follows (in thousands):
Year Ending December 31,    
     
2021 (remaining) $44 
2022  161 
2023  159 
2024  66,432 
2025  29 
     
  $66,825 

Included in the 2021 Bonds above is Bond Premium of $0.7 million and Debt Issuance Costs of $2.6 million in the principal portion. During the three and nine months ended September 30, 2021, Bond Premium amortization was $0.1 million and $0.1 million, respectively, and Debt Issuance Cost amortization was $0.3 million and $0.5 million, respectively, based on the effective interest method and was included in "Interest expense" in the Consolidated Statements of Operations. 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 
Future payments for Loans Payable - Other are as follows (in thousands):
Year ending December 31,    
     
2020 (remaining) $134 
2021  763 
2022  290 
2023  65 
2024 and thereafter  35 
     
  $1,287 

10. Equity Incentive Plans

 

2010 Stock Incentive Plan. In February 2011, the Company’s stockholders approved the Gevo, Inc. 2010 Stock Incentive Plan (as amended and restated to date, the "2010"2010 Plan"). The 2010 Plan provided for the grant of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units and other equity awards to employees and directors of the Company. On June 10, 2019,9, 2021, with approval of stockholders at the 2021 Annual Meeting of Stockholders, the 2010 Plan was amended and restated, which increased the number of shares of common stock reserved for issuance to 3,266,661 shares. On June 3, 2020,under the 2010 Plan was amended and restated, which increased the number of shares of common stock reserved for issuance by 3,713,413 shares to a total of 6,980,07422,980,074 shares.

 

Restricted common stock and non-qualified stock option activity during the nine months ended September 30, 2020 2021 consisted of the following:

 

Period

 

Total Number of Restricted Shares Issued

  

Total Number of Non-qualified Stock Options Granted

 

Vesting Periods Years

          

January 1, 2021 to March 31, 2021

 

(121,499

)

(1) 

—    

N/A

 

April 1, 2021 to June 30, 2021

 

(89,673

)

(2)(3) 

—  

 

0

to

4

July 1, 2021 to September 30, 2021

 

3,915,502

 

(2)(4)(6)

4,668,727

(5)(7)

2

to

3

          

Total

 

3,704,330

  

4,668,727

    

(1)

In February 2020, the Company issued 109,337 shares of restricted common stock, vesting over three years, and 1,258 shares of restricted common stock, vesting over two years, to certain of its employees in relation to restricted stock awards granted on February 27, 2020.

In March 2020, the Company withheld 4,055Includes shares of common stock to settle income taxescancelled related to the vestedunvested restricted stock awards for certain employees.of a director and an employee who resigned.
(2)Includes shares withheld from employees to cover tax withholding obligations upon the vesting of restricted stock awards.
(3)In April 2020, the Company issued 239,155 shares of restricted common stock in relation toIncludes restricted stock awards granted to its employees on April 1, 2020 in connection with the 20% salary reduction discussed in Footnote 1, which vested on 7, 2021, May 15, 2020. Also in April 2020, the Company issued 29,032 of restricted stock units in exchange for services rendered, which vested immediately. 3, 2021, and June 7, 2021. 
(4)
During the three months ended June 30, 2020, the Company withheld 77,768 shares of common stock to settle income taxes related to the vested restricted stock awards for certain employees.
During July 2020, the Company issued 115,156 shares of restricted common stock in relation toIncludes restricted stock awards granted to its employees and directors on July 1, 2020 in connection with the 20% salary reduction vesting on July 31, 2020. In addition, the Company issued 3,989,140 shares of restricted commonAugust 20, 2021.
(5)Includes non-qualified stock options granted to employees and directors and 101,730 restricted stock units in exchange for services rendered, vesting over two years. on August 20, 2021.
(6)
During the three months ended September 30, 2020, the Company withheld 245,990Includes shares of common stock to settle income taxescancelled related to the vestedunvested restricted stock awards forof certain employees.
(7)Includes non-qualified stock options cancelled related to the unvested option awards granted to an employee.

 

At September 30, 2020, 1,242,9052021, 8,857,302 shares remainremained available for awards under the 2010 Plan.

 

Employee Stock Purchase Plan. In February 2011, the Company’s stockholders approved the Employee Stock Purchase Plan (the "ESPP"). The offering periods for the ESPP are from January 1 to June 30 and from July 1 to December 31 of each calendar year. The Company has reserved 190 shares of common stock for issuance under the ESPP, of which 190 shares as of JuneSeptember 30, 2020 2021 are available for future issuance. The purchase price of the common stock under the ESPP is 85% of the lower of the fair market value of a share of common stock on the first or last day of the purchase period. There were no0 purchases of common stock under the ESPP during the nine months ended September 30, 2020 2021 or 2019.2020.

 

24

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

 

11. Stock-Based Compensation

 

Stock-Based Compensation Expense. The Company records stock-based compensation expense during the requisite service period for share-based payment awards granted to employees and non-employees.

Our stock-based compensation is classified as either an equity award or a liability award in accordance with generally accepted accounting principles. The fair value of an equity-classified award is determined at the grant date and is amortized on a straight-line basis over the vesting life of the award. The fair-value of a liability-classified award is determined on a quarterly basis through the final vesting date and is amortized based on the current fair value of the award and the percentage of vesting period incurred to date.

 

The following table sets forth the Company’s stock-based compensation expense (in thousands) for the periods indicated:

 

 

Three Months Ended September 30,

  Nine Months Ended September 30,  

Three Months Ended September 30,

  Nine Months Ended September 30, 
 2021  2020  2021  2020 

Equity Classified Awards

 
Stock options 
Research and development $188 $0 $188 $0 
Selling, general and administrative 598 0 598 0 
 2020  

2019

  2020  2019  

Restricted stock

                 

Research and development

 $142  $68  $353  $129  273  142   519   353 
Selling, general and administrative  821   500   1,995  1,122 
 

Total equity classified awards

  1,880  642  3,300  1,475 
 

Liability Classified Awards

 
Restricted stock 
Selling, general and administrative  500   236   1,122   581  2,368  2,368  
                 
Stock appreciation rights                 
Research and development  16   132   (61)  114  (40) 16  149 (61)

Selling, general and administrative

  16   132   (67)  114   (2)  16   6   (67)
                 

Total liability classified awards

  2,326  32  2,523  (128)
 

Total stock-based compensation

 $674  $568  $1,347  $938  $4,206  $674  $5,823  $1,347 

 

Stock Option Award Activity. Stock option activity under the Company’s stock incentive plans at September 30, 20202021 and changes during the threenine months ended September 30, 2020 2021 were as follows:

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

 

Remaining

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

Contractual

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Term

 

 

Intrinsic

 

 

 

Options

 

 

Price (1)

 

 

(years)

 

 

Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2019

 

 

1,561

 

 

$

928.79

 

 

 

6.56

 

 

$

 

Granted

 

 

 

 

$

 

 

 

 

 

 

 

 

 

Canceled or forfeited

 

 

(9

)

 

$

72,891.04

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options outstanding at September 30, 2020

 

 

1,552

 

 

$

556.13

 

 

 

5.83

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options exercisable at September 30, 2020

 

 

1,552

 

 

$

556.13

 

 

 

5.83

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options vested and expected to vest at September 30, 2020

 

 

1,552

 

 

$

556.13 

 

 

5.83

 

 

$

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

Weighted-

 

Remaining

 

 

 

 

 

 

 

 

 

 

Average

 

Contractual

 

Aggregate

 

 

 

 

Number of

 

 

Exercise

 

Term

 

Intrinsic

 

 

 

 

Options

 

 

Price (1)

 

(years)

 

Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options outstanding at December 31, 2020

 

1,552

 

 

$

556.13

 

5.6

 

$

 

 

Granted

 

4,670,324

 

 

$

4.98

 

  

 

  

 

Canceled or forfeited

 

(1,597

)

 

$

130.67  

 

 

  

 

Exercised

 

0

 

 

$

0

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

  

 

Options outstanding at September 30, 2021

 

4,670,279 

 

$

5.12

 

9.9

 

$

7,750,148  

 

 

 

 

 

 

 

 

 

 

 

  

 

Options exercisable at September 30, 2021

 

1,515

 

 

$

431.34 4.9

 

$

0 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

Options vested and expected to vest at September 30, 2021

 

4,435,359 

 

$

5.12 9.9

 

$

7,360,181  

 

(1)(1)  Exercise price of options outstanding range from $20.00$4.98 to $99,300.00$56,460 as of September 30, 2020.2021.

 

2825

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

The following table shows the number of stock options granted under the Company’s stock incentive plans and the assumptions used to determine the fair value of those options using a Black-Scholes option-pricing model during the nine months ended September 30, 2021:

Period Ended

 

Total Stock Options Granted 

 

Weighted-Average Exercise Price 

 

Weighted-Average Expected Term

 

Weighted Average Volatility

 

Weighted-Average Risk-Free Interest Rate

 

Expected Dividends

 

Weighted-Average Grant Date Fair Value

September 30, 2021

 

4,670,324

 

4.98

 

5.75 years 

 

144%

 

0.87%

 

$

0

 

$

4.57

NaN stock options were granted under the Company's stock incentive plans during the nine months ended September 30, 2020. 

During the three and nine months ended September 30, 2021, the Company included stock-based compensation costs related to stock option awards of $0.2 million in "Research and development expense" and $0.6 million in "Selling, general and administrative expense" in the Consolidated Statements of Operations, respectively. The Company did not recognize any stock-based compensation expenses related to stock option awards during the three and nine months ended September 30, 2020. 

No stock options vested during the nine months ended September 30, 2021. As of September 30, 2021, the total unrecognized compensation expense, net of estimated forfeitures, relating to stock options was $18.7 million, which is expected to be recognized over the remaining weighted-average period of approximately 2.9 years.

Restricted Stock. Non-vested restricted stock awards at September 30, 2020 2021 and changes during the threenine months ended September 30, 2020 2021 were as follows:

 

 

 

 

 

 

Weighted-

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Average

 

 

 

 

 

Average

 

 

Number of

 

Grant-Date

 

 

Number of

 

Grant-Date

 

 

Shares

 

Fair Value

 

 

Shares

 

Fair Value

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-vested at December 31, 2019

 

1,308,613

 

$

1.91 

Non-vested at December 31, 2020

 

4,701,556 

 

$

0.79 

Granted

 

4,454,046

 

$

0.63

 

 

4,807,378 

 

$

5.08

 

Vested

 

(1,015,336

)

 

$

1.47

 

 

(2,585,547)

 

$

0.99 

Canceled or forfeited

 

 

(6,974

)

 

$

1.90

 

 

(129,149)

 

$

0.84

 

 

 

 

 

 

 

 

  

 

 

 

 

Non-vested at September 30, 2020

 

 

4,740,349

 

$

0.80 

Non-vested at September 30, 2021

 

6,794,238 

 

$

3.75 

 

The total fair value of restricted stock that vested during the nine months ended September 30, 2020 totaled $1.5 2021 was $2.6million. As of September 30, 2020, 2021, the total unrecognized compensation expense, net of estimated forfeitures, relating to restricted stock awards was $3.1$24.8 million, which is expected to be recognized over the remaining weighted-average period of approximately 1.62.7 years. As of September 30, 2021, we had recorded a liability of $0.9 million for earned and unvested liability-classified restricted stock awards based on the fair value of our common stock as of September 30, 2021. 

 

 

12. Commitments and Contingencies

 

Legal Matters. From time to time, the Company has been, and may again become, involved in legal proceedings arising in the ordinary course of its business. The Company is not presently a party to any litigation and is not aware of any pending or threatened litigation against the Company that it believes could have a material adverse effect on its business, operating results, financial condition or cash flows.

 

Indemnifications. In the ordinary course of its business, the Company makes certain indemnities under which it may be required to make payments in relation to certain transactions. As of September 30, 2020 and December 31, 2019, 2021, the Company did not have any liabilities associated with indemnities.

 

In addition, the Company, as permitted under Delaware law and in accordance with its amended and restated certificate of incorporation and amended and restated bylaws, in each case, as amended to date, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The duration of these indemnifications, commitments, and guarantees varies and, in certain cases, is indefinite. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that may enable it to recover a portion of any future amounts paid. The Company accrues for losses for any known contingent liability, including those that may arise from indemnification provisions, when future payment is probable. No such losses have been recorded to date.

 

Environmental Liabilities. The Company’s operations are subject to environmental laws and regulations adopted by various governmental authorities in the jurisdictions in which it operates. These laws require the Company to investigate and remediate the effects of the release or disposal of materials at its locations. Accordingly, the Company has adopted policies, practices and procedures in the areas of pollution control, occupational health and the production, handling, storage and use of hazardous materials to prevent material environmental or other damage, and to limit the financial liability which could result from such events. Environmental liabilities are recorded when the Company’s liability is probable, and the costs can be reasonably estimated. No environmental liabilities have been recorded as of September 30, 2020.2021.

 

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

 

13. Fair Value Measurements

 

Accounting standards define fair value, outline a framework for measuring fair value, and detail the required disclosures about fair value measurements. Under these standards, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. Standards establish a hierarchy in determining the fair market value of an asset or liability. The fair value hierarchy has three levels of inputs, both observable and unobservable. Standards require the utilization of the highest possible level of input to determine fair value.

 

Level 1 – inputs include quoted market prices in an active market for identical assets or liabilities.

 

Level 2 – inputs are market data, other than Level 1, that are observable either directly or indirectly. Level 2 inputs include quoted market prices for similar assets or liabilities, quoted market prices in an inactive market, and other observable information that can be corroborated by market data.

 

Level 3 – inputs are unobservable and corroborated by little or no market data.

The carrying value and fair value, by fair value hierarchy, of the Company's financial instruments at September 30, 2021 and December 31, 2020, respectively, are as follows (in thousands):

      

Fair Value Measurements at September 30, 2021

(In thousands)

 
  

Fair Value at

September 30,

2021

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

  

Significant Other

Observable Inputs

(Level 2)

  

Significant

Unobservable

Inputs

(Level 3)

 
Recurring                
Marketable securities                
U.S. Treasury notes $266,892  $266,892  $0  $0 
U.S. Government-sponsored enterprise securities  119,347   119,347   0   0 
                 
Other                
Liability-classified restricted stock awards  (904)  (904)  0   0 
Derivative warrant liability  (35)  0   0   (35)
Total $385,300  $385,335  $0  $(35)
                 

Nonrecurring

                

Corn and palladium

 $

504

  $504  $0  $0 

 
      

Fair Value Measurements at December 31, 2020

(In thousands)

 
  

Fair Value at

December 31,

2020

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

  

Significant Other

Observable Inputs

(Level 2)

  

Significant

Unobservable

Inputs

(Level 3)

 

Recurring

                

Derivative Warrant Liability

 $31  $0  $0  $31 
                 

Nonrecurring

               

Corn and palladium and finished goods inventory

 $866  $235  $631  $0 

 

3027

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

 These tables present the carrying value and fair value, by fair value hierarchy, of our financial instruments, excluding cash and cash equivalents, accounts receivable and accounts payable, which approximate fair value due to their short-term nature, at September 30, 2020 and December 31, 2019, respectively (in thousands):

      

Fair Value Measurements at September 30, 2020

(In thousands)

 
  

Fair Value at

September 30,

2020

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

  

Significant Other

Observable Inputs

(Level 2)

  

Significant

Unobservable

Inputs

(Level 3)

 

Recurring:

                
2020/21 Notes Embedded Derivative Liability $29  $  $  $29 
                 

Nonrecurring

                

Corn and finished goods inventory

 $599  $  $599  $ 

      

Fair Value Measurements at December 31, 2019

(In thousands)

 
  

Fair Value at

December 31,

2019

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

  

Significant Other

Observable Inputs

(Level 2)

  

Significant

Unobservable

Inputs

(Level 3)

 

Recurring:

                

Derivative Warrant Liability

 $8  $  $  $8 
                 
                 

Nonrecurring

                

Corn and finished goods inventory

 $940  $267  $673  $ 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

The following table provides changes to those fair value measurements using Level 3 inputs for the threenine months ended September 30, 20202021 (in thousands):

 

  

Fair Value Measurements Using Significant Unobservable Inputs

(Level 3)

 
         
  

Derivative Warrant

Liability

  

2020/21 Notes Embedded

Derivative

 
         

Balance, December 31, 2019

 $8  $ 
         
Issue of 2020/21 Notes embedded derivative liability     2,848 

Total (gains) included in earnings

  (8)  (2,819)
         
Balance, September 30, 2020 $  $29 
  

Fair Value Measurements Using Significant Unobservable Inputs

(Level 3)

 
  

Derivative Warrant Liability 

 
     

Balance, December 31, 2020

 $31 
     

Total loss included in earnings

  4 
     
Balance, September 30, 2021 $35 

 

There were no transfers to or from Level 3 in the threenine months ended September 30 2020., 2021.

 

The Company's investment in marketable securities and liability-classified restricted stock awards are recorded at fair value based on quoted market prices. The Company believes that the carrying value of its cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities and loans payable - other approximate fair value due to their short maturities.

During the nine months ended September 30, 2021, the Company recorded the following realized (loss) from the sale of available-for-sale marketable securities:

Sales proceeds

$34,332 

Amortized cost

 (34,365
    

Realized (loss)

$(34)

For the 2021 Bonds, the fair values are estimated using the Black-Derman-Toy interest rate lattice framework. The carrying values and estimated fair values of the 2021 bonds as of September 30, 2021 are summarized as follows:

  September 30, 2021 
  Carrying Value  Estimated Fair Value 
         
2021 Bonds  $68,155   $69,075 

Inventories. The Company records its corn and palladium inventory at fair value only when the Company’s cost of corn and palladium purchased exceeds the market value for corn.corn and palladium. The Company determines the market value of corn and dry distiller’s grainpalladium based upon Level 1 inputs using quoted market prices. The Company records its ethanol, isobutanol and hydrocarbon inventory at market using Level 2 inputs.

 

2020/21 Notes Embedded Derivative. The Company had estimated the fair value of the embedded derivative on a stand-alone basis to be $0.03 million at September 30, 2020 based upon Level 3 inputs. Changes in the fair value of the embedded derivative is recognized each reporting period as a “Change in fair value of 2020/21 Notes embedded derivative” in the consolidated Statements of Operations and Statements of Cash Flows. See Note 7, Embedded Derivatives, for the fair value inputs used to estimate the fair value of the embedded derivative.

Derivative Warrant Liability. The Company valued the Series F Warrants and Series K Warrants using a Monte-Carlo model (Level 3)3) and other warrants using Black-Scholes models comprised of some inputs requiring the use of Monte-Carlo models (Level 3)3)

The Company has estimatednot elected the fair value option for any of the derivative warrant liability to be $0 and $.01 million as of September 30, 2020 and December 31, 2019, respectively.its instruments.

 

While the Company believes that its valuation methods

28

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

The Company's investments in marketable securities are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine thestated at fair value of certain financial instruments could resultand are available-for-sale. The Company had no investments in a different estimate of fair valuemarketable securities at December 31, 2020. The following table summarizes the reporting date.Company's investments in marketable securities (in thousands):

 

     

Available-for-Sale Securities at September 30, 2021

 
 Maturity 

Amortized Cost Basis

  

Gross Unrealized Losses

  

Fair Value

 
              
Short-term marketable securities             
U.S. Treasury notesWithin one year $233,552  $(178) $233,374 
U.S. Government-sponsored enterprise securitiesWithin one year  51,911   (49)  51,862 
Total  $285,463  $(227) $285,236 
              

Long-term marketable securities

             
U.S Treasury notesWithin two years $33,532  $(15) $33,517 
U.S. Government-sponsored enterprise securitiesWithin two years  67,540   (54)  67,486 
Total  $101,072  $(69) $101,003 

 

14. Segments

 

The Company has determined that it has twoCompany's chief operating segments: (i) Gevo segment;decision maker is provided with and (ii) Gevo Development/Agri-Energy segment. The Company organizesreviews a monthly executive package which separately identifies its business segments based on the nature of the products and services offered through each of its consolidated legal entities. In January 2021, the Company began to separately identify the Renewal Natural Gas Segment and Net-Zero Segment in the monthly executive package. As such, the Company has determined that it has four operating segments: (i) Gevo segment; (ii) Agri-Energy segment; (iii) Renewable Natural Gas segment; and (iv) Net-Zero segment. Transactions between segments are eliminated in consolidation.

 

Gevo Segment. The Gevo segment is responsible for all research and development activities related to the future production of isobutanol, including the development of our proprietary biocatalysts, the production and sale of bio jet fuel, the Company’s retrofit process and the next generation of chemicals and biofuels that will be based on the Company’s isobutanol technology. The Gevo segment also develops, maintains and protects its intellectual property portfolio, develops future markets for its isobutanol and provides corporate oversight services.

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

Gevo Development/Agri-Energy Segment. The Gevo Development/Agri-Energy segment is currently responsible for the operation of the Company’s Luverne Facility and the production of isobutanol, ethanol isobutanol and related products.

 

Renewable Natural GasSegment. The Renewable Natural Gas segment produces low-carbon methane from the manure of cows and pigs for the production of energy.

Net-Zero Segment. The Net-Zero segment is responsible for the production of energy dense liquid hydrocarbons using renewable energy and our proprietary technology. The concept of a Net-Zero Project is to convert renewable energy (photosynthetic, wind, renewable natural gas, biogas) into energy dense liquid hydrocarbons.

29

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

The Company’s chief operating decision maker is provided with and reviews the financial results of each of the Company’s consolidated legal entities, Gevo, Inc., Gevo Development, LLC and Agri-Energy, LLC.LLC, as well as its Renewable Natural Gas and Net-Zero projects. The Company organizes its business segments based on the nature of the products and services offered through each of its consolidated legal entities. AllSubstantially all revenue is earned, and all assets are held, in the U.S.

 

 

Three Months Ended September 30,

  Nine Months Ended September 30,  

Three Months Ended September 30,

  Nine Months Ended September 30, 
 2020  

2019

  2020  2019  2021  2020  2021  2020 

Revenues:

                 

Gevo

 $176  $550  $1,198  $1,381  $104  $176  $465  $1,198 

Gevo Development / Agri-Energy

  16   5,560   3,807   16,218 

Agri-Energy

 38  16  192 3,807 

Renewable Natural Gas

 0  0  0 0 
Net-Zero  0   0   0   0 
                 

Consolidated

 $192  $6,110  $5,005  $17,599  $142  $192  $657  $5,005 
                 

Loss from operations:

                 

Gevo

 $(3,831) $(3,830) $(9,896) $(9,463) $(10,968) $(3,508) $(22,471) $(9,197)

Gevo Development / Agri-Energy

  (2,272)  (4,173)  (9,440)  (10,661)

Agri-Energy

 (3,473) (2,272) (12,629) (9,440)
Renewable Natural Gas (218) (323) (286) (699)
Net-Zero  (53)  0   (8,226)  0 
                 

Consolidated

 $(6,103) $(8,003) $(19,336) $(20,124) $(14,712) $(6,103) $(43,612) $(19,336)
                 

Interest expense:

                 

Gevo

 $465  $605  $1,546  $2,127  $67  $465  $67  $1,546 

Gevo Development / Agri-Energy

  8      13    

Agri-Energy

 0  8  6 13 
Renewable Natural Gas 0  0  5 0 
Net-Zero  0   0   0   0 
                 

Consolidated

 $473  $605  $1,559  $2,127  $67  $473  $78  $1,559 
                 

Depreciation and amortization expense:

                 

Gevo

 $53  $50  $159  $152  $112  $53  $214  $159 

Gevo Development / Agri-Energy

  1,423   1,578   4,595   4,697 

Agri-Energy

 

1,088

  1,423  3,358 4,595 
Renewable Natural Gas 0  0  0 0 
Net-Zero  0   0   0   0 
                 

Consolidated

 $1,476  $1,628  $4,754  $4,849  $1,200  $1,476  $3,572  $4,754 
                 

Acquisitions of plant, property and equipment:

                

Acquisitions of patents, plant, property and equipment:

 

Gevo

 $  $  $79  $62  $9,536  $0  $10,377  $79 

Gevo Development / Agri-Energy

  106   781   1,325   4,862 

Agri-Energy

 3,154  106  5,062 1,325 
Renewable Natural Gas 14,450  0  31,551 0 
Net-Zero  5,975   0   5,975   0 
                 

Consolidated

 $106  $781  $1,404  $4,924  $33,115  $106  $52,965  $1,404 
                 
Revenue by geographic area                 
United States $

12

  $5,560  $3,853  $16,218  $49  $12  $282  $3,853 
Other  180   550   1,152   1,381   93   180   375   1,152 
                 
Consolidated $192  $6,110  $5,005  $17,599  $142  $192  $657  $5,005 

 

3330

 

GEVO, INC.

Notes to Consolidated Financial Statements

(unaudited)

 

  September 30,  December 31, 
  2020  

2019

 
         

Total assets

        

Gevo

 $152,762  $91,861 

Gevo Development / Agri-Energy

  133,790   143,349 

Intercompany eliminations (1)

  (133,065)  (141,851

)

         

Consolidated (2)

 $153,487  $93,359 

  September 30,  December 31, 
  2021  

2020

 
         

Total assets

        

Gevo

 $574,179  $152,177 

Agri-Energy

  144,552   131,893 
Renewable Natural Gas  112,594   0 
Net-Zero  6,944   0 

Intercompany eliminations (1)

  (162,914)  (131,971)
         

Consolidated (2)

 $675,355  $152,099 

 

(1

(1)

Includes intercompanyIntercompany sales of $0.1 millionhydrocarbon during the nine months ended September 30, 2020 2021 and $0.4 million for the year ended December 31, 2019 for hydrocarbon sales.

2020 was $0 and $0.1 million, respectively.

(2

(2)

All other significant non-cash items relate to the activities of Gevo.

 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used anywhere in this Report, the words “expect,” “believe,” “anticipate,” “estimate,” “intend,” “plan” and similar expressions are intended to identify forward-looking statements. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. These forward-looking statements include, among other things, statements about: the impact of the novel coronavirus ("COVID-19") pandemic on our business, our financial condition, our results of operation and liquidity, risks and uncertainties related to our ability to sellfinance and construct our products,Net-Zero 1 Project (as defined below), our ability to expand or continue production of isobutanol, renewable hydrocarbonproduce our products and ethanol at our production facility in Luverne, Minnesota (the “Luverne Facility”), or elsewhere, our ability to meet production, financial and operational guidance, our strategy to pursue low-carbon or "net-zero" carbon renewable fuels for sale into California and elsewhere, our ability to replace our fossil-based energy sources with renewable energy sources at our production facilities,Net-Zero 1 Project, our Luverne Facility and elsewhere, our ability and plans to construct a greenfield commercial hydrocarbon facility to produce sustainable aviation fuel ("SAF") and renewable premium gasoline and jet fuel,gasoline/isooctane, our ability to raise additional funds to continue operations and/or expandfinance our production capabilities,business, our ability to perform under our existing renewable hydrocarbon offtake agreements and other supply agreements we may enter into in the future, our ability to enter into additional hydrocarbon supply agreements, our ability to obtain project finance debtsuccessfully construct and third-party equity foroperate our renewable natural gas ("RNG") project in Iowa, our ability to produce isobutanol and renewable hydrocarbon products and ethanol onat a commercial level and at a profit, achievement of advances in our technology platform, the success of our upgraded production facility, the availability of suitable and cost-competitive feedstocks, our ability to gain market acceptance for our products, the expected cost-competitiveness and relative performance attributes of our isobutanol, renewable hydrocarbon products, and ethanol,our strategy to pursue ethanol-to-SAF, additional competition and changes in economic conditions and the future price and volatility of petroleum and products derived from petroleum. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements such as those contained in documents we have filed with the U.S. Securities and Exchange Commission (the “SEC”), including this Report in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations”Operations,” our Annual Report on Form 10-K for the year ended December 31, 20192020 (our “Annual Report”), and subsequent reports on Form 10-Q, including Item 1A. "Risk Factors" of this Report.our Annual Report and subsequent reports on Form 10-Q. All forward-looking statements in this Report are qualified entirely by the cautionary statements included in this Report and such other filings. These risks and uncertainties or other important factors could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this Report. These forward-looking statements speak only as of the date of this Report. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on the forward-looking statements as representing the Company’s views as of any date subsequent to the date of the filing of this Report.

 

Unless the context requires otherwise, in this Report the terms “we,” “us,” “our” and the “Company” refer to Gevo, Inc. and its subsidiaries.

 

The following discussion should be read in conjunction with our unaudited consolidated financial statements and the related notes and other financial information appearing elsewhere in this Report. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including, without limitation, the disclosures in our Annual Report.

 

Company Overview

 

We are a growth-oriented company focused on transforming renewable energy into energy dense liquid hydrocarbons that can be used as renewable fuels, company that is commercializing the next generation ofsuch as sustainable aviation fuel and renewable low-carbon liquid transportation fuelsisooctane (which we refer to as “renewable premium gasoline”), with the potential to achieve a “net zero” greenhouse gas (“GHG”("GHG") footprint and address global needs of reducing GHG emissions with sustainable alternatives to petroleum fuels. We currently own one production facility, the Luverne Facility. We plan to develop, own (in whole or in part), and operate additional production facilities that use a combination of (i) renewable energy sources such a photosynthetic energy, renewable electricity, biogas, renewable hydrogen, and (ii) renewable carbon sources such as residual carbohydrates. The residual carbohydrates we are initially focused on are those from sustainably grown field corn because of amount of protein that can be captured and delivered to the food chain. We also have the potential to use residual carbohydrates from woody biomass, municipal solid waste, molasses, sugar, agriculture residues and the like. The choice of feedstock depends upon the sustainability profile of the carbohydrate, its cost and the reliability of the supply chain for that feedstock.

As next generation renewable fuels, our hydrocarbon transportation fuels have the advantage of being “drop-in” substitutes for conventional fuels that are derived from crude oil, working seamlessly and without modification in existing fossil-fuel based engines, supply chains and storage infrastructure. In addition, with SAF, the carbon footprint of air travel can be reduced, or in the long run, eliminated on a net carbon basis, without changes to planes or fuel systems. In addition to the potential of net zeronet-zero carbon emissions across the whole fuel life-cycle, our renewable fuels should eliminate other pollutants associated with the burning of traditional fossil fuels such as particulates and sulfur, while delivering superior performance. We believe that the world is substantially under-supplied with low-carbon, drop-in renewable fuels that can be immediately used in existing transportation engines and infrastructure, and we are uniquely positioned to grow in serving that demand. We call this approach our “Net-Zero Business Model,” in reference to the reduction and elimination of fossil-based emissions on a net carbon basis across the whole of the life cycle.

We have a strong proprietary technology position. Our technology pathway converts carbohydrates to alcohols via a fermentation process. The alcohols are then converted to hydrocarbon fuels using a catalytic chemical process. By using renewable energy across the production process, in combination with sustainable feedstocks, like low carbon non-food corn, the greenhouse gas emissions can be substantially reduced or eliminated as measured across the whole of the life cycle. The processes used to convert carbohydrates to drop-in hydrocarbons using isobutanol as the intermediate alcohol is protected by a patent portfolio with more than 500 patents, as well as proprietary processes and know-how. The production technology to convert ethanol to hydrocarbons has been exclusively licensed to Gevo in the United States by Axens North America, Inc. (“Axens”), and incorporates more than 60 patents, as well as proprietary production technology and know-how.

Net-Zero Projects

In early 2021, we announced the concept of “Net-Zero Projects” as a series of planned facilities to produce energy dense liquid hydrocarbons using renewable energy and our proprietary technology. The concept of a Net-Zero Project is to convert renewable energy (photosynthetic, wind, renewable natural gas, biogas) from a variety of sources into energy dense liquid hydrocarbons that when burned in traditional engines, have the potential to achieve net-zero GHG emissions across the whole lifecycle of the liquid fuel: from the way carbon is captured from the atmosphere, processed to make liquid fuel products, and including the end use (burning as a fuel for cars, planes, trucks and ships). We announced that our initial Net-Zero project (“Net-Zero 1 Project") is currently planned to be constructed at Lake Preston, South Dakota. We expect that the Net-Zero 1 Project will have the capability to produce liquid hydrocarbons that when burned have a “net-zero” greenhouse gas footprint. We currently expect the Net-Zero 1 Project to have a capacity of approximately 46 MGPY of hydrocarbons (for renewable premium gasoline and SAF, backed by our current portfolio of take-or-pay contracts), to produce more than 340,000,000 pounds per year of high-value nutritional products for use in the food chain, to produce more than 30,000,000 pounds per year of corn oil and to produce smaller volumes of excess isobutanol for sale in the market. 

Ethanol-to-SAF Strategy

On October 12, 2021, we announced that we entered into an agreement with Axens that establishes a strategic alliance aimed at accelerating the commercialization of sustainable ethanol-to-SAF ("ETSAF") projects in the United States. As part of the alliance, Axens brings technologies with over 60 related patents, engineering packages, proprietary catalysts and certain proprietary equipment required to convert ethanol into SAF. Axens would also provide process guarantees to us for commercial ETSAF projects. We plan to develop, own and operate ETSAF plants to produce SAF alone or with partners, applying the principles of our Net-Zero Business Model.

Renewable Natural Gas Projects

In 2019, we began developing RNG projects. Animal manure can be digested anaerobically to produce RNG. RNG has value in markets such as California as well as in Gevo’s hydrocarbon production process by helping us achieve carbon negative GHG emissions on our renewable hydrocarbon products. The end products resulting from such a decarbonization process have lower carbon intensity scores and increased market value, in addition to having a more positive impact on the environment. We developed Gevo's initial RNG project, Gevo NW Iowa RNG, LLC (“Gevo RNG”), to generate RNG captured from dairy cow manure which will be supplied by three dairies located in Northwest Iowa totaling over 20,000 milking cows. When fully operational, the Gevo RNG project is expected to generate approximately 355,000 MMBtu of RNG per year. During the third quarter of 2021, Gevo entered into agreements with BP Canada Energy Marketing Corp. and BP Products North America Inc. (collectively, “bp”) for the sale of Gevo RNG. The RNG is expected to be sold into the California market under dispensing agreements bp has in place with Clean Energy Fuels Corp., the largest fueling infrastructure in the U.S. for RNG. We expect RNG sale revenues will benefit from California’s Low Carbon Fuel Standard program and the U.S. Environmental Protection Agency’s Renewable Identification Number program. We financed the construction of the Gevo RNG project in April 2021 with the $68,155,000 of Solid Waste Facility Revenue Bonds (Gevo NW Iowa RNG, LLC Renewable Natural Gas Project), Series 2021 (Green Bonds) (the “2021 Bonds”) issued by the Iowa Finance Authority in a public offering for the benefit of Gevo RNG and we commenced its construction in April 2021. The Gevo RNG project is expected to begin producing RNG in 2022.

 

 

WeRecent Developments 

Butamax Patent Estate. On September 21, 2021, we and Butamax Advanced Biofuels LLC and its affiliate, Danisco US Inc. (collectively, “Butamax”), entered into an Asset Purchase Agreement (the "Purchase Agreement"), pursuant to which we purchased all of Butamax’s rights, title and interests in certain U.S. and foreign patents and patent applications, subject to specified conditions and encumbrances, relating to the production, recovery and use low-carbon, renewable resource-based raw materialsof biobutanol that were owned by Butamax (the “Purchased Assets”). The Purchased Assets were previously subject to the terms and conditions of the Patent Cross-License Agreement, effective August 22, 2015, by and between us and Butamax. Except with respect to certain existing licenses granted by Butamax pursuant to the PCLA and other terms set forth in the Purchase Agreement, the PCLA was terminated as feedstocks. Inof the near-term, our feedstocks will primarily consisteffective date of non-food corn. As our technology is applied globally, feedstocks can consistthe Purchase Agreement.

At-the-Market Offering Program. During the nine months ended September 30, 2021, we issued 24,420,579 shares of sugar cane, molasses orcommon stock under the at-the-market offering program for total proceeds of $135.8 million, net of commissions and other cellulosic sugars derived from wood, agricultural residuesoffering related expenses of $3.6 million. There were no shares issued during the three months ended September 30, 2021. Additionally, On September 9, 2021, we amended the at-the-market offering program to expand the availability up to $500 million of shares of the Company’s common stock. See Note 1, Nature of Business, Financial Condition and waste. Our patented fermentation yeast biocatalyst produces isobutanol, a four-carbon alcohol, via the fermentationBasis of renewable plant biomass carbohydrates. The resulting renewable isobutanol has a variety of direct applications but, more importantlyPresentation, to our fundamental strategy, serves as a building block to make renewable isooctane (which we refer to as renewable premium gasoline) and renewable jet fuel using simple and common chemical conversion processes. We also reduce or eliminate fossil-based process energy inputs by replacing them with renewable energy such as wind-powered electricity and renewable natural gas (“RNG”).consolidated financial statements included herein for further discussion.

 

COVID-19

 

The COVID-19 pandemic has had an adverse impact on global commercial activity, including the global transportation industry and ourits supply chain, and has contributed to significant volatility in the financial markets. It resulted in travel restrictions and extended shutdowns of businesses in various industries including, among others, the airline industry, and significantly reduced overall economic output. It is possible that that the impact of the COVID-19 pandemic on general economic activity could continue to negatively impact our revenue and operating results for 2021 and beyond. In light of the current and potential future disruption to our own business operations and those of ourits customers, suppliers and other third parties with whom we do business, we considered the impact of the COVID-19 pandemic on our business. This analysis considered our business' resilience and continuity plans, financial modeling and stress testing of liquidity and financial resources.

We expect that theThe impact of the COVID-19 pandemic on general economic activity will negatively impactthe global transportation industry could continue to result in less demand for our revenuetransportation fuel products, which could have a material adverse effect on our business, financial condition and operating resultsour prospects for at least the remainderforeseeable future.

During the first quarter of 2020, we suspended our ethanol production at the Luverne Facility due to COVID-19 and beyond.an unfavorable commodity environment, largely the result of greater corn costs as compared to national markets than the region has historically produced. The suspension of ethanol production at our Luverne Facility and a reduction in our workforce that occurred during the first quarter of 2020 due to the impact of COVID-19 had an adverse impact on our financial results for the third quarter of 2020nine months ended September 30, 2021, reducing revenue by 97%87% compared to the same periodnine months ended September 30, 2020. The change in 2019. We expect thatrevenue for the suspension of ethanol production atthree months ended September 30, 2021 was negligible compared the Luverne Facility and reduction in workforce will allow us to continue to reduce our cash burn duringthree months ended September 30, 2020.

With many of our employees work remotely, we face the risk that unusual working arrangements could impact the effectiveness of our operations or controls. A potential COVID-19 infection of any of our key employees could materially and adversely impact our operations. In addition, it is possible that COVID-19 restrictions could create difficulty for satisfying our legal or regulatory filing or other obligations, including with the SEC and other regulators.

There is also a risk that COVID-19 could continue to have a material adverse impact on the development of our Net-Zero 1 Project, customer demand and cash flow, for the remainder of 2020 and beyond. We will continue to monitor the situation and assess possible implications to our business and our stakeholders and will take appropriate actions to help mitigate adverse consequences. The extent to which COVID-19 continues to impact our business and financial position will dependdepending on future developments, which are difficult to predict, including the severity, duration and scope of the COVID-19 outbreak as well as the types of measures imposed by governmental authorities to contain the virus or address its impact and the duration of those actions and measures.

We have considered multiple scenarios, with both positive and negative inputs, as part of the significant estimates and assumptions that are inherent in our financial statements and are based on trends in customer behavior and the economic environment throughout the quarter ended September 30, 2020 and beyond as the COVID-19 pandemic has impacted the industries in which we operate. These estimates and assumptions include the collectability of billed and unbilled receivables, the estimation of revenue and tangible and intangible assets. With regard to collectability, we believe we may face atypical delays in client payments going forward but we have not experienced delays in collection as of September 30, 2020. In addition, we believe that the demand for certain discretionary lines of business may decrease, and that such decrease will impact our financial results in succeeding periods. Non-discretionary lines of business may also be adversely affected, for example because reduced economic activity or disruption in hydrocarbon markets reduces demand for or the extent of alcohol-to-jet ("ATJ"), isooctane and isooctene. We believe that these trends and uncertainties are comparable to those faced by other registrants as a result of the COVID-19 pandemic.

In response to the impact of the COVID-19 pandemic, each of Patrick R. Gruber, our Chief Executive Officer, Christopher M. Ryan, our President, Chief Operating Officer and Chief Technology Officer, L. Lynn Smull, our Chief Financial Officer, Timothy J. Cesarek, our Chief Commercial Officer, Geoffrey T. Williams, Jr., our General Counsel and Secretary, and Carolyn M. Romero, our Vice President - Controller and Principal Accounting Officer (collectively, the “Officers”) accepted 20% reductions to their base salaries as of April 1, 2020 and continued until July 31, 2020. In connection with the 20% salary reduction, the Officers were granted Company stock in the form of restricted stock awards in an amount equal to the 20% reduction. Certain remaining employees that earn above a certain dollar threshold also agreed to take a 20% salary reduction effective April 1, 2020 and continued through July 31, 2020, with the 20% portion to be paid in the form of restricted stock awards.future production activities.

 

In addition, the effectiveness of external parties, including governmental and non-governmental organizations, in combating the spread and severity of COVID 19 could have a material impact on demand for our business. Further, steps taken by market counter parties such as commercial airlines could have an impact on their ability to perform agreements to which we are a party, which could impact our business. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID 19 on our business.

COVID-19 has materially disrupted, and could continue to materially disrupt, our own business operations and the services we provide, as well as the business operations of our customers, suppliers and other third parties with whom we interact. As an increasing percentage of our colleagues work remotely, we face the risk that unusual working arrangements could impact the effectiveness of our operations or controls. A potential COVID-19 infection of any of our key colleagues could materially and adversely impact our operations. In addition, it is possible that COVID-19 restrictions could create difficulty for satisfying our legal or regulatory filing or other obligations, including with the SEC and other regulators.

New Contracts. As previously disclosed, on April 4, 2019, Gevo, Inc. and Praj Industries Ltd. (“Praj”) entered into a Construction License Agreement (“CLA”), that certain Joint Development Agreement, effective as of April 1, 2018 (as amended, the “Feedstock JDA”) and that certain Development License Agreement, effective as of April 1, 2018. On August 13, 2020, we entered into a Master Framework Agreement (the “MFA”) with Praj to collaborate on providing renewable jet fuel and premium gasoline in India and neighboring countries. The MFA replaces the CLA effective August 13, 2020.

Under the MFA, Praj has exclusive rights to cause us to enter into negotiations with third-parties (each, a “Plant Operator”) that own or operate refineries for the production of Biobutanol (defined in the MFA), including conversion of ethyl alcohol to Biobutanol or for the production of isooctane, jet fuel and/or similar hydrocarbons (the “Hydrocarbon Transportation Fuel”) either in the Territory (as defined in the MFA) or who are named on the Plant List (as defined in the MFA). Provided the Plant Operator and the Company enter into such license, the MFA allows Praj to provide services (such as basic engineering and design package, supply of critical equipment, supervision services, engineering, procurement and construction services and additional related services) (the “Services”) to the applicable Plant Operator for (a) production of Biobutanol from juice, syrup, and/or molasses from sugarcane, beets, bagasse, rice straw, wheat straw or corn stover, and other additional feedstocks using the process design package developed under the Feedstock JDA and (b) for the production of Hydrocarbon Transportation Fuel using the Hydrocarbon PDPs (as defined in the MFA) for the conversion of Biobutanol to Hydrocarbon Transportation Fuel. Praj has no rights to commercially produce Biobutanol or otherwise convert Biobutanol to Hydrocarbon Transportation Fuel under the MFA.

We will receive certain finder’s fees to the extent one of our third party licensees (a) is not previously identified in the various agreements or not located in certain specified areas, (b) uses Praj’s enfinity Technology (as defined in the MFA) in concert with the Feedstock PDP and (c) the constructed facilities are of a certain commercial scale. The MFA will continue in effect for ten years, unless earlier terminated by either party, and automatically renews for additional one year terms until terminated. If Praj fails to fully commission Authorized Plants (as defined in the MFA) with the cumulative capacity to generate five million gallons per year of Biobutanol or Hydrocarbon Transportation Fuel by the fifth contract year, the exclusive license grants will terminate (unless otherwise mutually agreed in writing by the parties).

On August 14, 2020, we entered into a Renewable Hydrocarbons Purchase and Sale Agreement (the “Agreement”) with Trafigura Trading LLC (“Trafigura”), pursuant to which we agreed to supply renewable hydrocarbons to Trafigura. The initial term of the Agreement is 10 years, and Trafigura has the option to extend the initial term. Performance under the Agreement is subject to certain conditions as set forth below, including acquiring a production facility to produce the renewable hydrocarbon products contemplated by the Agreement and closing a financing transaction for sufficient funds to acquire and retrofit the production facility contemplated by the Agreement. We are required to use commercially reasonable efforts to cause the “Commercial Operations Date” to occur on or before December 31, 2023. We will sell the renewable hydrocarbons to Trafigura at certain indexed prices as set forth in the Agreement.

If we do not provide to Trafigura the design, capabilities (including the expected annual production capacity), specifications, required governmental authorizations, delivery logistics and location of an additional new project that we plan to develop or acquire (the “Production Facility”) (collectively, the “Facility Design”) to meet the requirements set forth in the Agreement on or before December 31, 2020, either party may terminate the Agreement. The parties respective obligations under the Agreement are also subject to certain Conditions Precedent (as defined in the Agreement), including, but not limited to, Gevo securing initial financing for the construction of the Production Facility, and Gevo having entered into engineering, procurement, and construction agreements for the construction of the Production Facility, in form and substance reasonably satisfactory to us.

Subject to the satisfaction or waiver of all of the Conditions Precedent, we are required to use commercially reasonable efforts to cause the “Commercial Operations Date” to occur on or before December 31, 2023. The Commercial Operations Date will be the date on which the Company determines that the production facility is capable of consistently producing renewable hydrocarbons conforming to specification and in quantities set forth under the Agreement, provided that the expected annual production capability is at least equal to 85% of the annual production capability contemplated by the Facility Design. If the Commercial Operations Date has not taken place on or before December 31, 2023 (as may be adjusted in accordance with the Agreement), then we will be required to pay Trafigura certain liquidated damages.

July 2020 Offering. On July 6, 2020, we completed a public offering (the “July 2020 Offering”) of (i) 20,896,666 Series 1 units (the “Series 1 Units”) at a price of $0.60 per Series 1 Unit, and (ii) 9,103,334 Series 2 units (the “Series 2 Units”) at a price of $0.59 per Series 2 Unit. The July 2020 Offering was made under a registration statement on Form S-1 filed with the Securities and Exchange Commission, declared effective on September 30, 2020.

Each Series 1 Unit consisted of one share of our common stock and one Series 2020-A warrant to purchase one share of our common stock (each, a “Series 2020-A Warrant”). Each Series 2 Unit consists of a pre-funded Series 2020-B warrant to purchase one share of our common stock (each, a “Series 2020-B Warrant” and, together with the Series 2020-A Warrants, the “Warrants”) and one Series 2020-A Warrant. The Series 2020-A Warrants are exercisable beginning on the date of original issuance and will expire five years from the date of issuance, at an exercise price of $0.60 per share. The pre-funded Series 2020-B Warrants are exercisable beginning on the date of issuance at a nominal exercise price of $0.01 per share of common stock any time until the Series 2020-B Warrants are exercised in full. In connection with the July 2020 Offering, the Company issued Series 2020-A Warrants to purchase an aggregate of 30,000,000 shares of common stock. As of September 30, 2020, all of the Series 2020-B Warrants were exercised.

The net proceeds to us from the July 2020 Offering were approximately $16.1 million, after deducting placement agent fees and other offering expenses payable by us, and not including any future proceeds from the exercise of the Warrants. We intend to use the net proceeds from the July 2020 Offering to fund working capital and for other general corporate purposes.

During the three months ended September 30, 2020, we received notices of exercise from holders of our Series 2020-A Warrants to issue an aggregate of 27,317,834 shares of common stock for total gross proceeds of approximately $16.4 million. Following these exercises, Series 2020-A Warrants to purchase 2,682,166 shares of our common stock remain outstanding at an exercise price of $0.60 per share.

August 2020 Offering. On August 25, 2020, we completed a registered direct offering pursuant to a securities purchase agreement with certain institutional and accredited investors providing for the issuance and sale by us of an aggregate of (i) 21,929,313 shares of our common stock (the “Shares”) at a price of $1.30 per share, and (ii) 16,532,232 pre-funded Series 2020-C warrants to purchase one share of our common stock (each, a “Series 2020-C Warrant”) at a price of $1.29 per Series 2020-C Warrant, in a registered direct offering (the “August 2020 Offering”). As of September 30, 2020, all of the Series 2020-C Warrants were exercised.

The net proceeds to us from the August 2020 Offering were approximately $45.8 million, after deducting placement agent fees and other estimated offering expenses payable by us, and not including any future proceeds from the exercise of the Warrants. We intend to use the net proceeds from the August 2020 Offering to fund working capital and for other general corporate purposes.

Conversion of 2020/21 Notes. On July 10, 2020, certain holders of the 2020/21 Notes converted $2.0 million in aggregate principal amount of 2020/21 Notes (including the conversion of an additional $0.3 million for make-whole payment) into an aggregate of 4,169,426 shares of common stock pursuant to the terms of the 2020/21 Indenture. We recorded a Loss on conversion of 2020/21 Notes of $0.5 million on our Consolidated Statements of Operations.

At-the-Market Offering Program. In February 2018, we commenced an at-the-market offering program, which allows it to sell and issue shares of its common stock from time-to-time. In August 2019, the at-the-market offering program was amended to provide available capacity under the at-the-market offering program of $10.7 million.

During the nine months ended September 30, 2020, we issued 1,343,121 shares of common stock under the at-the-market offering program for total proceeds of $2.2 million, net of commissions and other offering related expenses. No shares were issued under the at-the-market offering program during the three months ended September 30, 2020.

As of September 30, 2020, we have remaining capacity to issue up to approximately $6.5 million of common stock under the at-the-market offering program.

 

Restructuring Expenses

During the first quarter of 2020, we suspended our ethanol production at the Luverne Facility. In addition, due to the impact of the COVID-19 pandemic on the global economy and our industry, we also reduced our workforce impacting 26 people at the Luverne Facility and four people at our corporate headquarters. 

We incurred $0.1 million related to severance costs and $0.2 million related to lease agreements for which we will no longer receive value during the nine months ended September 30, 2020, which are recorded as Restructuring expenses on the Consolidated Statements of Operations.

We intend to continue developing our hydrocarbon business, including the planned expansion of the Luverne Facility, and we expect to move forward in securing the project funding needed to expand the Luverne Facility. The expansion is designed to allow us to produce large quantities of low carbon isobutanol, sustainable aviation fuel and renewable isooctane. We also expect to continue engineering efforts for the expansion of isobutanol production and the construction of a commercial renewable hydrocarbon production facility, as well as additional decarbonization projects, at the Luverne Facility.

Financial Condition

 

We have incurred consolidated net losses since inception and we had a significant accumulated deficit as of September 30, 2020.2021. Our cash, and cash equivalents and restricted cash at September 30, 20202021 totaled $80.6$136.2 million and marketable debt securities totaled $386.2 million, which is primarily being used for the following: (i) identification, development, of the Luverne Facility expansion plan; (ii) identificationacquisition and construction of new production facilities and to plan for expanded production to fulfill existing off-take agreements;agreements, including the Company's Net Zero Projects; (ii) investment in the Gevo NW Iowa RNG facility; (iii) development of the Luverne Facility; (iv) development, acquisition and operation of sustainable ETSAF plants to produce SAF alone or with partners; (v) operating activities at the Company’sour corporate headquarters in Colorado, including research and development work; (iv) development expenses associated with our RNG projects; (v)(vi) exploration of strategic alternatives and additional financings, including project financing; and (vi)(vii) future debt service obligations.

 

The continued operation of our business is dependent upon raising additional capital through future public and private equity offerings, debt financings or through other alternative financing arrangements. In addition, successful completion of our research and development programs and the attainment of profitable operations are dependent upon future events, including our ability to raise sufficient capital to expanddevelop, construct and finance our commercial production facility,Net-Zero 1 Project, completion of our development activities resulting in sales of isobutanol or isobutanol-derived products and/or technology, achieving market acceptance and demand for our products and services and attracting and retaining qualified personnel.

 

We expect to incur future net losses as we continue to fund the development and commercialization of our products and product candidates. We have primarily relied on raising capital to fund our operations and debt service obligations by issuing common stock and warrants in underwritten public offerings. Those issuances have caused significant dilution to our existing stockholders. While we have sought, and will continue to seek, other, less dilutive forms of financing to fund our operations and debt service obligations, there is no assurance that we will be successful in doing so.

 

Our transition to profitability is dependent upon, among other things, the successful development and commercialization of our productsproduct candidates, construction of our Net-Zero 1 Project and product candidates,additional production facilities to support our offtake agreements, the achievement of a level of revenues adequate to support our cost structure, and securing sufficient financing for the expansion of the Luverne Facility or a facility at another suitable location. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to needability to raise capital to complete the construction of our Net-Zero 1 Project and additional cash.production facilities. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we may seek additional capital through arrangements with strategic partners or from other sources and we will continue to address our cost structure.sources. Notwithstanding, there can be no assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations especially in light ofon acceptable terms, or at all. We believe we have adequate cash to fund operations for at least one year from the impact of the COVID-19 pandemic on us anddate the financial markets in general.statements are issued.

 

 

Results of Operations

 

Comparison of the Three Months Ended September 30, 2021 and 2020 and 2019

 

 Three Months Ended September 30,      Three Months Ended September 30,    

(in thousands)

 2020  

2019

  

Change

  2021  2020  

Change

 

Revenue and cost of goods sold

                  

Ethanol sales and related products, net

 $21  $5,554  $(5,533) $16  $21  $(5)

Hydrocarbon revenue

  101   550   (449) 104  101  3 
Other revenue  70   6   64 
Grant and other revenue  22   70   (48)

Total revenues

  192   6,110   (5,918) 142  192  (50)
          

Cost of goods sold

  2,260   9,893   (7,633)  3,482   2,260   1,222 
          

Gross loss

  (2,068)  (3,783)  1,715   (3,340)  (2,068)  (1,272)
             

Operating expenses

                   

Research and development expense

  870   1,789   (919) 1,541  870  671 

Selling, general and administrative expense

  3,215   2,431   784  9,335  2,892  6,443 

Restructuring costs

  (50)     (50)
Preliminary stage project costs 313  323  (10)
Loss on disposal of assets 183    183 

Restructuring expenses

     (50)  50 
          

Total operating expenses

  4,035   4,220   (185)  11,372   4,035   7,337 
             

Loss from operations

  (6,103)  (8,003)  1,900   (14,712)  (6,103)  (8,609)
             

Other income (expense)

                   

Interest expense

  (473)  (605)  132  (67) (473) 406 
(Loss) on conversion of 2020/21 Notes to common stock (543)   (543)   (543) 543 

Gain from change in fair value of derivative warrant liability

     (2)  2  6    6 

Gain (loss) from change in fair value of 2020/21 Notes and 2020 Notes embedded derivative liability

  247      247 

Other income

  36   (9)  45 
Gain from change in fair value of 2020/21 Notes embedded derivative liability   247  (247)
Other income (expense), net  393   36   357 
          

Total other income (expense), net

  (733)  (616)  (117)  332   (733)  

1,065

 
             

Net loss

 $(6,836) $(8,619) $1,783  $(14,380) $(6,836) $(7,544)

The Luverne Facility re-commenced operations during July 2021. The Luverne Facility began producing isobutanol that will be used as a feedstock for us to produce SAF and renewable premium gasoline to fulfill existing sales contracts. These renewable hydrocarbons will be produced at the South Hampton Resources, Inc. facility near Houston, Texas (the "South Hampton Facility"). We also expect to utilize some of the isobutanol produced to develop certain isobutanol specialty markets and for testing and development. The production operations at the Luverne Facility will allow also us to test and evaluate certain potential unit operations that may be incorporated into the Net-Zero 1 Project. Additionally, if there is a positive change in market conditions for ethanol, we may consider restarting the production of ethanol at the Luverne Facility. In September 2021, we announced our plans to deploy a hydrocarbon pilot unit at the Luverne Facility to produce market development quantities of SAF, renewable premium gasoline, other renewable fuel products, as well as provide capability to supply market development quantities of chemical products. The installation is estimated to begin in the third quarter 2022 with startup demonstration production expected in the fourth quarter 2022. Installation of the pilot unit at the Luverne Facility is part of the plan to use the facility as a technology development and piloting site. We intend to utilize the fermentation and hydrocarbon processing units at the Luverne Facility to provide critical, hands-on training for staff at our Net-Zero 1 and other future projects. We do not expect to generate significant revenue from the operation of the Luverne Facility.

 

Revenue.As a result of COVID-19 and in response to an unfavorable commodity environment, we suspended ethanol and distiller's grains production at the Luverne Facility in March 2020. Revenue from the sale of ethanol, isobutanol and related products for the three months ended September 30, 2021 and 2020 was $0.02 million, a decrease of $5.5 million compared to the three months ended September 30, 2019. This decrease was primarily the result of terminating ethanol and distiller's grains production at the Luverne Facility in March 2020 as a result of COVID-19 and in response to an unfavorable commodity environment. During the three months ended September 30, 2020, we sold 0 gallons of ethanol compared to 3.4 million gallons of ethanol sold in the three months ended September 30, 2019. We do not expect to earn revenue from the sale of ethanol, isobutanol and related products while the Luverne Facility's operations are suspended.

Hydrocarbon revenues are comprised of ATJ, isooctane and isooctene sales. Hydrocarbon sales decreased by $0.4 million during the three months ended September 30, 2020 as a result of decreased shipments of finished products fromnil. Currently, our demonstration plant located at the South Hampton Resources, Inc. facility near Houston, Texas (the “South Hampton Facility”).Facility is not producing renewable premium gasoline or SAF. 

 

CostHydrocarbon revenues are comprised of goods sold. Cost of goods sold was $2.3 million during the three months ended September 30, 2020, compared with $9.9 million during the three months ended September 30, 2019, a decrease of approximately $7.6 million, primarily the result of terminating ethanol production in March 2020 as a result of COVID-19SAF, isooctane and in response to an unfavorable commodity environment. Cost of goods sold included approximately $0.9 million associated with the maintenance of the Luverne Facility and approximately $1.4 million in depreciation expense during the three months ended September 30, 2020.isooctene sales.

 

 

Until the Luverne Facility restarts production, costCost of goods sold. Cost of goods sold will primarily be comprised of costs to process ATJ, isooctane and isooctene at our South Hampton Facility as well as costs to maintain the Luverne Facility. In late October of 2020, we began producing approximately 50,000 gallons of isobutanol at the Luverne Facility which will be shipped to the South Hampton Facility for use in production of renewable hydrocarbons during the first quarter of 2021. We plan to produce an additional 50,000 gallons of isobutanol during the second quarter of 2021 for use at the South Hampton Facility.

Research and development expense. Research and development expense decreased by approximately $0.9was $3.5 million during the three months ended September 30, 2021, compared with $2.3 million during the three months ended September 30, 2020, an increase of approximately $1.2 million. We began producing isobutanol at the Luverne Facility during the three months ended September 30, 2021 resulting in higher production costs. Cost of goods sold included approximately $2.4 million associated with production of isobutanol and maintenance of the Luverne Facility, including inventory write down to net realizable value of $1.2 million, and approximately $1.1 million in depreciation expense during the three months ended September 30, 2021.

Research and development expense. Research and development expense increased by approximately $0.7 million during the three months ended September 30, 2021, 2020, compared with the three months ended September 30, 2019,2020, due primarily to a decreasean increase in personnel costs related to increased headcount and stock-based compensation and consulting expenses.expenses as we work to improve our process for growing and fermenting yeast strains.

 

Selling, general and administrative expense. Selling, general and administrative expense increased by approximately $0.8$6.4 million during the three months ended September 30, 2021, 2020, compared with the three months ended September 30, 2019,2020, due primarily to an increaseincreases in personnel consultingcosts related to increased headcount and insurance expenses andstock-based compensation, professional fees offset by a decreaserelated to new contracts and higher costs for insurance, and increased consulting fees related to documenting our compliance with Section 404(b) of the Sarbanes-Oxley Act ("SOX").

Preliminary stage project costs. Preliminary stage project costs are related to our Gevo RNG and Net-Zero projects. During the three months ended September 30, 2021,  preliminary stage project costs were approximately the same as the three months ended September 30, 2020. During the three months ended September 30, 2021, the preliminary stage project costs were primarily related to consulting for preliminary engineering costs and for personnel expenses to support the growth in investor relations expenses.business activity at our Net-Zero projects. During the three months ended September 30, 2020, the preliminary project costs related primarily to consulting for preliminary engineering costs and personnel expenses to support the growth in business activity at our Gevo RNG project. During the three months ended September 30, 2021, we began capitalizing our Net-Zero 1 project costs after completing certain front-end engineering studies and determining it was probable that we would build Net-Zero 1 in Lake Preston, SD.

 

Loss on disposal of assets. A s a result of suspending the production of ethanol at the Luverne Facility, we wrote-off $0.2 million of costs related to the removal of the fractionation equipment returned to the manufacturer during the three months ended September 30, 2021.
Interest expense. Interest expense during the three months ended September 30,, 2020 was $0.5 million, a decrease of $0.1 2021  decreased by $0.4 million compared to the three months ended September 30, 2019,2020 , due to lower amortization of original issue discounts and debt issuance costs andthe conversion of $2.0 millionall of our then-outstanding 12% convertible senior secured notes due 2020/2021 (the "2020/21 NotesNotes") to common stock during July 2020.
 

(Loss) on conversion of 2020/21 Notes to common stock. During the three months ended September 30, 2020, we incurred a $0.5 million loss related to the conversion of $2.0 million of 2020/21 Notes into common stock during July 2020.

 

(Loss) gain from change in fair value of the 2020/21 Notes and 2020 Notes embedded derivative liability. During We incurred no gain (loss) from the three months ended September 30, 2020, the estimatedchange in fair value of the 2020/21 Notes embedded derivative liability increased resulting in a non-cash gainthe three months ended September 30, 2021 since the 2020/21 Notes were converted to common stock in 2020.

Other (expense) income. Other income during the three months ended September 30, 2021 was $0.4 million, an increase of $0.2$0.4 million compared to the three months ended September 30, 2020, primarily due to the revaluation of the embedded derivative liability.income earned on marketable securities and restricted cash.

 

 

Comparison of the Nine Months Ended September 30, 20202021 and 20192020

 

 Nine Months Ended September 30,      

Nine Months Ended September 30,

     

(in thousands)

 2020  

2019

  

Change

  

2021

  

2020

  

Change

 

Revenue and cost of goods sold

                  

Ethanol sales and related products, net

 $3,804  $16,184  $(12,380) $16  $3,804  $(3,788)

Hydrocarbon revenue

  1,085   1,381   (296) 463 1,085 (622)
Other revenue  116   34   82 

Grant and other revenue

  178  116  62 

Total revenues

  5,005   17,599   (12,594) 657 5,005 (4,348)
          

Cost of goods sold

  13,043   27,306   (14,263)  8,270  13,043  (4,773)
          

Gross loss

  (8,038)  (9,707)  1,669   (7,613)  (8,038)  425 
             

Operating expenses

                  

Research and development expense

  2,127   3,712   (1,585) 4,323 2,127 2,196 

Selling, general and administrative expense

  8,917   6,705   2,212  18,027 8,179 9,848 

Restructuring costs

  254      254 

Preliminary stage project costs

 8,512 700 7,812 
Loss on disposal of assets 5,137 38 5,099 

Restructuring expenses

    254  (254)
          

Total operating expenses

  11,298   10,417   881   35,999  11,298  24,701 
             

Loss from operations

  (19,336)  (20,124)  788   (43,612)  (19,336)  (24,276)
             

Other income (expense)

                  
Gain on forgiveness of SBA loans 641  641 

Interest expense

  (1,559)  (2,127)  568  (78) (1,559) 1,481 

(Loss) on modification of 2020 Notes

  (726)     (726)

(Loss) from modification of 2020 Notes

  (726) 726 
(Loss) on conversion of 2020/21 Notes to common stock (543)   (543)  (543) 543 

Gain from change in fair value of derivative warrant liability

  8   1   7 

(Loss) gain from change in fair value of 2020/21 Notes and 2020 Notes embedded derivative liability

  (29)  394   (423)

Other income

  53   11   42 

(Loss) gain from change in fair value of derivative warrant liability

 (4) 8 (12)

(Loss) from change in fair value of 2020/21 Notes embedded derivative liability

  (29) 29 

Other income (expense), net

  363  53  310 
          

Total other income (expense), net

  (2,796)  (1,721)  (1,075)  922  (2,796)  3,718 
             

Net loss

 $(22,132) $(21,845) $(287) $(42,690) $(22,132) $(20,558)

The Luverne Facility re-commenced operations during July 2021. The Luverne Facility began producing isobutanol that will be used as a feedstock for us to produce SAF and renewable premium gasoline to fulfill existing sales contracts. These renewable hydrocarbons will be produced at the South Hampton Facility. We also expect to utilize some of the isobutanol produced to develop certain isobutanol specialty markets and for testing and development. The production operations at the Luverne Facility will also allow us to test and evaluate certain potential unit operations that may be incorporated into the Net-Zero 1 Project. Additionally, if there is a positive change in market conditions for ethanol, we may consider restarting the production of ethanol at the Luverne Facility. In September 2020, we announced our plans to deploy a hydrocarbon pilot unit at the Luverne Facility to produce market development quantities of  SAF, renewable premium gasoline, other renewable fuel products, as well as provide capability to supply market development quantities of chemical products. The installation is estimated to begin in Q3 2022 with startup demonstration production expected in Q4 2022. Installation of the pilot unit at the Luverne Facility is part of the plan to use the facility as a technology development and piloting site. We intend to utilize the fermentation and hydrocarbon processing units at the Luverne Facility to provide critical, hands-on training for staff at our Net-Zero 1 and other future projects. We do not expect to generate significant revenue from the operation of the Luverne Facility.

 

Revenue. RevenueAs a result of COVID-19 and in response to an unfavorable commodity environment, we suspended ethanol and distiller's grains production at the Luverne Facility in March 2020. Revenue from the sale of ethanol, isobutanol and related products for the nine months ended September 30,, 2020 2021 was $3.8 million,negligible, a decrease of $12.4$3.8 million compared to the nine months ended September 30, 2019. This decrease was primarily the result of terminating ethanol and distiller's grains production at the Luverne Facility in March 2020 as a result of COVID-19 and in response to an unfavorable commodity environment.2020. During the nine months ended September 30,, 2020, 2021, we sold 2.4 million gallons ofdid not sell any ethanol compared to 10.22.4 million gallons of ethanol sold in the nine months ended September 30, 2019.2020. Currently, the South Hampton Facility is not producing renewable premium gasoline or SAF. We expect to produce isobutanol during 2021 to supply the South Hampton Facility so that renewable premium gasoline or SAF can be produced in 2021.

Hydrocarbon revenues are comprised of SAF, isooctane and isooctene sales. Hydrocarbon sales decreased by $0.3$0.6 million during the nine months ended September 30,, 2020 2021 as a result of decreased shipments of finished products from our demonstration plant locatedlower production volumes at the South Hampton Facility.

Cost of goods sold.Cost of goods sold was $8.3 million during the nine months ended September 30, 2021, compared with $13.0 million during the nine months ended September 30,, 2020, compared with $27.3 million during the nine months ended September 30, 2019, a decrease of approximately $14.3$4.7 million, primarily the result of terminatingsuspending ethanol production in March 2020 as a result of COVID-19 and in response to an unfavorable commodity environment. We began producing isobutanol at the Luverne Facility during the three months ended September 31, 2021  resulting in higher production costs. Cost of goods sold included approximately $8.4$4.9 million associated with the production of ethanol and related productsisobutanol and maintenance of the Luverne Facility, including inventory write down to net realizable value of $2.0 million, and approximately $4.6$3.4 million in depreciation expense during the nine months ended September 30,, 2020.
42

2021.

 

Until
Prior to the Luverne Facility restartsrestarting production, cost of goods sold willwas primarily be comprised of costs to process ATJ,SAF, isooctane and isooctene at theour South Hampton Facility as well as costs to maintain the Luverne Facility. In late October of 2020, we began producing approximately 50,000 gallons of isobutanol which will be shipped to the South Hampton Facility for use in production of renewable hydrocarbons during the first quarter of 2021. We plan to produce an additional 50,000 gallons of isobutanol during the second quarter of 2021 for use at the South Hampton Facility.

Research and development expense. Research and development expense decreased by approximately $1.6 million during the nine months ended September 30, 2020, compared with the nine months ended September 30, 2019, due primarily to a decrease in personnel and consulting expenses.

Selling, general and administrative expense. Selling, general and administrative expense increased by approximately $2.2 million during the nine months ended September 30,, 2020, 2021, compared with the nine months ended September 30, 2019,2020, due primarily to an increasepersonnel costs from increased headcount and stock-based compensation and consulting expenses as we work to improve our process for growing and fermenting yeast strains.

Selling, general and administrative expense. Selling, general and administrative expense increased by approximately $9.8 million during the nine months ended September 30, 2021, compared with the nine months ended September 30, 2020, due primarily to increases in personnel consultingcosts related to increased headcount, recruiting costs and insurance expenses andstock-based compensation, professional fees offset by a decrease in investor relationsrelated to new contracts and travel expenses.

extensive shareholder outreach for the annual stockholder meeting, higher costs for insurance and increased consulting fees related to documenting our compliance with Section 404(b) of SOX.

 

Restructuring Costs. Preliminary stage project costs. Preliminary stage project costs increased by approximately $7.8 million during the nine months ended September 30, 2021, compared with the nine months ended September 30, 2020, due primarily to increased consulting and research and development expenses related to our Gevo RNG and Net-Zero projects. During the nine months ended September 30,, 2021, the preliminary stage project costs were primarily related to consulting for preliminary engineering costs and for personnel expenses to support the growth in business activity for our Renewable Natural Gas and Net-Zero projects. During the nine months ended September 30, 2020, the preliminary stage project costs were primarily related to consulting for preliminary engineering costs and for personnel expenses to support the growth in business activity at our Gevo RNG project. During the three months ended June 30, 2021, we incurred $0.3began capitalizing the Gevo RNG project costs after completing certain front-end engineering studies and determining it was probable that we would build the Gevo RNG project. During the three months ended September 30, 2021, we began capitalizing our Net-Zero 1 project costs after completing certain front-end engineering studies and determining it was probable that we would build Net-Zero 1 in Lake Preston, SD.

Loss on disposal of assets. A s a result of suspending the production of ethanol at the Luverne Facility, we wrote-off $5.1 million of restructuring chargescosts related to the restructuringinstallation of Agri-Energy, terminationthe fractionation equipment returned to the manufacturer during the nine months ended September 30, 2021.
Gain on forgiveness of employees at Agri-EnergySBA Loans. During the nine months ended September 30, 2021, the Small Business Administration forgave the entire balance of $0.6 million of the Company's SBA Loans and Gevo and renegotiating contracts.

accrued interest.

Interest expense. Interest expense during the nine months ended September 30,, 2020 was $1.6 million, a decrease of $0.6 2021 decreased by $1.5 million compared to the nine months ended September 30, 2019,2020, due to lower amortization of original issue discounts and debt issuance costs andthe conversion of $2.0 million ofthe 2020/21 Notes to common stock during July 2020.

 

(Loss) from modification of 2020 Notes.During the nine months ended September 30,, 2020, we incurred $0.7 million of legal and professional fees to modify the 2020 Notes into the 2020/21 Notes.

 

(Loss) on conversion of 2020/21 Notes to common stock. During the ninethree months ended September 30, 2020, we incurred a $0.5 million loss related to the conversion of $2.0 million of 2020/21 Notes into common stock during July 2020.

(Loss) gain from change in fair value of the 2020/21 Notes and 2020 Notes embedded derivative liability. During We incurred no gain (loss) from the nine months ended September 30, 2020, the estimatedchange in fair value of the 2020/21 Notes embedded derivative liabilityduring the nine months ended September 30, 2021 since the 2020/21 Notes were converted to common stock in 2020.

Other (expense) income. Other income during the nine months ended September 30, 2021 increased resulting in a non-cash loss of $0.03$0.3 million compared to the nine months ended September 30, 2020, primarily due to the revaluation of the embedded derivative liability as a result of the modification of the 2020 Notes.

income earned on marketable securities and restricted cash.

 

Sources of Our Revenues

 

Our revenues are primarily derived from: (i) the sale of isobutanol ethanol and related products; (ii) hydrocarbon sales consisting primarily of the sale of biojet fuelSAF and isooctane derived from our isobutanol for purposes of certification and testing; and (iii) government grants and research and development programs. During the first quarter of 2020, we suspended our ethanol production at the Luverne Facility due to the impact of the COVID-19 pandemic on the economy and our industry as a whole. We do not anticipate earning revenue from the sale of ethanol during the remainder of 2020.

Principal Components of Our Cost Structure

Cost of Goods Sold. Our cost of goods sold consists primarily of costs directly associated with ethanol production and initial operations for the production of isobutanol at the Luverne Facility such as costs for direct materials, direct labor, depreciation, other operating costs and certain plant overhead costs. Direct materials include corn feedstock, denaturant and process chemicals. Direct labor includes compensation of personnel directly involved in production and maintenance operations at the Luverne Facility. Other operating costs include utilities and natural gas usage.

43

 

Research and Development. Our research and development costs consist of expenses incurred to identify, develop and test our technologies for the production of isobutanol and the development of downstream applications thereof. Research and development expenses include personnel costs (including stock-based compensation), consultants and related contract research, facility costs, supplies, depreciation and amortization expense on property, plant and equipment used in product development, license fees paid to third parties for use of their intellectual property and patent rights and other overhead expenses incurred to support our research and development programs.

Selling, General and Administrative. Selling, general and administrative expenses consist of personnel costs (including stock-based compensation), consulting and service provider expenses (including patent counsel-related costs), legal fees, marketing costs, insurance costs, occupancy-related costs, depreciation and amortization expenses on property, plant and equipment not used in our product development programs or recorded in cost of goods sold, travel and relocation expenses and hiring expenses.

Interest Expense. Our 2020/21 Notes have, and the 2020 Notes had, a fixed interest rate of 12%. As of September 30, 2020, the 2020/21 Notes had a principal balance of $12.7 million. As of December 31, 2019, the 2020 Notes had a principal balance of $14.1 million.

Liquidity and Capital Resources

As of September 30, 2021, we had cash and cash equivalents totaling $16.2 million, short and long-term restricted cash totaling $120.0 million and short and long-term marketable securities totaling $386.2 million. The marketable securities are highly liquid and can be converted to cash when it is needed for operations.

 

Since our inception in 2005, we have devoted most of our cash resources to manufacturing ethanol, isobutanol and related products, research and development and selling, general and administrative activities related to the commercialization of ethanol, isobutanol as well asand related products from renewable feedstocks. We have incurred losses since inception and expect to incur losses through at least 2021.for the foreseeable future. We have financed our operations primarily with proceeds from multiple sales of equity and debt securities, borrowings under debt facilities and product sales.

 

The continued operation of our business is dependent upon raising additional capital through future public and private equity offerings, debt financings or through other alternative financing arrangements. In addition, successful completion of our research and development programs and the attainment of profitable operations are dependent upon future events, including our ability to raise sufficient capital to expand our commercial production capabilities, completion of our development activities resulting in sales of isobutanol or isobutanol-derived products and/or technology, achieving market acceptance and demand for our products and services and attracting and retaining qualified personnel.

 

We expect to incur future net losses as we continue to fund the development and commercialization of our products and product candidates. We have primarily relied on raising capital to fund our operations and debt service obligations by issuing common stock and warrants in underwritten public offerings. Those issuances have caused significant dilution to our existing stockholders. While we have sought, and will continue to seek, other, less dilutive forms of financing to fund our operations and debt service obligations, there is no assurance that we will be successful in doing so.

Our transition to profitability is dependent upon, among other things, the successful development and commercialization of our productsproduct candidates, the development, acquisition and product candidates,construction of additional production facilities to support our offtake agreements, the achievement of a level of revenues adequate to support our cost structure and securing sufficient financing for the expansion of the Luverne Facility or a Retrofit facility at other suitable locations. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to needability to raise capital to finance the development, acquisition and construction of additional cash.productions facilities. We intend to fund future operations through additional private and/or public offerings of debt or equity securities. In addition, we may seek additional capital through arrangements with strategic partners or from other sources, and weit will continue to address ourits cost structure. Notwithstanding, there can be no assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.
operations on acceptable terms, or at all.

 

The Company has incurred consolidated net losses since inception and has a significant accumulated deficit as of September 30, 2020. As of

September 30, 2020, we had cash and cash equivalents totaling $80.6 million.

 

The following table sets forth the major sources and uses of cash for each of the periods set forth below (in thousands):

 

 Nine Months Ended September 30,  Nine Months Ended September 30, 
 2020  

2019

  2021  2020 
        

Net cash used in operating activities

 $(14,581) $(14,798) $(28,693) $(14,581)

Net cash used in investing activities

 $(1,756) $(7,260) $(427,985) $(1,756)

Net cash provided by financing activities

 $80,656  $9,268  $514,513  $80,656 

 

Operating Activities

 

Our primary uses of cash from operating activities are personnel related expenses, research and development relateddevelopment-related expenses including costs incurred under development agreements, costs of licensing of technology, legal-related costs, expenses for maintenanceproduction of isobutanol, ethanol and related products, logistics, manufacturing of isobutanol at the Luverne Facility and for the operationfurther processing of isobutanol at our South Hampton Facility.

 

During the nine months ended September 30, 2020,2021, net cash used for operating activities was $14.6$28.7 million compared to $14.8$14.6 million for the nine months ended September 30, 2019.2020. The $0.2$14.1 million decrease in operating cash flows was primarily due to reducedincreased cost of goods sold associated with beginning production atof isobutanol during the third quarter 2021 and maintenance of the Luverne Facility, offset by increased engineering and development fees on our Gevo RNG projects.

Duringand Net-Zero 1 projects, increases in personnel expenses to support the first quarter of 2020, we suspended our ethanol production at the Luverne Facility duegrowth in business activity, professional fees related to COVID-19new contracts and an unfavorable commodity environment, largely the result of greater corn costs as compared to national markets than the region has historically produced. We are currently maintaining the Luverne Facility until we arrange financing of its expansionextensive shareholder outreach for the productionannual stockholder meeting and consulting to support the preparation of hydrocarbons.

We currentlyplan to spend approximately $7 million - $10 million over the next 15 months for engineeringour first ESG report and development costs related to the expansioncompliance with Section 404(b) of the Luverne Facility and our RNG projects. We expect that additional expenditures will be required during the next 15 months for engineering and development work related to the expansion of the Luverne Facility, the RNG projects and other business initiatives.SOX.

 

Investing Activities

 

During the nine months ended September 30, 2020,2021, we used $1.8$428.0 million in cash for investing activities, substantially all of which $422.4 million related to capital expenditures atpurchasing marketable securities and $31.0 million primarily related to construction in process attributable to the Gevo RNG project and to a lesser extent, the purchase of a Hydrocarbon-Process Pilot Unit for our Luverne Facility. We are installing equipment to fractionate distillers grains atFacility and Net-Zero 1 project, and $9 million for the Luverne Facility totaling approximately $2.0purchase of patents, which was partially offset by proceeds of $34.3 million asfrom the sale of September 30, 2020. The cost of the fractionation machine has been funded with a financing lease. No amounts are payable on this financing lease until the equipment is operational. The fractionation machine is expected to be operational in the first half of 2023.marketable securities.

 

We are developing ancurrently constructing the Gevo RNG project comprised of anaerobic digesters to be located at three dairy farms in northwest Iowa, plus associated gas upgrading equipment, to supply our Luverne Facility with renewable thermal energy upon its startup in 2023. Weand expect to financeinvest an additional $32 million in the RNG project, including finance-related costs and initial working capital, with approximately $65 million of combined project finance debt and third-party equity. Agri-Energy is expected to have a purchase option on approximately 50% of the RNG project’s estimated annual 350,000 MMBtu of RNG production. The RNG project is expected to be operational in early 2022, subject to securing adequate financingaggregate to complete the Gevo RNG project in the remainder of 2021 and into 2022 for completion of the project. We currentlyplan to spend approximately $337 million for engineering, development, long-lead equipment deposits, debt financing costs, and project construction equity investment commitments over the next 12 months for the Net-Zero 1 Project.

 

Financing Activities

 

During the nine months ended September 30, 2020,2021, we generated $80.7$514.5 million in cash from financing activities, which primarily consisted of $2.2 million of net proceeds under our "at-the-market" offering program, receiving $16.1$321.9 million from the sale of common stock and warrants in the July 2020January 2021 Offering, $45.8$135.8 million of net proceeds under our "at-the-market" offering program and $69.0 million from the sale2021 Bonds proceeds offset by $5.1 million net settlement of common stock for taxes under our stock plans and pre-funded warrants in the August 2020 Offering, $16.6$3.0 million from the exercise of Series 2020-A Warrants, Series 2020-B Warrants and Series 2020-C Warrants, and $1.0 million from the Small Business Administration's Paycheck Protection Program (“SBA PPP”) discussed below, offset by $0.5 million paidpayments on loans payable - other.finance lease liabilities.

 

 

On July 6, 2020, we completed a public offering (the “July 2020 Offering”) of (i) 20,896,666 Series 1 units (the “Series 1 Units”) at a price of $0.60 per Series 1 Unit, and (ii) 9,103,334 Series 2 units (the “Series 2 Units”) at a price of $0.59 per Series 2 Unit. The net proceeds to us from the July 2020 Offering were approximately $16.1 million, after deducting placement agent fees and other estimated offering expenses payable by the Company, and not including any future proceeds from the exercise of the Warrants. The Company intends to use the net proceeds from the July 2020 Offering to fund working capital and for other general corporate purposes. See Note 1,Nature of Business, Financial Condition and Basis of Presentation,  to our consolidated financial statements included herein for additional information regarding the July 2020 Offering.  As of September 30, 2020, all of the Series 2020-B warrants were exercised.

During the quarternine months ended September 30, 2020,2021, we received notices of exercise from holders of our Series 2020-A Warrants to issue an aggregate of 27,317,8341,866,558 shares of common stock for total gross proceeds of approximately $16.4$1.1 million. Following these exercises, Series 2020-A Warrants to purchase 2,682,16690,608 shares of our common stock remain outstanding at an exercise price of $0.60 per share.

 

On August 25, 2020, we completed a registered direct offering pursuant to a securities purchase agreement with certain institutional and accredited investors providing for the issuance and sale by us of an aggregate of (i) 21,929,313 shares of our common stock (the “Shares”) at a price of $1.30 per share, and (ii) 16,532,232 pre-funded Series 2020-C warrants to purchase one share of our common stock (each, a “Series 2020-C Warrant”) at a price of $1.29 per Series 2020-C Warrant, in a registered direct offering (the “August 2020 Offering”). The net proceeds from the August 202 Offering were approximately $45.8 million, after deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the August 2020 Offering to fund working capital and for other general corporate purposes. See Note 1,Nature of Business, Financial Condition and Basis of Presentation,  to our consolidated financial statements included herein for additional information regarding the August 2020 Offering.  As of September 30, 2020, all of the Series 2020-C warrants were exercised.

At-the-Market Offering Program. In February 2018, we commenced an at-the-market offering program, which allows us to sell and issue shares of our common stock from time-to-time. In August 2019,September 2021, the at-the-market offering program was amended to provide available capacity of $500 million.

No shares of common stock were issued under the at-the-market offering program of $10.7 million.

during the three months ended September 30, 2021. During the nine months ended September 30, 2020,2021, we issued 1,343,12124,420,579 shares of common stock under the at-the-market offering program for nettotal proceeds of $2.2$135.8 million, net of commissions and other offering related expenses. No shares were issued under the at-the-market offering program  in the three months ended September 30, 2020.expenses of $3.6 million. As of September 30, 2020,2021, we hadhave remaining capacity to issue up to $6.5approximately $500 million of common stock under the at-the-market offering program.

 

Finance Leases. The Company has four finance leases for land under arrangements related to Gevo RNG. Under current SEC rulesthese contracts, the Company leases land from dairy farmers on which it is building three anaerobic digesters, related equipment and regulations, ifpipelines to condition raw biogas from cow manure provided by the aggregate market value of our common stock held by non-affiliates, or public float, fallsfarmers. The partially conditioned biogas will be transported from the three digester sites to less than $75 million (calculated as set forth in Form S-3 and SEC rules and regulations)a central gas upgrade system located at the time of filing of our next Annual Report on Form 10- K,fourth site that will upgrade the amount we can raisebiogas to pipeline quality natural gas for sale. The Company also has one finance lease for office equipment. The finance leases pay interest between 5% and 21%, have total annual payments ranging from $4,000 to $4.8 million and mature at various dates through primary public offerings of our securities in any twelve-month period using a registration statement on Form S- 3 will be limited to one-third of our public float.December 2050.

 

2020/21 Notes. 2021 Bonds.On January 10, 2020,April 15, 2021, the Company entered into an Exchange and Purchase Agreement (as amended,closed the “2020/21 Purchase Agreement”) with2021 Bonds offering totaling $68,155,000 to finance the guarantors party thereto (the "Guarantors"), the holderconstruction of the 2020 Notes and Whitebox Advisors LLC ("Whitebox"), in its capacity as representativeGevo RNG project. The proceeds of the holder. Pursuant2021 Bonds, combined with Gevo equity, will be used to finance (1) the termsconstruction of the 2020/21 Purchase Agreement, the holderGevo RNG project which is comprised of the 2020 Notes, subject(A) three anaerobic digesters and related equipment situated on dairy farms located in Northwest Iowa that will produce partially conditioned raw biogas from cow manure, (B) gathering pipelines to certain conditions, agreedtransport biogas to exchange all of the outstanding principal amount of the 2020 Notes, which was approximately $14.1 million including unpaid accrued interest, for approximately $14.4 milliona centrally located gas upgrade system, (C) a centrally located gas upgrade system located in aggregate principal amount of the Company's newly created 2020/21 Notes (the “2020/21 Exchange”). PursuantDoon, Iowa that will upgrade biogas to the 2020/21 Purchase Agreement, the Company also granted an optionpipeline quality RNG and interconnect to purchase upNorthern Natural Gas’ interstate pipeline, and (D) other related improvements; (2) to an additional aggregate principal amount of approximately $7.1 million of 2020/21 Notes (the “2020/21 Option Notes”), at a purchase price equal to the aggregate principal amount of such 2020/21 Option Notes purchased less an original issue discount of 2.0%, having identical terms (other than with respect to the issue date and restrictions on transfer relating to compliance with applicable securities law) to the 2020/21 Notes issued, at any time during the period beginning on the date of closing of the 2020/21 Exchange and ending on the later of (a) 180 days thereafter, and (b) 30 days following June 3, 2020. In addition, on January 10, 2020, the Company completed the 2020/21 Exchange and cancelled the 2020 Notes. In addition, the Company entered into an Indenture by and among the Company, the guarantors named therein (the “2020/21 Notes Guarantors”) and FSB, as trustee and as collateral trustee (the “Original Indenture”), as supplemented by that certain First Supplemental Indenture, dated as of April 7, 2020 (the “First Supplemental Indenture”), that certain Second Supplemental Indenture, dated as of July 2, 2020 (the “Second Supplemental Indenture”), and that certain Third Supplemental Indenture, dated as of August 24, 2020 (the “Third Supplemental Indenture” and, together with the Original Indenture, the First Supplemental Indenture and the Second Supplemental Indenture, the “2020/21 Notes Indenture”), pursuant to which the Company issued the 2020/21 Notes. During the nine months ended September 30, 2020, the Company recognized an approximately $0.7 million loss on the 2020/21 Exchange within the Consolidated Statements of Operations.

The 2020/21 Notes will mature on December 31, 2020, provided that the maturity date will automatically be extended to April 1, 2021 if the aggregate outstanding principal balance of the 2020/21 Notes (including any 2020/21 Option Notes) as of December 15, 2020 is less than $7 million. The 2020/21 Notes bear interest at a rate equal to 12% per annum (with 4% potentially payable as PIK Interest (as defined below) at our option), payable on March 31, June 30, September 30, and December 31 of each year. Under certain circumstances, we have the option to paycapitalize a portion of the interest due on the 2020/21 Notes by either (a) increasing2021 Bonds during the principal amountconstruction period; and (3) to pay a portion of the 2020/21 Notes bycosts of issuing the amount of interest then due or (b) issuing additional 2020 Notes with a principal amount equal2021 Bonds. The draw down on the receivable from bond trustee funds were used to offset the investing activities above related to construction in process attributable to the amount of interest then due (interest paid in the manner set forth in (a) or (b) being referred to as “PIK Interest”).

The 2020/21 Notes are convertible into shares of our common stock, subject to certain terms and conditions. The initial conversion price of the 2020/21 Notes is equal to $2.442 per share of common stock, or 0.4095 shares of common stock per $1 principal amount of 2020 Notes.

On July 10, 2020, certain holders of the 2020/21 Notes converted $2.0 million in the aggregate principal amount of 2020/21 Notes (including the conversion of an additional $0.3 million for make-whole payment) into 4,169,428 shares of common stock pursuant to the terms of the indenture. There was $12.5 million principal outstanding for the 2020/21 Notes upon completion of the conversion of the 2020/21 Notes.

See Note 9, Debt, to our consolidated financial statements included herein for further discussion of the 2020/21 Notes.Gevo RNG project.

 

Loans Payable - Other. During the first quarter of 2020, we purchased equipment under a financing lease. During the fourth quarter of 2019, we financed part of our insurance obligation. The equipment notes and financing lease pay interest between 4% and 21%5%, have total monthlyannual payments of $0.1 million and mature at various date from August 2020 to February 2025.dates through December 2024. The equipment loans are secured by the related equipment.

 

The rapidly evolving changes in financial markets could have a material impact on our ability to obtain financing, which could impact our liquidity. In April 2020, wethe Company and Agri-Energy each entered into twoa loan agreementsagreement with Live Oak Banking Company, pursuant to which wethe Company and Agri-Energy obtained two loans from the Small Business Administration's Paycheck Protection Program (“SBA PPP”)PPP totaling $1.0 million in the aggregate (the "SBA Loans").aggregate.

On April 15, 2021, the Small Business Administration forgave the entire balance of $0.5 million of the Company's and $0.1 million of Agri-Energy's loans and accrued interest obtained through the SBA PPP. The remaining SBA Loans will matureLoan for Agri-Energy totals $0.4 million, bears interest at 1.0% and matures in April 2022 and bear interest at a rate equal to 1% per annum, subject to the potential for partial or full loan forgiveness as dictated by U.S. federal law. Principal and interest are deferred until August2025. Monthly payments of $8,000 began on June 5, 2021 and interest continues to accrue during the deferral period. The SBA Loans are payable monthly beginning August 5, 2021, with aggregate payments totaling $0.06 million per month, including interest and principal. The SBA Loans must be used for payroll, rent payments, mortgage interest payments and utilities payments as governed by the SBA PPP and are subject to partial or full forgiveness for the initial 24-week period following the loan disbursement if all proceeds are used for eligible purposes and within certain thresholds, we maintain certain employment levels and the we maintain certain compensation levels. No assurance can be given that we will obtain forgiveness of the loan in whole or in part. The loan contains customary events of default relating to, among other things, payment defaults, making materially false and misleading representations to the lender or breaching the terms of the loan documents.through April 2025.

 

See Note 9, Debt, to our consolidated financial statements included herein for further discussion.

 

 

Critical Accounting Policies and Estimates

 

ThereLeases, Right-of-Use Assets and Related Liabilities. We enter into various arrangements which constitute a lease as defined by ASC 842, Leases, as part of its ongoing business activities and operations. Leases represent a contract or part of a contract that conveys the right to control the use of identified property, plant or equipment (an identified asset) for a period of time in exchange for consideration. Such contracts result in both (a) right-of-use assets, which represent our right to use an underlying asset for the term of the contract; and (b) a corresponding lease liability which represents our obligation to make the lease payments arising from the contract. The Company has elected not to recognize a right-of-use asset and lease liability for any lease with an original lease term of 12 months or less. Lease expense for such leases is recognized on a straight-line basis over the lease term.

A lease is classified as a finance lease when one or more of the following criteria are met: (1) the lease transfers ownership of the asset by the end of the lease term, (2) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (3) the lease term is for a major part of the remaining useful life of the asset, (4) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, and (5) the asset is of such a specialized nature that it is expected to have been no alternative use to the lessor at the end of the lease term. If a lease does not meet any of these criteria, the lease is classified as an operating lease.

Lease liabilities are initially measured at the lease commencement date based on the present value of lease payments over the lease term, discounted using an estimate of our incremental borrowing rate for a collateralized loan with the same term and payment as the lease. Right-of-use assets are measured based on the amount of the lease liability adjusted for any lease payments made to the lessor at or before the lease commencement date less any lease incentives received. All right-of-use assets are evaluated for impairment in accordance with accounting standards applicable to long-lived assets as further described in the significant changes toaccounting policy “Impairment of Property, Plant and Equipment” in our critical accounting policies sinceAnnual Report on Form 10-K for the year ended December 31, 2019. 2020.

Renewal options are included in the calculation of our right-of-use assets and lease liabilities when we determine that the option is reasonably certain of exercise based on an analysis of the relevant facts and circumstances. Certain of our leases require variable lease payments that do not depend on an index or rate and such payments are excluded from the calculation of the right-of-use asset and lease liability and are recognized as variable lease cost when incurred.

We have elected the practical expedient to account for the lease and non-lease components as a single lease component for our dairy lease and fuel supply asset class. This results in a significantly higher ROU assets and lease liabilities than if the Company had not elected this practical expedient.

Lease cost for operating leases consists of the fixed lease payments recognized on a straight-line basis over the lease term plus variable lease payments as incurred. Lease cost for finance leases consists of amortization of the right-of-use assets on a straight-line basis over the lease term, interest expense on the lease liability and variable lease payments as incurred.

For a description of our other critical accounting policies and estimates that affect our significant judgments and estimates used in the preparation of our consolidated financial statements, refer to our Annual Report.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2020,2021, we did not have any material off-balance sheet arrangements.

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide information under this item.

 

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosures.

 

Management, including the participation of our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation (pursuant to Rule 13a-15(b) of the Exchange Act) of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30,, 2020. 2021. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable but not absolute assurance that the objectives of the disclosure controls and procedures are met. The design of any disclosure control and procedure also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Changes in Internal Control Over Financial Reporting

 

There have beenwas no changeschange in our internal control over financial reporting during the quarter ended September 30,, 2020 2021 that have materially affected, or areis reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

From time to time, we have been and may again become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any litigation and we are not aware of any pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results, financial condition or cash flows.

 

 

Item 1A. Risk Factors.

 

You should carefully consider the risk factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report, which could materially affect our business, financial condition, cash flows or future results. Except as set forth below, thereThere have been no material changes in our risk factors included in our Annual Report. The risk factors in our Annual Report are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

 

We will be unable to issue sufficient additional shares for future capital raising transactions or strategic transactions unless we obtain stockholder approval to amend our certificate of incorporation toOurincreasethenumberofauthorizedsharesof our common stock available for issuance.

We have 250,000,000 authorized shares of common stock. As of October 29, 2021, we had 201,879,978 shares of common stock outstanding and 13,693,244 shares of common stock reserved for future issuance related to the Gevo, Inc. 2010 Stock Incentive Plan and warrants. As a result, as of October 29, 2021, we had approximately 34,426,778 shares of authorized shares of common stock available for future issuance. We operate in a capital-intensive industry and we do not believe we have sufficient unissued shares of common stock for future issuances to raise funds to execute on our business has been impactedplans. Having additional authorized common stock available is critical to our continued efforts to pursue our strategic goals and we will be limited by the COVID-19 pandemic,number of shares available for future capital raising transactions or business development transactions unless we obtain stockholder approval of an amendment to our certificate of incorporation to increase the number of authorized shares of common stock. We plan to solicit the approval of our stockholders to amend our certificate of incorporation to increase the number of authorized shares of common stock, but we cannot be certain that our stockholders will approve the amendment, particularly since we have a large retail stockholder base as of October 29, 2021. A delay in securing, or a failure to secure, stockholder approval to amend our certificate of incorporation could cause a delay in our future capital raising, collaboration, partnership or other strategic transactions, and our financial condition, results of operations and liquidity may be materially and adversely impacted by it in the future.

The COVID-19 pandemic has had an adverse impact on global commercial activity, including the global transportation industry and its supply chain, and has contributed to significant volatility in financial markets, including, among other effects, a decline in equity markets, changes in interest rates and reduced liquidity. It has also resulted in increased travel restrictions and extended shutdowns of businesses in various industries including, among others, the airline industry, and significantly reduced overall economic output. We expect that the impact of the COVID-19 pandemic on general economic activity will negatively impact our revenue and operating results for at least the remainder of 2020 and beyond. The impact of the COVID-19 pandemic on the global transportation industry could continue to result in less demand for our transportation fuel products which could have a material adverse effect on our business and financial condition. The suspension

We will require substantial additional financings to achieve our goals, and a failure to obtain this capital when needed or on acceptable terms could force us to delay, limit, reduce or terminate our development and commercialization efforts.

We operate in a capital-intensive industry and will need substantial amount of ethanol production at our Luverne Facility and reduction in our workforce during the first quarter of 2020 duecapital to the impact of COVID-19 had an adverse impactexecute on our financial resultsbusiness plans. We believe that we will continue to expend substantial resources for the third quarterforeseeable future on further developing our business, including developing, constructing, financing and acquiring facilities necessary for the production of 2020 reducing revenue by 97% compared to the same period in 2019. There is alsoour products on a risk that COVID-19 could have a material adverse impact on customer demand and cash flow.

The risks generallycommercial scale. These expenditures will include costs associated with the COVID-19 pandemic could magnify other risks discussed in this reportour Net-Zero Projects, research and any of our SEC filings. For example, the rapidly evolving changes in financial markets could have a material impact on our ability to obtain additional financing, which could impact our liquidity. For example, volatility in the financial markets could make it more difficult to raise money from selling equity on the capital markets, the impact of COVID-19 on financial markets could limit potential lenders’ ability to provide funds for project finance of the planned expansion ofdevelopment, modifying and expanding the Luverne Facility to produce our products, developing biogas processing projects and wind projects, obtaining government and regulatory approvals, acquiring or constructing storage facilities and negotiating supply agreements for the termsproducts we produce. In addition, other unanticipated costs may arise. Because the costs of any project finance transactions could be worse than anticipated.developing our technology at a commercial scale are highly uncertain, we cannot reasonably estimate the amounts necessary to successfully commercialize our production.

To date, we have funded our operations primarily through equity offerings, issuances of debt and revenues earned primarily from the sale of ethanol and related products. Based on our current plans and expectations, we will require additional funding to achieve our goals. In addition, the effectivenesscost of external parties, including governmentalpreparing, filing, prosecuting, maintaining and non-governmental organizations,enforcing patent, trademark and other intellectual property rights and defending against claims by others that we may be violating their intellectual property rights may be significant. Moreover, our plans and expectations may change as a result of factors currently unknown to us, and we may need additional funds sooner than planned and may seek to raise additional funds through public or private debt or equity financings in combating the spread and severity of COVID-19 could have a material impact on demand for our business. Further, steps taken by market counterparties such as commercial airlines could have an impact on their ability to perform under agreements to which we are a party, which could impact our business. For example, in connection with the impact that the COVID-19 pandemic has had on the economy and on the resulting disruption to the airline industry specifically, we and Delta amended portions of our previously disclosed Fuel Sales Agreement in April 2020, as discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Company Overview—COVID-19.” Other commercial counterpartiesnear future. We may also choose to seek additional capital sooner than required due to amend supply agreement in the future.

The COVID-19 pandemic could further and materially disrupt our own business operations and the services we provide, as well as the business operations of our customers, suppliers and other third parties with whom we interact. As an increasing percentage of our employees work remotely, we also face the risk that unusual working arrangements could impact the effectiveness of our operationsfavorable market conditions or internal controls. In addition, a potential COVID-19 infection of any of our key employees could materially and adversely impact our operations. It is possible that COVID-19 restrictions could create difficulty for satisfying our legal or regulatory filing or other obligations, including with the SEC and other regulators.strategic considerations.

 

 

There is also a risk that the COVID-19 pandemic could continue to have a material adverse impact on customer demand and cash flow for the remainder of 2020 and beyond. We will continue to monitor the situation and assess possible implications to our business and its stakeholders and will take appropriate actions to help mitigate adverse consequences. The extent to which COVID-19 continues to impact our business and financial positionOur future capital requirements will depend on future developments, which are difficultmany factors, including:

•              the timing of and costs involved in financing and constructing our Net-Zero Project, including our Net-Zero 1 Project;

•              the timing of and costs involved in obtaining permits;

•              the ability for us to predict, includingdeploy strains of yeast with improved performance that help to lower capital cost;

              the severity, durationtiming and scopecosts associated with constructing our RNG project;

•              the costs involved in making changes to our operations at the Luverne Facility;

•              the timing of the COVID-19 outbreak as well as the types of measures imposed by governmental authorities to contain the virus or address its impact and the duration of those actions and measures.costs involved in developing adequate storage facilities for the products we produce;

 

We have considered multiple scenarios, with both positive and negative inputs, as part of the significant estimates and assumptions that are inherent in its financial statements and are based on trends in customer behavior and the economic environment throughout the quarter ended September 30, 2020 and beyond as the COVID-19 pandemic continues to impact the industries in which we operate. These estimates and assumptions include the collectability of billed and unbilled receivables and the estimation of revenue and tangible and intangible assets. With regard to collectability, we believe we may face atypical delays in client payments going forward but we have not experienced delays in collection as of September 30, 2020. In addition, we believe that the demand for certain discretionary lines of business may decrease, and that such decrease will impact our financial results in succeeding periods. Non-discretionary lines of business may also be adversely affected, for example because reduced economic activity or disruption in hydrocarbon markets reduces demand for or the extent of renewable alcohol-to-jet fuel, isooctane and isooctene. We believe that these trends and uncertainties are comparable to those faced by other registrants as a result of the COVID-19 pandemic.

All of the foregoing events or potential outcomes, including in combination with other risk factors included in this Quarterly Report on Form 10-Q or our Annual Report, could cause a material adverse effect on our results of operations in any period and, depending on their severity, could also materially and adversely affect our financial condition. In addition, such events and outcomes could potentially impact our reputation with clients and regulators, among others. The rapid development and fluidity of the pandemic precludes any prediction as to the ultimate impact of the COVID-19 pandemic on us. The full extent of the impact and effects of the COVID-19 pandemic on our business, operations, liquidity, financial condition and results of operations remain uncertain at this time.

We may face substantial delays in obtaining regulatory approvals for use of our renewable premium gasoline product, which could substantially hinder              our ability to commercialize ourgain market acceptance for isobutanol as a raw material for the production of renewable premiumhydrocarbons and as a specialty chemical and gasoline product in the U.S.blendstock;

 

Commercialization•              our ability to negotiate additional supply agreements for the products we produce, and the timing and terms of those agreements, including terms related to sales price;

•              our ability to negotiate sales of our renewable premium gasoline product inproducts and the U.S. requires approvals from state and/or federal agencies. Before we cantiming and terms of those sales, including terms related to sales price;

•              our ability to sell our renewable premium gasoline productthe iDGs left as a fuelco-product of fermenting isobutanol from corn as animal feedstock;

•              our ability to establish and maintain strategic partnerships, licensing or asother arrangements and the timing and terms of those arrangements; and

•              the cost of preparing, filing, prosecuting, maintaining, defending and enforcing patent, trademark and other intellectual property claims, including litigation costs and the outcome of such litigation.

Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If needed funds are not available to us on a gasoline blendstock,timely basis, we must obtain certain approvalsmay be required to delay, limit, reduce or certifications fromterminate:

•              our Net-Zero Projects, including the U.S. Environmental Protection Agency (“EPA”). There canNet-Zero 1 Project;

•              our plans to enter into agreements with strategic partners;

•              our production of products at the Luverne Facility;

•              our development of RNG products;

•              our production of renewable hydrocarbons at the South Hampton Facility, or any other future facilities;

•              our efforts to prepare, file, prosecute, maintain and enforce patent, trademark and other intellectual property rights and defend against claims by others that we may be no assurancesviolating their intellectual property rights; and/or

•              our activities in developing storage capacity and negotiating and performing under supply agreements that the EPA will grant such approvals or certifications. Any delay or failure in receiving approval will slow or preventmay be necessary for the commercialization of our renewable premium gasoline product, which could have a material adverse effect on our business, financial condition and results of operations.products.

 

Additionally, California requires that fuels meet both its fuel certification requirements and a separate state low-carbon fuel standard. Any delay or failure in receiving approval for our renewable premium gasoline product will slow or prevent the commercialization of our renewable premium gasoline product, which could have a material adverse effect on our business, financial condition and results of operations.

There are also various third-party certification organizations, such as ASTM International and Underwriters’ Laboratories, Inc., involved in standard-setting regarding the transportation, dispensing and use of liquid fuel in the U.S. and abroad. These organizations may change the current standards and additional requirements may be enacted that could prevent or delay approval of our renewable premium gasoline product. The process of seeking required approvals and the continuing need for compliance with applicable standards may require the expenditure of substantial resources, and there is no guarantee that we will satisfy these standards in a timely manner, if ever.

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Issuer Purchases of Equity Securities

 

Period

 

Total Number

of Shares

Purchased

 

Average Price

Paid per Share

 

Total Number

of Shares

Purchased as

Part of Publicly

Announced

Plans or

Programs

 

Maximum

Number of

Shares that

May Yet Be

Purchased

Under the Plans

or Programs

             

July 1, 2020 - July 31, 2020 (1)

 

 

37,434

 

$

0.55

 

 

 

 

August 1, 2020 - August 31, 2020

 

 

 

$

 

 

 

 

September 1, 2020 - September 30, 2020

 

 

 

$

 

 

 

 

             

Total

 

 

37,434

 

$

0.55

 

 

 

 

Period

 

Total Number

of Shares

Purchased

 

Average Price

Paid per Share

 

Total Number

of Shares

Purchased as

Part of Publicly

Announced

Plans or

Programs

 

Maximum

Number of

Shares That

May Yet Be

Purchased

Under the Plans

or Programs

             
July 1, 2021 - July 31, 2021 (1)  749,890 $6.85    
August 1, 2021 - August 31, 2021   $    
September 1, 2021 - September 30, 2021   $    
             

Total

 

 

749,890

 

$

6.85 

 

 

 

 

(1)  Represents shares withheld from employees to cover tax withholding obligations upon the vesting of restricted stock awards. The average prices listed in the above table are averages of the fair market prices at which we valued shares withheld for purposes of calculating the number of shares to be withheld.

 

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

 

Item 5. Other Information.

 

None.

 

 

Item 6. Exhibits.

 

The exhibits listed below are filed or furnished as part of this report. 

 

Exhibit

Number

 

 

Description

 

Previously Filed

 

Included

Herewith

 

 

 

 

 

Form

 

File No.

 

Filing Date

 

Exhibit

 

 

 

 

 3.1

 

 

Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

10-K

 

 

001-35073

 

 

March 29, 2011

 

 

3.1

 

 

 

 

 3.2

 

 

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

8-K

 

 

001-35073

 

 

June 10, 2013

 

 

3.1

 

 

 

 

 3.3

 

 

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

8-K

 

 

001-35073

 

 

July 9, 2014

 

 

3.1

 

 

 

 

 3.4

 

 

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

8-K

 

 

001-35073

 

 

April 22, 2015

 

 

3.1

 

 

 

 

 3.5

 

 

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

8-K

 

 

001-35073

 

 

January 6, 2017

 

 

3.1

 

 

  3.6  

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 8-K 001-35073 June 4, 2018 3.1  

 

 

 3.7

 

 

Amended and Restated Bylaws of Gevo, Inc.

 

 

10-K

 

 

001-35073

 

 

March 29, 2011

 

 

3.2

 

 

 

 

 4.1

 

 

Form of Gevo, Inc. Common Stock Certificate.

 

 

S-1

 

 

333-168792

 

 

January 19, 2011

 

 

4.1

 

 

 

 

 4.2†

 

 

 

Stock Issuance and Stockholder’s Rights Agreement, dated July 12, 2005, by and between Gevo, Inc. and California Institute of Technology.

 

 

S-1

 

 

333-168792

 

 

August 12, 2010

 

 

4.3

 

 

Exhibit

Number

 

 

Description

 

Previously Filed

 

Filed

Herewith

 

 

 

 

 

Form

 

File No.

 

Filing Date

 

Exhibit

 

 

 

 

 3.1

 

 

Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

10-K

 

 

001-35073

 

 

March 29, 2011

 

 

3.1

 

 

 

 

 3.2

 

 

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

8-K

 

 

001-35073

 

 

June 10, 2013

 

 

3.1

 

 

 

 

 3.3

 

 

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

8-K

 

 

001-35073

 

 

July 9, 2014

 

 

3.1

 

 

 

 

 3.4

 

 

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

8-K

 

 

001-35073

 

 

April 22, 2015

 

 

3.1

 

 

 

 

 3.5

 

 

 

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 

 

8-K

 

 

001-35073

 

 

January 6, 2017

 

 

3.1

 

 

  3.6  

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Gevo, Inc.

 8-K 001-35073 June 4, 2018 3.1  

 

 

 3.7

 

 

Amended and Restated Bylaws of Gevo, Inc.

 

 

10-K

 

 

001-35073

 

 

March 29, 2011

 

 

3.2

 

 

 

 

 4.1

 

 

Form of Gevo, Inc. Common Stock Certificate.

 

 

S-1

 

 

333-168792

 

 

January 19, 2011

 

 

4.1

 

 

 

 

Exhibit

Number

 

 

Description

 

Previously Filed

 

Included

Herewith

 

 

 

 

 

Form

 

File No.

 

Filing Date

 

Exhibit

 

 

 

 

 4.3*

 

 

 

Indenture, dated January 10, 2020, by and among Gevo, Inc., the guarantors party thereto, and Wilmington Savings Fund Society, FSB, as trustee and as collateral trustee.

 

 

8-K

 

 

001-35073

 

 

January 13, 2020

 

 

4.1

 

 

 

 4.4 

  First Supplemental Indenture, by and among Gevo, Inc., the guarantors party thereto, Wilmington Savings Fund Society, FSB, as trustee and as collateral trustee, the requisite holders and Whitebox Advisors LLC. 8-K 001-35073 April 9, 2020 4.1  
 4.5  Second Supplemental Indenture, dated July 2, 2020, by and among Gevo, Inc., the guarantors party thereto, Wilmington Savings Fund Society, FSB, as trustee and collateral trustee, and the Requisite Holders. 8-K 001-35073 July 8, 2020 4.3  
 4.6  Third Supplemental Indenture, dated August 24, 2020, by and among Gevo, Inc., the guarantors party thereto, Wilmington Savings Fund Society, FSB, as trustee and collateral trustee, and the Requisite Holders. 8-K 001-35073 August 26, 2020 4.2  

 

 

 4.7

 

 

 

Registration Rights Agreement, dated January 10, 2020, by and among Gevo, Inc. and the investors named therein.

 

 

8-K

 

 

001-35073

 

 

January 13, 2020

 

4.1

 

 

 

 

 

 4.8

 

 

Form of Series D Warrant to Purchase Common Stock.

 

 

8-K

 

 

001-35073

 

 

December 15, 2015

 

 

4.1

 

 

 

 

 4.9

 

 

Form of Amendment No. 1 to Series D Warrant

 

 

8-K

 

 

001-35073

 

 

June 13, 2016

 

 

4.1

 

 

Exhibit

Number

 

 

Description

 

Previously Filed

 

Filed

Herewith

 

 

 

 

 

Form

 

File No.

 

Filing Date

 

Exhibit

 

 

 

 

 4.10

 

 

Form of Series F Warrant to Purchase Common Stock.

 

 

8-K

 

 

001-35073

 

 

April 5, 2016

 

 

4.1

 

 

 

 

 4.11

 

 

Form of Series I Warrant to Purchase Common Stock

 

 

8-K

 

 

001-35073

 

 

September 15, 2016

 

 

4.1

 

 

 

 

 4.12

 

 

Form of Series K Warrant to Purchase Common Stock

 

 

8-K

 

 

001-35073

 

 

February 22, 2017

 

 

4.1

 

 

  4.13  Form of Series 2020-A Warrant to Purchase Common Stock. 8-K 001-35073 July 8, 2020 4.1  
  4.14  Form of Series 2020-B Warrant to Purchase Common Stock. 8-K 001-35073 July 8, 2020 4.2  
  4.15  Form of Series 2020-C Warrant to Purchase Common Stock. 8-K 001-35073 August 26, 2020 4.1  
  10.1  Form of Securities Purchase Agreement. 8-K 001-35073 July 8, 2020 10.1  
  10.2††  Master Framework Agreement, dated August 13, 2020, by and between Gevo, Inc. and Praj Industries Ltd. 8-K 001-35073 August 18, 2020 10.1  
  10.3††  Renewable Hydrocarbons Purchase and Sale Agreement, dated August 14, 2020, by and between Gevo, Inc. and Trafigura Trading LLC. 8-K 001-35073 August 20, 2020 10.1  
  10.4  Form of Securities Purchase Agreement. 8-K 001-35073 August 24, 2020 10.1  

 

 

 31.1

 

 

Section 302 Certification of the Principal Executive Officer.

 

 

 

 

 

 

 

 

 

 

X

 

 

 31.2

 

 

Section 302 Certification of the Principal Financial Officer.

 

 

 

 

 

 

 

 

 

 

X

 

 

 32.1

 

 

Section 906 Certification of the Principal Executive Officer and Principal Financial Officer.**

 

 

 

 

 

 

 

 

 

 

X**

 

 

 101

 

 

 

Financial statements from the Quarterly Report on Form 10-Q of Gevo, Inc. for the quarterly period ended September 30, 2020, formatted in XBRL: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Cash Flows, and (iv) Notes to the Consolidated Financial Statements.

 

 

 

 

 

 

 

 

 

 

X

Exhibit

Number

 

 

Description

 

Previously Filed

 

Filed

Herewith

 

 

 

 

 

Form

 

File No.

 

Filing Date

 

Exhibit

 

 

 

 

 4.2

 

 

Form of Series K Warrant to Purchase Common Stock

 

 

8-K

 

 

001-35073

 

 

February 22, 2017

 

 

4.1

 

 

  4.3  Form of Series 2020-A Warrant to Purchase Common Stock. 8-K 001-35073 July 8, 2020 4.1  
 10.1+  Base Contract for Sale and Purchase of Natural Gas, dated July 22, 2021, by and between Gevo NW Iowa RNG, LLC, BP Canada Energy Marketing Corp. and BP Products North America Inc. 8-K 001-35073 August 9, 2021 10.1  
 10.2+  Special Provisions Attached to and Forming Part of the Base Contract for Sale and Purchase of Natural Gas dated July 22, 2021, by and between Gevo NW Iowa RNG, LLC, BP Canada Energy Marketing Corp. and BP Products North America Inc. 8-K 001-35073 August 9, 2021 10.2  
 10.3+  Biogas Supply Addendum – Vehicle Fuel Segment-Supply Side, dated July 22, 2021, by and between Gevo NW Iowa RNG, LLC, BP Canada Energy Marketing Corp. and BP Products North America Inc. 8-K 001-35073 August 9, 2021 10.3  
 10.4+  Transaction Confirmation relating to the Base Contract, by and between Gevo NW Iowa RNG, LLC and BP Canada Energy Marketing Corp. 8-K 001-35073 August 9, 2021 10.4  
 10.5  Amendment to At-The-Market Offering Agreement, dated September 9, 2021, between Gevo, Inc. and H.C. Wainwright & Co., LLC. 8-K 001-35073 September 9, 2021 10.1  
 10.6+  Asset Purchase Agreement, date September 21, 2021, between Butamax Advanced Biofuels LLC and Danisco US Inc., and Gevo, Inc. 8-K 001-35073 September 23, 2021 10.1  

 

 

 31.1

 

 

Section 302 Certification of the Principal Executive Officer.

 

 

 

 

 

 

 

 

 

 

X

 

 

 31.2

 

 

Section 302 Certification of the Principal Financial Officer.

 

 

 

 

 

 

 

 

 

 

X

 

 

 32.1

 

 

Section 906 Certification of the Principal Executive Officer and Principal Financial Officer.**

 

 

 

 

 

 

 

 

 

 

X**

 

 

 101

 

 

 

Financial statements from the Quarterly Report on Form 10-Q of Gevo, Inc. for the quarterly period ended September 30, 2021, formatted in Inline XBRL: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Cash Flows, and (iv) Notes to the Consolidated Financial Statements.

 

 

 

 

 

 

 

 

 

 

X

 104  Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)          

 

Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.

††+Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.
*Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

 

**

Furnished herewith.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Gevo, Inc.

(REGISTRANT)

  

 

 

By:

/s/ Carolyn M. Romero

 

Carolyn M. Romero, CPA

VP - ControllerChief Accounting Officer

(Principal Accounting OfficerOfficer)

 

Date:        November 10, 20202021

 

 

55
50